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ABSTRACT OF DISSERTATION 
NOVEL TARGETS FOR MITOCHONDRIAL DYSFUNCTION FOLLOWING 
TRAUMATIC BRAIN INJURY 
Mitochondrial dysfunction is a phenomenon observed in models of 
Traumatic Brain Injury (TBI). Loss of mitochondrial bioenergetics can result in 
diminished cellular homeostasis leading to cellular dysfunction and possible 
cellular death. Consequently, the resultant tissue damage can manifest as 
functional deficits and/or disease states. Therapeutic strategies to target this 
mitochondrial dysfunction have been investigated for models TBI and have 
shown promising effects.   
For this project, we tested the hypothesis that mitoNEET, a novel 
mitochondrial membrane protein, is a target for pioglitazone mediated 
neuroprotection. To test this, we used a severe Controlled Cortical Impact (CCI) 
injury model in mitoNEET null and wild-type mice. We then dosed these animals 
with pioglitazone or NL-1, which is a compound that has a similar structure to 
pioglitazone allowing us to hone in one the importance of mitoNEET binding. 
Wild-type animals treated with the mitoNEET ligands, both pioglitazone and NL-
1, had improved mitochondrial function, tissue sparing and functional recovery, 
compared to mitoNEET null animals.  
In addition to this specific hypothesis tested, our experiments provided 
insight casting doubt on the central dogma that mitochondrial dysfunction 
following TBI is the result of vast oxidative damage and consequential 
irreversible mitochondrial loss. The data from these studies show that when 
mitoNEET is targeted with pioglitazone at 12 hours’ post-injury, mitochondrial 
dysfunction can be reversed. Additionally, when bypassing proteins upstream of 
Complex I with an alternative biofuel, such as beta-hydroxybuterate (BHB), TBI 
related mitochondrial dysfunction is once again reversed. This leads to novel 
hypothesis for future work which posits mitoNEET as a redox sensitive switch; 
when mitoNEET senses changes in redox, as seen in TBI, it inhibits 
mitochondrial respiration. When targeted with an agonist/ligand or bypassed with 
a biofuel TBI mitochondrial dysfunction can be reversed.  
These studies support the role of mitoNEET in the neuropathological 
sequelae of brain injury, supporting mitoNEET as a crucial target for pioglitazone 
mediated neuroprotection following TBI. Lastly, these studies propose a 
mechanism of TBI related mitochondrial dysfunction which can reversed with 
pharmacological agents. 
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CHAPTER 1: THE POWERHOUSE OF THE CELL: MITOCHONDRIA 
Mitochondria are key to cellular energetics and cellular homeostasis and 
have profound implications in the initiation of cell death. The study of these 
microscopic organelles has provided fundamental insights into the workings of a 
cell that covers a broad spectrum from genetics to biophysics to cell biology. 
Studies have a demonstrated their importance in various neurodegenerative 
diseases and have been linked to the secondary injury cascade following a brain 
injury. For these reasons, mitochondria occupy a central position in the science 
of Cell Biology and Neurobiology.  
Neuronal homeostasis and function has been found to be dependent on 
mitochondrial bioenergetics. As the “Power Plant” of the cell, mitochondria 
provide 90 to 95% of the energy needed for the cell to function properly [1-8]. As 
mitochondria become dysfunctional, cellular dysfunction soon follows. Therefore, 
research has focused on the discovery of pharmaceutical interventions that 
target mitochondrial dysfunction associated with various diseased states. Many 
therapeutic interventions that target mitochondrial function is these diseased 
states have shown positive results. One disease model that is characterized by 
vast mitochondrial dysfunction and has shown improved outcome when 
dysfunctional mitochondria are targeted is Traumatic Brain Injury, TBI. In this 
chapter there will be a historical overview of mitochondria in the scientific 
literature. Mitochondrial bioenergetics and their importance to proper brain 
function will also be discussed. The following chapters will explain cell specific 
and age related changes that occur within mitochondria with a detailed 
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explanation into the pathobiology of traumatic brain injury. Further details will 
also be provided on therapeutic interventions that target mitochondria leading to 
improved outcomes.  
History of Mitochondria 
Mitochondria have a very rich history in the scientific literature. They have 
been a subject of study for many Nobel Prizes, demonstrating their importance 
to overall cellular homeostasis. Although their history is rich, the time between 
initial observations of mitochondria and the understanding into their functions 
was long, initially being overshadowed by the discovery of the nucleus. The first 
official observations of mitochondria date back to the 1841 when cytologist 
Jakob Henle observed mitochondria in the muscles of insects [9-11]. In 1856, 
Von Kölliker, a Swiss Anatomist and Physiologist, described this 
“sarcomere”/organelle with more detail during his studies in spermatogenesis 
[12]. However, at this point, the function of these unknown intracellular 
structures was still ill defined, at the time hypothesized as a physical structure 
that had a role in the transmission of genetic information.  
Remarkably, in the 1890s, Richard Altmann termed these intracellular 
granules “bioplasts” and proposed them to be autonomous, forming bacterial-
like colonies within their host cells [13]. Based on our current knowledge and the 
evolutionary theory of a prokaryotic and eukaryotic symbiosis being formed 
billions of years ago, this was indeed a very astute observation. However their 
significance was still unappreciated [14-16]. Scientists in the field continued to 
described these intracellular structures by terms like “chondros”, “Korn” and 
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“grain’. Then, in 1898, with the development of improved staining techniques, 
the Greek term “mitos” was adopted by Carl Benda leading to the new term 
“mitochondria” [review by Chowdry 1918,  quoted in [17] and [13].  
Following the discovery of these organelles from a physical perspective, 
much time passed in the scientific literature before mitochondria were brought up 
by name again. However, during this down time, researchers were on track for 
some big findings due to continued progress in the field of cellular metabolism 
and cellular respiration. Dehydrogenase studies completed by Battelli and 
Sterns, which was later expanded upon by Heinrich Otto Wieland, and the 
discovery of insoluble iron containing “respiratory enzymes” (Atmungsferment, 
which are ironcolloid complexes) by Otto Heinrich Warburg lead to the initial 
findings which gave insoluble cellular enzymes credit for cellular respiration. 
However, these founding studies were also followed by great debate. Due to his 
work with iron containing molecules, Warburg hypothesized that cellular 
respiration was mediated through oxygen transfer between enzymes. Wieland, 
due to his investigations into dehydrogenases, believed respiration was mediated 
through hydrogen transfers. Then, in 1925, David Keilin, during his research 
involving cytochromes, provided deeper insight into the understanding of the 
electron transport chain that included dehydrogenases at one end and 
Atmungsferments (ironcolloids) are the other end, ending the current debate 
between Weiland and Warburg. Further research was completed by David Keilin, 
and his understudy E. F. Hartree, leading to the acknowledgement of an 
“unspecific colloidal structure” which localized these respiratory enzymes that 
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were the topic of such great debate. It wasn’t until work from Cleland and Slater 
in the 1950s that these “unspecific colloidal structures” were defined as 
phospholipids in the membrane of the mitochondria. Additionally, the 
dehydrogenases that were upstream to the ironcollloid structures were eventually 
defined by Hans Adolf Krebs as the Citric Acid Cycle, which is often called the 
Krebs Cycle. 
When attempting to understand the importance of mitochondria a 
discussion about adenosine triphosphate, ATP, is crucial. ATP is a crucial 
macromolecule in the cell with an importance debated as second to DNA. It was 
first discovered in 1929 by a German Chemist name Karl Lohmann. However, it 
wasn’t until the work of Vladimir Engelhart, in 1935, and then Fritz Lipmann in the 
early 40s, that this compound was credited for many important functions in the 
cell. Work from Engelhart showed that ATP was necessary for proper muscle 
contraction. Building upon that, Lipmann was then credited for coining the term 
“energy-rich phosphate bonds” when he discovered that ATP is the main bearer 
of chemical energy for the cell. Now, it is well accepted that ATP is made up of 
the nucleoside adenosine that is bound to three phosphate groups. 
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Figure 1.1 Chemical Equation for Hydrolysis of ATP: Hydrolysis of ATP leads 
to the generation of 30.5 kJ/mol of energy plus an ADP molecule and a free 
inorganic phosphate. [18] 
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Upon the removal of the outermost, third, phosphate group, adenosine 
diphosphate (ADP) is formed. The cleavage of this phosphate group leads to the 
release of ~30.5 kJ/mol of energy. Conversely, generating an ATP molecule 
requires an ADP molecule with the addition of an inorganic phosphate group, 
which is more often than not completed in the mitochondria. Large quantities of 
ATP are formed and consumed in the human body daily. One report made the 
assumption that the average adult male has approximately 1 trillion metabolically 
active cells in the body. Each cell contains roughly 1 billion ATP molecules at any 
given time. With these values, one can calculate 1023 ATP molecules in the 
human body at any given time [19]. As mentioned previous, 90-95% of these 
ATP made in the body is carried out within the mitochondria by the enzyme ATP 
synthase, leading into further insight into the importance of these, once ill 
defined, organelles.  
The time of the discovery of ATP, Warburg sought out to discover how 
these molecules were made. Keeping in mind that he was a proponent of 
oxidative phosphorylation, he attempted to describe the production of ATP 
through substrate level phosphorylation in which an ATP molecule was produced 
as a result of the enzymatic oxidation of a specific compound. As we currently 
understand cellular metabolism, his hypothesis was not wrong since we do 
observe substrate phosphorylation during glycolysis and the Krebs cycle. 
However, this process does not account for the majority of ATP made by the cell. 
Conversely, H.M. Kalckar proposed a separate method to explain ATP 
production. He hypothesized that the process of phosphorylating ADP to 
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generate ATP was linked respiration. Specifically, the energy generated in the 
process of oxidizing the nutrients within our bodies was harnessed to make ATP, 
which is a process now termed oxidative phosphorylation [20-25]. As we know, 
this method is favored in cells with active mitochondria.  
About the time that progress was being made in the field of ATP and ATP 
production, Albert Claude pioneered a separation technique allowing 
researchers to isolate functioning mitochondria. Within this technique he defined 
the appropriate buffers and tissue fractionation method based on differential 
centrifugation [26-31]. These techniques were then applied by Albert L. 
Lehninger and his group to further validate his previous work concluding that 
fatty acid oxidation is primarily completed in the mitochondria and that the rate 
of reactions within the citric acid cycle was high enough to provide the majority 
of energy to liver cell [32-38]. This observation has never been disproven 
considering that mitochondria function within liver cells is known to be very high. 
During these studies, they also determined that fatty acid oxidation and citric 
acid cycle activity lead to ATP production in a manner that was dependent on 
oxidative phosphorylation, confirming Klackar’s previous work [35]. 
With the invention of electron microscopes in the earlier 50s, the structure 
of mitochondria could be better defined. It is now well accepted that 
mitochondria are intracellular organelles with a dual (inner and outer) membrane 
system, each responsible for specific functions.  
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Figure 1.2 An electron micrograph of mitochondria: This image shows the 
dual membrane nature and intact cristae observed within mitochondria [39] 
Cristae
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 The outer membrane (OM) contains many transporter proteins 
tasked with the import and export of ions and proteins necessary to maintain 
mitochondrial function [40]. This includes the Voltage Dependent Anion Channel 
(VDAC) as well as Translocase of the Outer Membrane (TOM) Channel. The 
inner membrane (IM) has many folds, termed cristae (Figure 1.2), and have 
areas enriched with inner mitochondrial membrane proteins such as Complex I, 
Complex III, Complex VI, ATP Synthase, the Adenosine Nucelotide Transporter 
(ANT), the mitochondrial Calcium Uniporter (mCU), and the Hydrogen Calcium 
and Sodium Calcium Exchangers (HCE and NaCE respectively), which will all 
be discussed later due to their importance in mitochondrial bioenergetics and 
dysfunction. It is these cristae which help to increase the surface area available 
for mitochondrial respiration and are the site of electron transport and oxidative 
phosphorylation (OXPHOS). The space between the outer and inner 
mitochondrial membrane is called the inner mitochondrial membrane space and 
the space enclosed by the inner membrane is termed the matrix. This matrix 
space contains the enzymes involved in the Krebs Cycle and electron rich 
compounds that feed into the electron transport chain.  
When discussing mitochondrial bioenergetics and the history of 
these important organelles, it is impossible to skip the Nobel Prize winning 
work of Peter Mitchell. Keep in mind that within the late 50s, the idea of 
substrate level phosphorylation and oxidative phosphorylation were both 
proposed as mechanisms leading to ATP production. Work from Edward 
Charles (Bill) Slater, who was trained under Keilin (cytochrome work in the 
mid-20s), proposed a 
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chemical nature for oxidative phosphorylation. In this “chemical-coupling 
hypothesis”, redox reactions could occur between 2 molecules generating the 
energy necessary to produce ATP [41-43]. However, this theory was lacking 
information in that a high-energy intermediate necessary to produce the ATP 
molecule from ADP + Pi was unknown. Then, in 1960s, two theories were 
proposed, both of which proposed the flux of protons as the energy source 
necessary for ATP synthesis. The first theory was proposed by Robert Joseph 
Paton Williams who thought that the flux of protons occurred within the lipid 
phase of the membrane [44]. The energetics allowed for a dehydration reaction 
leading to condensation of ADP and Pi to ATP. Mitchell, on the other hand, 
proposed a more physics based approach in which the lipid membrane acted as 
a resistor and capacitor helping to separate charges in a manner similar to a 
battery. This revolutionary theory was called the Chemiosmotic Hypothesis of 
Oxidative Phosphorylation and will be discussed in further detail later in this 
chapter [45-49].  
At the time that researchers were trying to understand cellular respiration 
and ATP production, Abraham E. Axelrod (1941) made an observation that 
Calcium uptake increased oxygen consumption [50]. Although he proposed a 
mechanism that was disproven, it is the first indication in the literature that 
hinted to mitochondrial mediated Calcium uptake. Once the proper 
mitochondrial isolation techniques were known, Siekewitz and Potter (1953) and 
then Lehninger (1970) both confirmed that mitochondria were able to buffer 
calcium in a manner that lead to increased oxygen consumption. To further 
 11 
expand upon this work, Vasington and Murphy (1961) showed that calcium 
uptake was dependent on the respiratory chain and could be inhibited with the 
use of 2,4 DNP and FCCP, two a well known membrane uncoupler [50]. As we 
now know, this calcium uptake is dependent on the mitochondrial Calcium 
Uniporters (mCU) that uses the membrane potential generated by the electron 
transport chain in buffer cytosolic calcium. 
In addition to ATP production and calcium cycling, mitochondria also 
seem to have an important role in cell survival. Although early on the topic was 
heavily debated as an in vitro artifact that had no pathophysiological relevance, 
the mitochondrial permeability transition pore (mPTP) is now pretty well 
accepted as a potential mechanism of cell death. In the early 50s and 60s, when 
mitochondrial bioenergetics were being heavily studied, the ability for 
mitochondrial swelling which was dependent on calcium, inhibited by Mg2+ and 
ADP, was well documented [51-64]. Additionally, Mitchell even discussed this 
phenomenon as a detriment to energy conservation during his proposal of his 
Chemiosmotic Hypothesis. However, the mechanisms behind this swelling were 
not explained fully until the late 1970s by Haworth and Hunter coined term 
“permeability transition”. During their studies they described the reversible 
opening of a proteinaceous pore in the inner mitochondrial membrane leading to 
the possible flux of ions and solutes up to 1500kDa from the mitochondria to the 
cytosol [65-68]. This theory was not well accepted until approximately 10 years 
later when it was discovered that this pore could be inhibited by submicromolar 
concentrations of cyclosporin A [69-75].   To date, the mPTP is thought to play a 
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role in oncosis and apoptotic mediated cell death, all which will be discussed 
later in detail due to their importance in cell death and, therefore, TBI. 
Since their initial discovery in the 1840s, mitochondria are now known to 
be an important and integral organelle in the cell. Their function, superficially, is 
to mediate cellular respiration and cellular metabolism, in which the mitochondria 
produce the energy rich compound, ATP, in order to provide an energetic 
environment within the cell. However, due to work in the 50s and 60s, it is also 
known that mitochondria have an important function in mediating calcium cycling, 
which is dependent upon the function of the mitochondrial calcium uniporter. This 
uniporter uses the potential in the inner membrane space to pump mitochondria 
from the cytosol into the matrix. Lastly, mitochondria seem to have a very 
important role in cell survival which can be mediated through the initiation of the 
mitochondrial permeability transition pore.  
Cellular Metabolism: Today’s Understanding  
Cellular energetics is directly linked to ATP production which occurs 
through cellular metabolism. Aerobic cellular metabolism can be broken down in 
4 separate steps. The first step is the generation of compounds which can be 
chemically recognized by metabolic proteins within the mitochondria and 
transport into the mitochondria. Anaerobic metabolism does not include the use 
of mitochondria generating ATP without the use of mitochondrial mediated 
oxidative phosphorylation. The next step in aerobic phosphorylation is the Krebs 
Cycle which is the site of production of the electron rich compounds NADH and 
succinate. These electron rich compounds are then able to feed into the 
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Electron Transport System/Chain (ETS), which is considered the third step of 
cellular metabolism. Lastly, the fourth step which is the site of the ATP synthase, 
producing an overwhelming majority of the ATP used by the cell. Each of these 
steps and key players within these step will be discussed throughout the rest of 
this chapter. 
Glycolysis, Fatty Acid Oxidation and Urea Cycling 
When the cell takes up metabolic compounds such as glucose, lactate, 
fatty acids or various amino acids, it has to have a mechanism to break them 
down into substrates that can be transported into the mitochondria and then 
recognized by appropriate metabolic proteins. Three processes which are 
important in generating substrates for mitochondria are Glycolysis, Fatty Acid 
Oxidation and Urea Cycling.  Glycolysis is a term generated from “glucose and 
lysis” referring to the metabolic process of breaking down glucose, a 6-carbon 
molecule, to pyruvate, a 3-carbon molecule. Pyruvate can be transported into the 
mitochondria through either diffusion or the mitochondrial pyruvate carrier (MPC). 
The existence of this transporter that has lead to some debate as to whether it is 
truly necessary for pyruvate transport, which is a topic that will be discussed 
some later in this chapter.  However, whether through diffusion or MPC, pyruvate 
will then translocate into the mitochondrial matrix where it will be further broken 
down into acetyl co-A by pyruvate dehydrogenase (PDH). During the 10 step 
glycolytic reactions that eventually produce pyruvate from glucose, 2 NADH 
molecules are generated as well as 2 ATP molecules.  
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There is a small subset of cells who produce the majority of their energy 
through glycolysis. One of the most documented and heavily researcher topic 
related to this are those cells who have undergone mutations, transforming them 
into cancer cells.  The scientific literature shows that cancer cells, which are 
primarily glycolytic, and have little to no mitochondrial contribution to their 
energetic profiles. These cells undergo a high rate of glycolysis followed by lactic 
acid fermentation, having very little contributions from mitochondria.  This is one 
of many situations in which different cells types as well as different regions within 
the body within the same cell type experience different metabolic profiles which 
arise as variations in mitochondrial bioenergetics. 
Another highly debated topic in terms of metabolic profiles of cells occur 
specifically within the brain tissue. It has been well accepted that the brain is 
considered immune privileged and is confined from the rest of the body by the 
blood brain barrier. The vasculature within the cranial vault is able to provide 
nutrients to the brain through either free diffusion of small lipid soluble molecules, 
like oxygen and carbon dioxide, or through active transport. Glucose is thought to 
reach cells within the brain through active transport by the GLUT1 or GLUT3 
transporters. GLUT transporters are enriched in astrocytes allowing for glucose 
to be favorably taken up by astrocytes and then broken down to pyruvate and 
then potentially lactate. Although this topic is heavily debated, it is thought that 
lactate is then transported from astrocytes to the neurons through the Astrocyte-
Neuron Lactate Shuttle, which was initially proposed by Pellerin and Magistretti in 
the late 90s [76-80]. Once lactate is shuttled into neurons, it can undergo a 
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dehydrogenation reaction with the assistance of lactate dehydrogenase (LDH) 
producing pyruvate. Pyruvate can then enter the mitochondria as mentioned 
previously. Differing opinions on this topic believe that neurons are able to take 
up glucose through the GLUT 3 transporter leading to the initiation of glyocolysis 
in a manner similar to what was described previously.  
Additionally, mitochondria can use byproducts of fatty acid oxidation, 
specifically fatty acetyl CoA, and urea cycle, specifically generating malate, as 
substrates for ATP production. These metabolic processes are often overlooked 
when energy to the brain is considered because traditionally glucose, and its 
derivative lactate, are considered the main energy source. However, it has been 
shown that up to 20% of the total brain’s energy is obtained through 
mitochondrial mediated fatty acid oxidation [81] . Additionally, in diseased states, 
such as following a traumatic brain injury, hypoglycemia is observed leaving cells 
within the brain to adapt to changes in glucose.  
Within this process a fatty acid molecule is shortened by 2 carbons for 
every turn of the fatty oxidation cycle, producing 1 acetyl coA molecule, 1 NADH 
molecule and 2 FADH2 molecules [82]. Additionally, the urea cycle has been 
found to be an important mechanism in the brain for the removal of free nitrogen. 
This cycle uses free ammonia in the body to feed into mitochondria at malate. In 
addition, this urea cycle seems to be an important mechanism when considering 
the generation of α-ketogluterate from glutamate, which is supported through 
GDH activity, since ammonia is given off a byproduct in this reaction. This 
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mechanism will be discussed later in this chapter, however is important to note 
when thinking about the entirety of mitochondrial related metabolism.  
Krebs Cycle  
Once the appropriate substrates have reached the mitochondrial matrix, 
the next important step in the metabolic process is initiation of the Krebs Cycle, 
also called the Citric Acid Cycle and the Tricarboxylic Acid Cycle. This is 
considered the central metabolic pathways for all aerobic organisms. The 
process begins with a 2 carbon compound, specifically acetate in acetyl coA, 
which is generated through the action of Pyruvate Dehydrogenase converting 
pyruvate. From acetyl coA, 8 chemical reactions completely oxidize the carbons 
to 2 carbon dioxide molecules, reducing NAD+ to NADH and generating 
succinate in the process. These two compounds can then be used as substrates 
within the electron transport chain, specifically at Complex I and Complex II 
respectively. Additionally, as mentioned previously, malate can be generated 
during amino acid oxidation feeding into the Krebs cycle during the 7th listed 
reaction and glutamate is fed into the Krebs Cycle through the activity of GDH 
producing α-ketoglurate (see below) 
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Figure 1.3 The Krebs Cycle: The multi-step Krebs cycle is the site where 
electron dense NADH and Succinate (FADH2) molecules are produced. These 
substrates can then donate their elections to either Complex I or Complex II, 
beginning a series of Redox which occur within the Electron Transport Chain. 
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Within the Krebs cycle, any of the intermediate steps can be substituted 
for molecules that are generated through processes outside of the Krebs Cycle. 
One important reaction which seems to have some importance when 
investigating the function of mitoNEET is the dehydrogenation reaction of 
Glutamate to α-ketogluterate by Glutamate Dehydrogenase. 
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Figure 1.4 Glutamate Dehydrogenase can produce α-ketogluterate: 
Glutamate Dehydrogenase (GDH) is able to condense glutamate into α-
ketogluterate while simultaneously generating an NADH molecule.  
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Glutamate Dehydrogenase (GDH) is an enzyme found in all organisms, 
however is specifically located in the mitochondria of humans. It catalyzes the 
reversible oxidative deamination of glutamate and H2O producing α-
ketogluterate and ammonia. α-Ketogluterate is then able to feed into the Krebs 
Cycle leading to more NADH for the electron transport chain and ammonia is 
then cleared from the mitochondria by the Urea Cycle. Interestingly, in lower 
order organisms, GDH is modulated through transcriptional regulation however 
in humans its modulation occurs through metabolites. Some important inhibitors 
are GTP, NADH, ATP and Zn2+ and some important activators include ADP 
and mitoNEET [83]. 
Traditionally speaking, PDH is thought to be the gatekeeper of 
mitochondrial respiration. However, with compelling evidence showing 
mitoNEET as a redox switch and showing mitoNEETs direct positive effects on 
GDH activity, it proposes a theory in that GDH mediates mitochondrial 
respiration through mitoNEET activity. This activity is inhibited in high oxidative 
states, such as during calcium cycling, leaded to decreased substrates feeding 
into the electron transport chain and therefore inhibiting state III mediated 
respiration.  
Electron Transport Chain 
The electron transport chain consists of a series of proteins that are 
located within the inner mitochondrial membrane, with the exception of complex 
II that is within the mitochondrial matrix. As mentioned previous, mitochondria 
have invaginations within their inner mitochondrial membrane which is called 
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cristae. Within these cristae there are the protein complexes that comprise the 
electron transport chain (ETC). The components of the ETC include complex I, 
II, III, IV as well as the mobile carriers, coenzyme Q10 and cytochrome C.   
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Figure 1.5 The Electron Transport System: The electron transport chain is 
the site for an overwhelming high production rate of ATP with respects to 
any other location in the cell. The ETC/ETS cycles through a series of redox 
reactions. This results in protons being pumped to the inner membrane 
space which generates a proton-motive force that is harnessed by Complex 
V to produce ATP.  
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As electrons are transferred through the electron transport chain, the 
redox potential of those electrons increase from -400mV, when they are 
associated with NADH, to 800mV which is where they terminate the process, 
associating with free oxygen. As the redox potential increases, the Gibbs Free 
energy decreases in the following manner: 
−Δ𝐺 = 𝑛𝐹∆𝐸 
Where n is the number of electrons being transferred, F is defined by 
Faraday’s Constant and ΔE is defined by: 
∆𝐸 = 	∆𝐸° +
𝑅𝑇
𝑛𝐹 ln
𝐴12 3	 𝐵567 3
𝐴567 3 𝐵12 3
For the following redox chemical reaction. 
𝐴567 +	𝐵12 → 𝐴12 +	𝐵567 
Within this equation, ΔE° = ΔE°(cathode) - ΔE°(anode) 
Within this process, the complexes act as an energy-conversion devices, 
using the free-energy to pump protons from the matrix into the inner membrane 
space.    
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Figure 1.6 ETS Energy Changes: This diagram provides the redox potential and 
the free energy changes that occur as electrons are cycled through the electron 
transport chain and protons are pumped into the inner membrane space.   
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Complex I 
As mentioned previously, once NADH is produced within the mitochondria 
it is able to diffuse to the site of the Electron Transport Chain (ETC), specifically 
to Complex I. Complex I acts as a “gatekeeper” or “entry point” of the ETC 
therefore serving as a direct link between glycolysis, the Krebs Cycle, fatty acid 
oxidation, GDH activity and the electron transport chain. It is often called NADH-
Ubiquinone Oxidoreductase, or NADH dehydrogenase, since it mediated the 
oxidation of NADH oxidation and the reduction of Ubiquinone. It is the largest 
catalytic complex within the electron transport chain having of mix of 45 nuclear 
and mtDNA generated subunits. Within this ~1000kDa structure are 7, out of the 
45, subunits that are encoded by the mitochondrial DNA (mtDNA).  Its molecular 
mass is little under 1000kDa and has a structure similar to a boot. The “foot” of 
this “boot” is hydrophobic and integrated into the inner mitochondrial membrane 
[84, 85]. This is the region which one would find the mtDNA encoded subunits. 
The “ankle” of this “boot” is hydrophilic and extends into the mitochondrial matrix. 
The exact coupling mechanism and structure of this protein is unknown 
however has been proposed by many scientists including Efremov [86]. Within 
the hydrophilic “ankle” region is the primary electron acceptor flavin 
mononucleotide (FMN) which is the initial redox site for the oxidation of NADH to 
NAD+. The electrons are then transferred strategically through seven conserved 
iron-sulfur (Fe-S) clusters, reaching the N2 cluster which is where the electrons 
are thought to then be transferred to the ubquinone binding site (Q-site). The 
hydrophilic region is also called NADH-ferricyanide reductase due to this exact 
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process. This Q-site is located at the interface of the membranous domain. The 
atomic structure of the hydrophobic region of complex I is unknown however 
within this region there are 3 well defined subunits (NuoL/Nqo12, NuoM/Ngio13, 
NuoN/Nqo14) which are homologous to one another and the Na+ or K+/H+ 
antiporter. It is thought that this is the site where proton translocation occurs 
however this too is debated. A scheme is provided below to better explain the 
previous process.  
The overall reaction that occurs at complex I is: 
NADH + CoQ + 5H+ à NAD+ CoQH2 + 4H+ 
In which NADH is converted to NAD+ by accepting an electron into the 
Fe-S center of the protein and then transferring them to coenzyme Q10 [87-91]. 
Historically, there are three well known inhibitors of Complex I that have 
been found to inhibit the reduction of ubiquinone. These inhibitors have been 
categorized into 2 to 3 different types depending on your source. This 
classification is dependent on kinetic studies including Class I/A-type, Class II/C-
type and C-type. Class I/A-type is represented by an antibiotic called piercidin A, 
Class II/B-type is represented by a fish poison called rotenone, and C-type is 
represented capsaicin [92, 93]. These inhibitors all seem to bind within the same 
relative region of the complex however the exact mechanism of action are 
seemingly different. Work from Fato found that the Class I and Class II, 
categorized into Class A, inhibitors have been shown to increase reactive 
oxygen species where the Class B, referred to as Class III/C-Type in other 
locations, leads to decreased ROS production. The mechanism of actions of 
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these inhibitors are important to know in order to A) further understand the exact 
structure of Complex I and B) to understand how mutations and toxins which 
effect the structure and function can lead to specific diseases.  
It is seemingly important to provide further clarification at this point. The 
use of mitochondrial inhibitors should not be confused with mitochondrial 
uncouplers. In the literature, the term uncoupler seems to be very freely. When 
using uncouplers, the redox reactions that occur within the electron transport 
chain persist, however the uncoupler in question depletes the membrane 
potential leading to no functionality at the ATP synthase, and therefore no ATP 
production. Specifically, uncouplers are able to unlink the redox reactions 
(electron flow) within the ETC from the  phosphorylation of ADP molecules at 
the site of the ATP synthase. During the use of uncouplers, the redox reactions 
within the ETC are generally running at maximum capacity in order to 
regenerate the concentration of hydrogen molecules within the inner membrane 
space. However, as these protons are pumped into this inner membrane space, 
they are immediately translocated back into the matrix, leading to no overall 
change in the membrane potential and no protonmotive force to run allow ATP 
synthase to function. On the contrary, when using mitochondrial inhibitors, this is 
a term that is specific for compounds that actually interact with proteins to stop 
their function, leading to a halt in the redox reactions at the ETC. For instance, 
rotenone is a commonly used Complex I inhibitor which will be discussed later in 
this document. Rotenone interacts with Complex I, inhibiting the flow of electros 
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through the complex. This leads to no electrons entering the ETC and therefore, 
no functionality of the ETC.  
ROS production is seemingly a hallmark of Complex I activity. It has been 
well documented that Complex I is one of the main sites of the production of 
reactive oxygen species for the ETC [94]. Within this complex, electrons are at 
their highest relative potential compared to any other site within the ETC. It is 
thought that this high potential leads to increased electron leak within the 
complex. As electrons leak out of the complex, they are able to bind to free O2 
generating superoxide anions. These anions can be neutralized by antioxidant 
defense mechanisms such as the mnSOD (manganese superoxide dismutase) 
however at times they are able to evade this mechanism and damage nearby 
proteins. The exact site of this electron leak is unknown however strong 
evidence has been proposed by Fato that it occurs at the N2 cluster mentioned 
previously, which is the site immediately before the electron is transferred to 
ubiquinone. However, contradicting evidence has also been proposed 
implicating ubisemiquinone, FMN, and the iron-sulfur cluster N1a as contributor 
to ROS. 
In addition to the damage that ROS can do to nearby proteins, mtDNA 
can also become damaged due to the havoc wrecked by ROS production. It is 
thought that throughout the life of an organism somatic mutations to 
mitochondrial DNA accumulate due to years of ROS, as well as RNS (reactive 
nitrogen species), mediated damage. This DNA damage leads to the production 
of damages proteins. Since Complex I has 7 subunits encoded by the 
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mitochondrial genome, it is thought that this protein takes the largest hit, leading 
to increased electron slippage. This theory is terms the “Mitochondrial Theory Of 
Aging” which will be discussed in more detail in Chapter 2. 
Complex II 
Complex II (Succinate:Ubiquinone Oxidoreductase), also referred to as 
Succinate Dehydrogenase), utilizes the conversion of succinate to fumarate to 
generate FADH2 from the FAD (flavin-adenine dinucleotide) coenzyme. This is 
the only Complex within the ETC that is also an integral part of the Krebs cycle, 
being utilized in the 6th chemical reaction where succinate is converted to 
fumarate [95].. This complex has a covalently linked FAD molecule within it. 
Once in contact with Succinate, electrons are donated to the FAD molecule, 
generating FADH2. From the production of FADH2, electrons are then 
transferred sequentially between 3 different Fe-S groups until reaching the 
membranous location of Complex II. At this point the electron is passed to heme 
b group (CybL-CybS) and then transferred to ubiquinone. This is the only 
complex within the ETC that does not contribute to the membrane potential 
discussed previously since there is no translocation of protons from the matrix to 
the IMS, making it a less energetically favored process compared to Complex I.  
The overall reaction generated by this complex is 
Succinate + Q ⇔ Fumarate + QH2 
Where Q is ubiquinone and QH2 is ubiquinol, the reduced form of 
ubiquinone.  
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Complex III 
Complex I and II transfer their electrons to Ubiquinone (Coenzyme Q10) 
located within the IM. Complex III is the next player in this process which 
oxidizes Ubiquinol producing Ubiquinone (Ubiquinol-Cytochrome-C 
Oxidoreductase) eventually reducing Cytochrome C via the protonmotive Q-
cycle. This complex is much smaller than Complex I containing only 11 subunits, 
3 of which are respiration subunits (cytochrome B, cytochrome C1 and Reiske 
protein which is an Fe-S cluster), 2 which are core proteins and 6 are low- 
molecular weight supporting proteins. 
2 electrons are transferred to Complex III when Ubiquinol is oxidized to 
Ubiquinone. One of these electrons is transferred onto the 2Fe-2S group of the 
Rieske center. Rieske proteins are a specific iron-sulfur proteins found within 
cytochrome bc1 and cytochrome b6f complexes. From this center, electrons are 
able to transfer to the heme group of Cytochrome C1 and then picked up by 
cytochrome c and diffuses to Complex IV. The other of the 2 electrons is 
transferred onto a heme group in cytochrome b before being transferred to a 
ubiquinone molecule. This leaves ubiquinone in a partially reduced form 
generating a semi-ubiquinol radical. Then, a second ubiquinol molecule diffuses 
to complex III donating its electrons in a similar manner. Now, the semi-
ubiquinol molecule can gain a second electron resulting in the production of 
another ubiquinol and the process repeats itself. During this process, 2 ubiquinol 
molecules are used to translocate 4 protons from the mitochondrial matrix to the 
inner membrane space.  
 31 
The overall reaction that occurs at the site of complex III is 
QH2 + 2Cyt C3 + 2H+ ⇔ Q + 2Cyt C2 + 4H+
As mentioned previously, Complex I contributes to a large amount of the 
electron leak that occurs within ETC. However, Complex III also contributes to 
this electron leak. It is thought that approximately 1 to 2% of the O2 used within 
the mitochondria is due to this electron leak [2, 96].  It has been discovered that 
the within the center of Complex III is a high reduction potential chain called Q0 
which contains the Rieske protein (Fe-S cluster). This is the site in which the 
majority of electron slippage is thought to occur.  
Complex IV 
As the last step in the ETC, Cytochrome C transports its electrons to 
Complex IV (Cytochrome-C Oxidase). Because of its position within the ETC, 
Complex IV is often considered a major regulator of Oxidative Phosphorylation. It 
is made up for 13 subunits which is contributed to by both nuclear (10 proteins) 
and mitochondrial (3 proteins) encoded proteins [97]. It is thought that the 
nuclear encoded proteins primarily regulate oxygen consumption and proton 
translocation and the mitochondrial encoded proteins are the catalytic sites.  
There are 4 redox-active centered within Complex IV. Listed in the order 
of function, CuA, heme a (Fea), heme a3 (Fea3) and CuB. CuA is initially reduced 
by cytochrome c. From here the electron travels to Fea and then enters the 
“catalytic” site of the complex (where Fea3 and CuB are located) where free 
oxygen is reduced eventually leading to the production of H2O. During this 
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process 2 protons are pumped from the mitochondrial matrix to the inner 
membrane space. 
The overall chemical reaction for Complex IV is 
4 Fe2+-cytochrome c + 8 H+ + O2 → 4 Fe3+-cytochrome c + 2 H2O + 4 H+ 
In which electrons are given off by a reduced form of cytochrome c, 
translocate through the complex until they reduces free oxygen and eventually 
produces H2O. During this process, H+ ions are pumped into the inner 
mitochondrial space helping to contribute to the membrane potential, which will 
be used by Complex V/ATP Synthase to generate ATP molecules.  
ATP Synthase 
Following the contribution of an NADH molecule and consequently 2 
electrons being donated to the ETC, 10 protons will be translocated into the IMS. 
As we know, the ETS is continuously cycling and therefore protons are 
continuously being pumped out of the matrix. As the concentration of protons 
within the IMS increases, a multi-component proton-motive force is generated 
having both a differential pH and an electrochemical gradient leading to a 
membrane potential (ΔΨ) [98]. This high energy environment is utilized by 
Complex V (ATP Synthase) to facilitate the phosphorylation of ADP into ATP. 
Complex V, like the other Oxidative Phosphorylation Complexes, is 
located, partially, within the inner mitochondrial membrane. It has multiple 
subunits which are contributed to by both nuclear and mitochondrial genes. In 
addition to having multiple subunits, this complex also has multiple domains 
including the Fo domain, the F1 domain and the stalk/accessory domain. The Fo 
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domain is the hydrophobic domain located within the membrane. This domain is 
often referred to as the “motor” of the complex. It has 1a, 2b and 12c (debated 
10-15c) subunits [99]. The c subunits are aligned in a ring shape forming the
proton channel that funnels the protons from the IMS to the F1 domain. These c 
subunits are thought to interact directly with the F1 domain to regulate proton 
flow and consequently ATP production [99].  
As mentioned previously, the Fo domain is often thought to be the motor 
of the complex. When the c-ring rotates, being “pushed” by the high-energy 
proton-motive force mentioned previously, it causes movement of the γ subunit 
within the F1 domain, which is attached to the c-ring. The ε subunit causes a 
confirmation change in the α and β subunit within the F1 domain. As these 
confirmation changes occur, it opens the α and β subunit to the matrix allowing 
the diffusion of ADP and Pi into the catalytic region of these subunits. Then, the γ 
subunit rotates again causing the condensation reaction for ADP + Pi to ATP 
generation. The next rotation of the γ subunit causes a third confirmation change 
to the α and β subunit which opens the site to the matrix again. This allows ATP 
to flow out and ADP + Pi to diffuse in, repeating the process [100].  
In addition to the Fo and F1 subunit, there is also an accessory/shaft 
domain which includes an Oligomycin Sensitivity Conferring Protein (OSCP) 
subunit. This is the site where a bacterial antibiotic called oligomycin interacts.  
When oligomycin binds to this OSCP subunit, it inhibits the rotation within the Fo 
domain and consequently blocks the catalytic site of the F1 subunit leading to a 
complete inhibition of the ATP Synthase [101].  
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Figure 1.7 ATP Synthase: A diagram of Complex V/ATP Synthase including 
the subunits where were specified previous within the text. 
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Chemiosmotic Coupling 
Properly defined, the principal of Chemiosmotic Coupling is based upon 
the physical chemical property called Chemiosmosis. Chemiosmosis is the 
physical movement of ions from a highly concentrated region to a lower 
concentration region when these regions are separated by a selectively 
permeable membrane. This process requires the use of a transport protein since 
the ions in question are not permeable across the selectively permeable 
membrane. This principle is analogous to the principles of osmosis however as 
opposed to the flow of water, chemiosmosis concentrates on the flow of ions. 
Within the mitochondria, these ions are protons. In 1961, Dr. Peter Mitchell was 
awarded a Nobel Prize for defining this process which is harnessed to make ATP 
within mitochondria and provides a physical chemical understanding to the ETS.  
Within mitochondria, Complex I, III, and IV use the energy rendered by 
local redox reaction to pump hydrogens into the IMS. These protons within the 
IMS are not permeable through the inner membrane, which is the selective 
permeable membrane in question. The ATP Synthase/Complex V then uses the 
principles of Chemiosmosis to provide the energetics necessary to generate the 
high energy ATP molecules. 
ROS Production 
Although OXPHOS is an amazing process, it does have the propensity to 
create toxic byproducts. Because of this, mitochondria are not only known as 
the cell’s power plant but they are also known as one of the cell’s major supplier 
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of Reactive Oxide Species (ROS) and Reactive Nitrogen Species (RNS). During 
OXPHOS, complex IV will release an electron to molecular oxygen (O2) allowing 
for the eventual formation of H2O. However, electrons “slippage” can also occur. 
This occurs as a result of inefficiencies within primarly Complex I and III, 
however slippage also occurs at Complex IV. Once an electron slips, or is 
released, from the ETC, it can reduce O2 and/or react with proteins, nucleic 
acids and fatty acids within the mitochondria and mitochondrial membrane 
leading to damage. This process is often referred to as metabolic mediated 
oxidative damage.  
Following slippage of an electron from the ETC, mitochondrial 
manganese superoxide dismutase (MnSOD, SOD2) which is a mitochondrial 
located metalloenyzme that is a crucial for the dismutation of this highly reactive 
O2•− into H2O2, can neutralize any reactive O2•− formed. This protein is located 
within the mitochondrial matrix, within the vicinity of the ETC. However, H2O2 is 
also a strong oxidizing agent and therefore needs to be further neutralized. 
Glutathione peroxidase, which is also located within the mitochondria, is then 
used to convert H2O2 into neutral H2O [102, 103].  
The mechanisms used to neutralize of these toxic byproducts are very 
efficient however even with them in place the cells within the brain still seem to 
be more vulnerable to oxidative stress compared to other tissues. This has been 
attributed to the fact that the brain is a high energy organ that consumes 
approximately 20% of the body’s total oxygen and has naturally lower levels of 
endogenous antioxidant activity relative to other tissue [104-106]. Neurons have 
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high energy demands compared to other cell types. The Na+/K+ ATPase pumps 
located within their cellular membrane function to maintain the membrane 
potential necessary for action potentials to be generated. It is estimated that 1/3 
of the entire body’s ATP production in 1 day is used by these pumps [107]. Due 
to the fact that neurons primarily use mitochondrial oxidative phosphorylation to 
generate their ATP pools, they produce more metabolic mediated oxidative 
stress which can be detrimental to the cell over time. 
Calcium Cycling 
In addition to producing 95% of the cell’s energy currency, ATP, and being 
a major source of oxidative stress, mitochondria also play an integral role in the 
buffering of cytosolic calcium. This is important since calcium is a potent 
intracellular signaling molecule which has beneficial and detrimental roles in 
neurons. In the brain during normal cellular interactions, neurons become 
activated following the binding of various neurotransmitters to their respective 
metabotropic and/or inotropic receptors. One interesting neurotransmitter that 
has been implicated in the calcium signaling pathway and has an important role 
in the secondary injury cascade of TBI is glutamate. Glutamate binds many 
receptors but one of importance when discussing calcium cycling is the α-amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor, also known as the AMPA
receptor. Voltage dependent Na+ channels within these same synaptic densities 
can also activated by glutamate. Once glutamate is bound, these ionotropic 
receptors move to an open confirmation leading to the influx of Na+ causing a 
local depolarization. This local depolarization leads to the displacement of the 
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Mg2+ blockage in the N-methyl-D-aspartate receptor, NMDA receptor. Once 
removed, the NMDA receptor has a higher probability of being in an “open” 
confirmation allowing Calcium to enter the neuron.  
As the NMDA receptors remain in an open confirmation, Calcium will 
continue to enter the neuron. At lower concentrations, this Calcium has been 
shown to regulate neurotransmitter release within the synaptic cleft. Also, as 
transient increases in cytosolic Calcium level occur, mitochondria sink Calcium in 
an electrogenic fashion, removing the ions from the cytosol. These increased 
Calcium levels within the mitochondria have been shown to directly regulate the 
Krebs cycle through activation of pyruvate dehydrogenase, PDH, NAD+-
dependent isocitrate dehydrogenase, ICDH and α-ketoglutarate dehydrogenase 
complex, KGDHC. Activation of these various metabolic proteins all leads to 
increased NADH production, which can, in turn, generate increased ATP 
production by the ETC.  Calcium mediated activation has also been shown to 
increase Complex V (ATP Synthase) activity resulting in increased ATP 
synthesis as well [108, 109].  
In addition to the direct effects of Calcium within the mitochondria, these 
ions also have indirect effects which is equally as important to mitochondrial 
function and therefore cellular metabolism. As mentioned previously, the ETC 
generates a negative membrane potential, ΔΨ, within the mitochondria. Calcium 
uniporters, located in the inner mitochondrial membrane, use this ΔΨ generated 
by the ETC to pump calcium ions down their electrochemical gradient into the 
mitochondrial matrix. As the calcium uniporters continue to translocate calcium 
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into the matrix, the ΔΨ diminishes leading to further activation of the ETC in an 
attempt to restore the depleted potential. This process provides an intimate 
relationship between mitochondrial bioenergetics, calcium homeostasis and ATP 
production. This same mechanism can eventually lead to mitochondrial 
dysfunction when calcium levels become too high. In many diseased state, such 
as following an injury to the CNS, calcium dysregulation is often observed. This 
can lead to electron slippage at the site of the ETC and pathogenic decreases in 
mitochondrial membrane potential. In the process, oxidative stress increases 
which can inititate the formation of the mitochondrial permeability transition pore, 
mPTP. 
Mitochondrial Permeability Transition Pore 
Healthy mitochondria generally maintain a Nernstian membrane potential 
of around 180mV. As mitochondrial matrix Calcium concentrations, oxidative 
stress and damage to ETC proteins increases, this ΔΨ can become depleted. 
Once around ~100-120mV, the ETC will begin to slow down, stop and potentially 
start running backwards.  Once this occurs, ATP production will decrease and if 
the ETC begins to run backwards, then ATP will be consumed by the ATP 
synthase\Complex V. Not only will this lead to decreased ATP stores but 
generates ROS and RNS [110]. The increase in ROS and RNS can then lead to 
increased oxidative damage within the mitochondria. Mitochondrial dysfunction is 
further exacerbated as the damage to lipid, protein and nucleic acid modifications 
continues. Eventually, the redox potential within the mitochondria changes and 
crucial mitochondrial proteins like adenine nucleotide translocator (ANT) undergo 
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oxidative modifications. This occurs specifically as a thiol oxidation on ANT 
resulting in a conformational change that promotes cyclophilin D (cypD) binding. 
Once ANT, an inner membrane mitochondrial protein, is bound to cypD, an 
appropriate conformational change occurs in order to promote ANT, cypD, and 
many other proteins within the complex to bind with voltage-dependent anion 
channel, VDAC [111-113]. VDAC is an outer membrane mitochondrial protein 
that once bound to this inner mitochondrial membrane protein complex, including 
Cyclophilin D, ANT, and many other proteins, forms the mitochondrial 
permeability transition pore, mPTP. The formation of the mPTP is a heavily 
debated topic with many models proposed. This specific mPTP description is the 
classic model which provides a good foundation for some of the therapeutic 
approaches which will be discussed further in Chapter 2. 
Whatever model you prefer for the mPTP formation, once formed the pore 
exposes the inner mitochondrial matrix to the cytosol, allowing the mitochondria 
to release apoptotic initiating factors like Cytochrome C, SMAC/diablo and AIF 
which all promote cell death. Additionally, mitochondria can also initiate another 
route of cell death called necrosis. This occurs as a result of ion concentration 
difference, like chlorine, across the mitochondria membrane. These ionic 
concentration differences allow water to freely diffuse cross the mitochondria 
membrane as a result of osmosis. As this perpetuates, swelling of the inner 
membrane occurs due to osmotic pressure, ATP production decreases due to 
dysfunction within the ETC, the mitochondrial membrane potential decreases and 
oxidative stress to increases. This causes a complete destruction of the 
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mitochondria as a result of the swelling of the inner mitochondrial membrane. 
Eventually these mitochondria will burst leading to the initiation of cell death.  
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Figure 1.8 The mechanisms of mitochondrial mediated cell death: 
Mitochondrial mediated methods to cellular death. This figure was adapted from 
[108] 
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Redox Sensitive Switch in Mitochondria 
In terms of history, to date, research related to mitochondrial homeostasis 
or dysfunction in various disease states is flourishing. Following the generation 
of a specific group of PPAR ligands called thiazolidinediones, TZDs or glitazone, 
which will be discussed at the end of chapter 3 and within chapter 4, a novel 
mitochondrial membrane protein was discovered (2004). This protein was found 
to bind to a specific TZD which is FDA approved for type 2 diabetes called 
pioglitazone. This novel mitochondrial membrane protein was termed mitoNEET 
due to its CDGSH-type zinc finger domain which actually binds iron, as opposed 
to zinc. mitoNEET has been labeled as an outer mitochondrial membrane 
protein however from the same report that published the work, it was found to 
have a localization within the inner mitochondrial membrane as well.  
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Figure 1.9 Location of mitoNEET is not just the outer mitochondrial 
membrane: Work from Wiley showing the mitoNEET is located within the outer 
membrane however can also be found in the inner mitochondrial membrane 
[114]. This figure was edited from [76] showing the presence of mitoNEET within 
inner membrane fractions.  
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Further supporting the notion that mitoNEET can also be localized within 
the inner mitochondrial membrane is work from Roberts et. al. at Eastern Illinois 
University. They found that mitoNEET is able to bind to Glutamate 
Dehydrogenase I (GDHI), which is a protein located in the mitochondrial matrix, 
and that this interaction leads to increased GDHI activity [83]. Additionally, within 
the work, mitoNEET was found to form homodimers proposing a mechanism is 
that mitoNEET binding GDHI leads to increased GDHI activity however in 
oxidized states mitoNEET can homodimerize leading to decreased GDHI activity 
[83]. Recent work from Landry also found that once oxidized, glutathione 
reductase is able to reduce mitoNEET back to its original structure, in theory 
rendering it active again [115].  
As mentioned previously, mitoNEET will be discussed further in the 
following chapters, however this protein has become of great interest to 
researchers who investigate redox shift within mitochondria. Due to its structure, 
which contained Fe-S clusters, this protein is structured perfectly to react to 
changes in redox state. Additionally, mitoNEET has also been shown to mediate 
mitochondrial respiration, allowing for the hypothesis that this protein would be 
able to sense possible harmful changes in redox and inhibit respiration to avoid 
damage to inter-mitochondrial proteins. This is a novel idea which will be 
expanded upon later in this document.  
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Methods Used to Measure Mitochondrial Respiration 
Prior to 1944, when Albert Claude published the first recipe for the 
appropriate buffers to isolate mitochondria, the field of mitochondrial studies were 
heavily based on microscopic studies. Upon the isolation of healthy, viable, 
respiring, well coupled mitochondria, many more studies could be done. Some of 
these initial methodologies are still used till this day.  
As mentioned previously, mitochondrial oxidative phosphorylation couples 
the use of oxygen, which is reduced to water at Complex IV, to the 
phosphorylation of ADP, which occurs at Complex V. Therefore, the rate at which 
oxygen is consumed by mitochondria will give insight into the bioenergetics, 
which is specific for the substrate given to allow the mitochondria to respire. 
Clark Electrode/Oxytherm 
In order to measure the amount of oxygen used by mitochondria, a 
method for measuring small changes in oxygen within a liquid had to be 
discovered. This was done by Leland Clark in 1953. Know as the “Father of 
Biosensors”, Dr. Clark used a Ag/AgCl electrode and a Pt cathode separated by 
a KCl electrolyte to measure oxygen within a sample. The principles of this 
design were adapted in 1972 by Hansatech Limited, a electronic company, 
located out of King’s Lynn in Northern Europe. Within this device, a potentiating 
voltage is applied across two electrodes. This causes the platinum to become 
negative and the silver to become positive, generating a cathode and anode 
respectively. These surfaces are then covered with a thin layer of KCl solution 
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and an oxygen permeable membrane. As oxygen diffuses through the 
membrane, it is reduced by the platinum allowing for a current to flow through the 
KCl solution. The silver is then oxidized and silver chloride is deposited on the 
anode. Figure 1.10 shows images of an oxytherm electrode being prepared and 
a diagram to indicate the importance of each component within the electrode.  
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Figure 1.10 Clark Electrode: Building the electrode is an important step 
when using the oxytherm. The electrode has a platinum cathode and silver 
anode within the device. A drop of KCl buffer is added to the top of the 
cathode and anode and then a piece of cigarette paper is added to the top of 
the electrode, which should have contact with the cathode and anode, in 
order to build the appropriate KCl bridge. A piece of Oxygen Permeable 
Membrane is then added to the top of the electrode and secured in place 
with a rubber o-ring.  
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The chemical reaction that occurs are each cell is as follows: 
At the platinum cathode:  
O: + H:O + 2e> → H:O: + 2OH> 
H:O: + 	2e> → 2OH> 
At the silver anode: 
4Ag	 → 4AgB + 4e> 
4AgB + 4Cl> → 4AgCl 
As one may notice, this leave 4AgCl as an end product. This does occur 
and leads to accumulation on the anode which has to be removed overtime. 
[116] 
Once the electrode is “built”, it is attached to a cord and the corded 
electrode is secured within the back of the Oxytherm Electrode Control Unit. The 
signal from the electrode then travels through the cord to the control unit where it 
is converted into a digital readout that is then read by the computer.  
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Figure 1.11 The Hansatech Oxytherm: The Oxytherm which is where the 
electrode from figure 1.10 is secured. Mitochondria with respiration buffer 
are placed within the chamber and the electrode is placed on the underside 
of the chamber. This allows the electrode to measure the change in oxygen 
content within the mitochondrial slurry located within the chamber. 
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Seahorse 
Another novel device that has gained increasing popularity over the last 
few years as a tool for measuring mitochondrial bioenergetics is the Seahorse 
Bioscience Flux Analyzer. This device uses an 8, 24 or 96 well microplate 
allowing the researcher the ability to measure multiple sample at one time. 
Similar to the Oxytherm, this device measures oxygen within a slurry however 
the measurement techniques are different and therefore allow for the 
measurement of the proton concentration as well. The Seahorse disposable 
assay kit has two parts. The first part is the sample cell culture microplate which 
is where your 5-10ug of mitochondrial protein are placed in approximately 500uL 
of respiration buffer (recipe provided in the methods section). The second portion 
of the cartridge is called the solid state biosensor cartridge. This cartridge has 
four injection ports and two biosensor sleeves per well. The four injection ports 
allow for the injection of 4 different mitochondrial substrates or drugs per well for 
your study. The biosensor sleeves are strategically placed in the center of the 
four ports and are the site at which oxygen, and proton, levels within the 
mitochondrial sample are measured.  
At the base of each sleeve are patented polymer embedded fluorophores. 
The oxygen biosensor quenches in the presence of oxygen and the other 
flurophore is sensitive to protons. As the substrates or drugs from the ports are 
injected, the mitochondria within the sample begin to respire respectively. This 
leads to a signal which is read by optic fibers within the actual seahorse machine. 
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Figure 1.12 Seahorse Diagram: Representative figures of the Seahorse 
Bioscience Flux Analyzer with the Biosensor Cartridge, microplate, polymer 
fluorphores and fiber optics (within the Seahorse) where the signal is read.  
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Pros and Cons of Both Methods 
Although both methods are efficient at measuring mitochondrial 
bioenergetics, depending on the experiment that one is running, one method may 
be superior to the other.  
Oxytherm 
Pros 
1. Allows for intricate studies where drug or substrate
concentrations can easily be adjusted throughout the
experiment.
2. No Limit on the number of substrates added.
Cons 
1. Requires 50-100ug of mitochondrial protein.
2. Can only run one sample per Oxytherm device. *Multiple
Oxytherm devices can be run in serial order
3. Takes approximately 15 minutes per sample
Seahorse: 
Pros 
1. Can run 8, 24 or 96 samples at one time.
2. Only requires 5-10ug of mitochondrial protein.
3. Takes approximately 37 minutes to run each plate, see table
in methods section for specific details.
Cons 
1. Only has 4 injection ports
 54 
2. Cannot vary any of the experiment once the plate is placed
in the Seahorse
3. If too much mitochondria or substrate is added during the
loading process of the plate, the reliability of the OCRs are
lost. This requires further calculations after the experiment is
run.
Copyright © Heather Marie Yonutas 2016 
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CHAPTER 2: MITOCHONDRIAL FUNCTION VARIES WITH AGE AND TISSUE 
TYPE 
 
 As discussed in Chapter 1, mitochondria are extremely important for 
normal cellular metabolism, ATP production, calcium cycling and the mediation of 
cell death. These functions lead to overall cellular homeostasis and, therefore, 
proper cellular function. When observing mitochondrial function however, it is 
important to consider the cellular environment of those specific mitochondria. It 
has been shown that mitochondria found in one tissue type may not act the same 
as mitochondria in another tissue type, such as spinal cord mitochondria 
compared to cortical tissue mitochondria or liver mitochondria. Additionally, even 
mitochondria within the same cell type, such as synaptic versus non-synaptic 
regions of a neuron, seem to exhibit different bioenergetics. To further confound 
this topic, in many diseased states mitochondrial dysfunction has been observed. 
Aging is one culprit which can lead to increased cellular damage resulting in 
cellular dysfunction. Throughout this chapter, the effects of aging within brain 
derived mitochondria and how these changes become more apparent within 
specific tissue types will be discussed. Additionally, from the research it seems 
as if TBI mediated mitochondrial dysfunction may mimic accelerated forms of the 
mitochondrial theory of aging. This is important because it proposes a 
therapeutic use of the pharmacological agents used to target the cellular and 
mitochondrial dysfunction related to pathological aging states to assist with TBI 
related dysfunction as well.  
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Age Related Changes in the Brain 
Throughout a person’s life, their brain is constantly undergoing structural 
changes. Imaging studies in humans have repeatedly shown that aged brains 
have decreased gray and white matter and enlarged ventricles [117-119]. 
However, surprisingly, these age related changes in brain volume do not seem to 
be due to a loss of neurons but are seemingly the result of shrinking neurons, 
reduced synaptic spines, decreases in synapses and changes in myelination 
[119-128].  As these structural changes in the brain occur, functional changes 
also ensue. With age related structural changes, the functional changes 
observed are generally thought to result in a deficit. For instance, reduced 
cognitive abilities, such as processing speed, attention, executive functions, and 
episodic memory, are all commonly seen in healthy aging [129-134]. In a large 
population these age related functional deficits can progress into a 
neurodegenerative disease states like Alzheimer’s Disease (AD).  
With age related structural and functional changes, increasing evidence 
has provided strong support that specific cellular changes occur in brain as well 
[135-138]. The cellular changes observed are thought to be linked to the 
anatomical and functional changes that occur in the aging brain. Some of the 
most common cellular changes observed with age are the oxidative damage of 
lipids, proteins, RNA and DNA. In the 1950’s, a researcher at the University of 
Berkley, Denham Harman, proposed a compelling mechanistic link between the 
functional and cellular changes observed with aging. At the time, Dr. Harman had 
conducted years of radiation experiments, which is known to induce free radicals 
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and therefore cause damage.  During these studies he also observed metabolic 
changes that were similar to what was seen in aging. With these findings he 
hypothesized that with aging free radical damage accumulated, similar to what 
was seen with radiation treatment. The years of accumulating free radicals 
eventually resulted in oxidative damage to intracellular components leading to 
cellular dysfunction and changes in metabolism. This theory became the 
foundation for the Free-Radical Theory of Aging (FRTA) [139] and provides a 
mechanistic link between oxidative damage, cellular dysfunction, changes in 
metabolism and age. To further support this theory, studies of human autopsy 
tissue show higher levels of oxidative damage to nucleic acids [140-142], 
proteins [141, 143-146] and lipids [142, 146, 147] in aged brain as compared to 
young brain and changes in brain metabolism has been linked to various age 
related disease [148-150]. 
As mechanistic studies into the sources of oxidative stress progressed, 
Chance et al showed that the mitochondrial electron transport chain was a 
source for the production of reactive H2O2 which is a strong oxidizing agent, 
which was mentioned earlier [151]. Further expanding upon these findings, it was 
also found that the H2O2 produced was a product of MnSOD converting O2•- to 
H2O2 [2, 152-154]. As mentioned previously, SOD2 is now knows as a 
mitochondrial located metalloenyzme that is a crucial for the dismutation of highly 
reactive O2•- into H2O2 and O2 [155]. This was an important finding for two 
reasons: One: It proved mitochondria were an important site for ROS production. 
Two: It proved, for the first time, that oxidative stress was linked directly to 
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metabolism. As mentioned previously, in normal metabolic processes, ROS and 
RNS are produced. [156-159]. In a healthy system, after production, these 
reactive species are immediately neutralized, avoiding deleterious 
consequences. However, if not neutralized, they can diffuse away from the site of 
production and damage proteins, lipids, DNA or RNA [156].  
With the production of ROS and RNS being understood as a byproduct of 
OXPHOS, Harman expanded upon FRTA to acknowledge mitochondria as the 
major source of oxidative stress within a cell. He modified FRTA to the 
mitochondrial free radical theory of aging (MFRTA) [139, 160]. Linking age 
related functional deficits to the function of an organelle became an important 
turning point in the study of aging. As the “powerhouse” of the cell, mitochondria 
are extremely important organelles for normal cellular homeostasis [7]. 
Interestingly, within anaerobic cells and tissues, 90% of oxygen consumed is 
used by mitochondria. Mitochondria primarily use this oxygen for the production 
of ATP during oxidative phosphorylation within the electron transport chain. In 
most aerobic healthy cells, mitochondria are the main source of the reactive 
oxygen species (ROS) produced [160-163]. However, due to the high production 
of ROS, mitochondria are extremely vulnerable to oxidative damage [164]. Well 
aligned with MFRTA is the understanding that one of the primary hallmarks of 
aging is mitochondrial dysfunction [161, 165]. The literature suggests that 
mitochondrial function is compromised with age in the human brain [158, 159, 
166, 167]. In normal aging, mitochondrial respiratory chain activity declines [168], 
mitochondrial metabolism-associated enzymatic activity such as aconitase 
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decreases [169] and the rate of somatic mitochondrial DNA (mtDNA) mutations 
increases [14, 170].  
MFRTA was the first theory of its kind to acknowledge a possible link 
between mitochondrial oxidative phosphorylation, ROS production, cellular 
damage and functional deficits related to aging [171]. In this theory, it is proposed 
that mitochondrial produced ROS will diffuse away from the site of production to 
damage proteins and mtDNA. This leads to increased damage to proteins within 
the ETC, resulting in continually increased ROS production as electron slippage 
occurs by the damaged proteins [15, 172]. Therefore, mitochondrial dysfunction 
and the production of ROS, combined with lower endogenous antioxidant activity, 
may lead to increasing oxidative damage to molecules critically important to 
neuronal function. The combination of mitochondrial dysfunction and production 
of ROS may be a key contributor to the deleterious effects of aging on the brain 
[14, 167, 173-179].  This mitochondrial dysfunction can lead to increased 
oxidative stress, changes in protein processing and changes in metabolism. 
Although there is evidence arising that contradicts the Dr. Harman’s MFRTA, 
there are still many supporters [171], This will be the mechanistic foundation 
used in this chapter to explain the deficits seen related to aging and the 
therapeutic rational for antioxidants and mitochondrial co-factors to improve 
aging and decrease the onset of cognitive disorders. 
Age Related Cellular Dysfunction as a causation for Neurodegenerative 
Diseases 
 
Many diseased states are thought to be precipitated by increased 
oxidative stress within the cell causing damage and consequently dysfunction. 
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This is congruent with the MFRTA which was discussed earlier. Further 
elaboration on this theory helps to explain the pathology seen in Alzheimer’s 
Disease [180] since oxidative damage has specifically been linked to age-
associated neurodegenerative diseases such as Alzheimer’s disease (AD) [181-
183]. AD is a progressive neurodegenerative disease that causes dementia in 
the elderly, affecting an estimated 5.5 million people in the United States [184]. It 
is characterized by the accumulation of beta-amyloid (Aβ) in extracellular senile 
plaques and intracellular hyperphosphorylated tau protein in neurofibrillary 
tangles [185].  Consequently, extensive neuron loss is observed in the AD brain 
in the cortex and particularly within the hippocampus, a region of the brain 
involved with memory.  In an AD affected brain, further increases in oxidative 
damage to protein [141, 144, 145, 186-193], lipid [142, 147, 194-197], DNA [198-
200] and RNA [175, 201, 202] are seen relative to elderly controls.  In addition,
endogenous antioxidant activity in the AD brain is reduced relative to age-
matched controls [141, 146, 203]. Proteins particularly vulnerable to oxidative 
damage have been identified by proteomics, with a subset of these proteins 
putatively involved directly or indirectly in the production and accumulation of AD 
neuropathology [204].  
Mitochondrial dysfunction also occurs in AD, with decreased respiratory 
chain activity [177, 205, 206] and increased mitochondrial DNA mutations [207] 
observed at higher rates when compared to age-matched controls. Further, 
decreased cytochrome oxidase activity in the posterior cingulate cortex of AD 
patients is correlated with hypometabolism seen by positron emission studies 
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[149]. A gene array study in the cingulate cortex shows that energy-metabolism 
related genes decrease in AD, with a 65% reduction in expression of 
mitochondrial electron transport chain genes [148].   
The mitochondrial dysfunction related to AD is further explained in the 
literature by a theory called the “Calcium hypothesis of AD”. As mentioned 
earlier, mitochondria are bioenergetically active due to the maintenance of a 
membrane potential that is primarily generated by the electron transport chain. 
As a result of this membrane potential, mitochondria are the cell’s best Calcium 
buffering mechanisms. As Calcium enters the cell, mitochondria are able to 
quickly uptake the Calcium in an electrogenic fashion. In the Calcium hypothesis 
of AD, mitochondria are inherently dysfunctional, therefore hindering their ability 
to generate the membrane potential necessary to properly buffer intracellular 
calcium. As cytosolic Calcium levels remain high, signaling cascades that affect 
synaptic stability and function are initiated, such as the activation of calcineurins 
and calpains, leading to detrimental neuronal health [208]. Based on the MFRTA, 
the initial mitochondrial dysfunction that inhibits proper Calcium buffering is the 
result of mitochondrial oxidative stress within the electron transport chain leading 
to diminished membrane potential.  Without the generation of an appropriate 
membrane potential, mitochondria are unable to buffer calcium. 
Based on these mechanistic theories that eloquently link mitochondrial 
function, oxidative stress and metabolism to aging and AD, diet seems to be an 
important factor in healthy aging. It is thought that proper dietary supplementation 
may hinder the onset of many age-related neurodegenerative diseases such as 
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AD. For instance, antioxidants are a critical component of the proper cellular 
homeostasis. These compounds are necessary for keeping levels of oxidative 
stress low and therefore decreasing damage to lipid, proteins, DNA and RNA 
[209]. Based on correlative human neuropathology studies, antioxidants are 
predictive of healthy aging, may reduce the risk of developing AD and may 
improve cognitive function in AD patients. However, studies in humans have 
shown either a positive effect of antioxidant use on cognition and risk reduction 
for developing AD [210-212] or no significant effects [213-216]. Few systematic 
and controlled clinical trials have evaluated the effects of antioxidants on 
cognition in aged individuals or patients with AD.  
Dietary Supplementation that target mitochondrial function to improve age 
related deficits 
 
As mentioned previously, mitochondria dysfunction, oxidative stress and 
changes in metabolism are important factors in natural aging. Based on the 
MFRTA, it is thought that appropriate dietary supplementation can help to avoid 
many of the age related deficits that arise, such as reduced cognition. Two major 
supplementations that have shown some promise are the use of antioxidants as 
well as mitochondrial co-factors.  
One specific antioxidant which has been well studied in aging and various 
age related neurodegenerative states is vitamin E. Vitamin E is an important 
lipid-soluble antioxidant that is obtained through the diet [217]. Commonly 
referred to as tocopherol, these vitamin E isomers are found in high 
concentrations in almonds, roasted sunflower seeds, various plant oils, such as 
olive oil, and can also be taken as a supplement. It is thought that proper 
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supplementation with Vitamin E can protect cells against deteriorating effects of 
oxidative damage and the progression of degenerative diseases and aging 
however findings in the literature has shown mixed results [209]. As a compound, 
vitamin E is an important antioxidant shown to protect against lipid peroxidation 
in cell culture models [218]. However in single-cell organisms, rotifers, 
Caenorhabditis elegans, Drosophila melanogaster and rodent models, vitamin E 
has shown the full gamut of results, being increased lifespan with 
supplementation, no observed changes in lifespan and detrimental effects with 
supplementation [219-231]. Similar to these previous finding, human clinical trials 
with vitamin E has also produced mixed results. In one study, intake of vitamin E 
delayed institutionalization of AD patients [232], suggesting some beneficial 
effects. However, vitamin E alone did not improve cognition in patients with mild 
cognitive impairment, which is thought to precede AD [233]. Further, in non-
demented elderly women, vitamin E treatment was associated with little 
improvement in cognition [215].  
Vitamin C is another antioxidant that has been studied for years but has 
shown mixed results in the treatment of various age related diseases. Since 
vitamin C is a water-soluble vitamin, it is not stored in the body and therefore is 
needed to be consumed regularly through diet. Not only has it shown to be 
important in the maintenance of connective tissues, it can also assist in 
the conversion of the amino acid, tryptophan, to the neurotransmitter, serotonin 
and is an antioxidant that protects body from free radical damage [234]. Foods 
rich in vitamin C are guava, kale and kiwi. To date, research using vitamin C as 
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an antioxidant are mixed and seemingly are improved when combined with other 
antioxidants such as vitamin E [235]. Research has found that in low 
concentrations, it has antioxidant properties, however at high concentrations is a 
potent pro-oxidant, with intra- and extracellular mechanisms that generate 
hydrogen peroxide [236]. Treatment with aspirin plus ascorbic acid/vitamin C in 
aged rats was also shown to enhance cognitive performance and increase the 
expressions of several receptors related to learning and memory process [237]. 
Another recent rodent student also saw that high supplementation of vitamin C 
was able to decrease the amyloid plaques found in the cortex and hippocampus 
of an AD transgenic mouse model that normally has increased amyloid plaques 
in the brain compared to wild-type mice [238].  However, even with the positive 
results found in animal testing, the results pertaining to human clinical trials are 
not as positive [239]. As study performed in Germany found that vitamin C and β-
carotene concentrations were significantly lower in the blood of demented than in 
control persons [240].   
Coenzyme Q10, which is also known as CoQ10, is another important 
naturally occurring compound that has be hypothesized as an integral 
component of various neurodegenerative diseases and cognitive disorders 
related to age [241]. As an important cofactor needed in the mitochondrial 
electron transport chain, CoQ10 is necessary for proper aerobic cellular 
respiration and ATP production, both which have been found to decline with age. 
It is thought that when CoQ10 is deficient, mitochondrial function decreases, 
ROS production increases and inflammation ensues [184, 242].  Also, in its 
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reduced form, CoQ10H2 is a fat-soluble antioxidant that is generally found in cell 
membranes. This important lipid soluble antioxidant is the only antioxidant that 
animal cells synthesize de novo [243]. Although it has an integral role in proper 
cellular function related to both metabolism and oxidative stress, its importance in 
aging and proper supplementation in many diseased states is highly debated. In 
laboratory studies where CoQ10 was supplemented in cell-culture and slice-
culture studies, it has been found to be neuroprotective through the reduction of 
oxidative stress leading to decreased cell death [244]. Rodent studies have also 
shown improvements in cognition with later life supplementation of CoQ10 [245]. 
Additionally, a study measuring cognition in aged beagles following statin usage 
found lower levels of serum CoQ10 in the parietal cortex was correlated with 
decreased cognition, suggesting the need for proper CoQ10 level in order to 
retain proper cognition [184]. Decreases in plasma CoQ10 levels seen in aged 
canines seemingly translate well to humans. A correlative study recently 
completed in humans found that plasma levels of CoQ10 are significantly 
reduced older patients suggesting decreased antioxidant capacity [246]. Since 
both cognition and CoQ10 levels tend to decline with age, it is hypothesized that 
decreases in CoQ10 may lead to the mitochondrial dysfunction seen with AD 
[247]. However, another interpretation of the data suggests that age related 
impaired mitochondrial function which may make aged cells more vulnerable to 
naturally occurring decreased levels of CoQ10 [248].  
Taken together, studies of dietary or supplemental antioxidant intake in 
humans reveal variable results and appear far less robustly associated with 
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positive functional outcomes than those reported in the rodent aging literature 
[164, 179, 249-256]. Variability in the outcomes of human antioxidant clinical 
trials outcomes may reflect inconsistencies in the amount of supplements 
provided, their form and source (e.g. lower AD brain neuropathology is 
associated with cerebrospinal fluid levels of alpha-tocopherol and not gamma-
tocopherol [257]), their duration and regularity of use and challenges in 
determining the exact background of dietary antioxidants [258]. Interestingly, 
combinations of antioxidants may be superior to single compound 
supplementation [259] and dietary intake of antioxidants is superior to 
supplements in human studies on cognition and risk of developing AD [260, 261]. 
Further, supplementation of elderly women with a combination of vitamins E and 
C can lead to improved memory [262]. Thus, antioxidants may prove to be more 
efficacious if administered in combination with other antioxidants (e.g. vitamin C, 
which helps to recycle Vitamin E) and through diet, rather than as a supplement.  
In addition to investigating the effects of cellular antioxidants on cognition 
and risk of AD, several studies examined the effects of targeted co-factors that 
improve mitochondrial function, including acetylcarnitine (ALCAR) and lipoic acid 
(LA). ALCAR and LA may improve mitochondrial function and reduce the 
production of ROS, thus also reducing oxidative damage to proteins, lipids and 
DNA/RNA [263]. In studies where ALCAR was administered to patients with 
moderate to severe AD, either improved cognition and/or slower deterioration 
was observed [264-267]. In early-onset AD patients (less than 65 years of age), 
only small cognitive improvements were noted [268], although younger patients 
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with AD (less than 61 years) may also have experienced slowed disease 
progression [269, 270]. When the results of all these studies are combined in a 
meta-analysis, ALCAR administration in patients with AD was clearly beneficial, 
particularly with respect to slowing cognitive decline [271]. Further, combining 
ALCAR with acetylcholinesterase therapy in AD may provide additional benefits 
[272]. Similar evidence of maintenance of function was observed in an open label 
study of 9 patients with AD or related dementias receiving 600 mg/day of LA for 
an average of 337 days [273]. In a larger follow up study of 48 patients for a 48 
month treatment period, maintenance of function was also observed [274].  
A panel of experts for the Duke Evidence-based Practice Center for the 
US Department of Health and Human Services recently reviewed the literature 
and, not surprisingly, reported no consistent or robust evidence to suggest that 
single or dual antioxidant use is protective against AD [275]. In terms of 
preventing cognitive decline with aging, vegetable intake was only weakly 
associated with decreased risk of developing AD, whereas cognitive training was 
strongly associated with decreased risk. Thus, the role of either dietary or 
supplemental antioxidants and level of protection against cognitive decline or AD 
has yet to be clearly established. Additional reasons for the small or negative 
effects of antioxidants on cognition in the elderly and for treatment of AD [249, 
276] include the limitations of animal models (primarily rodent) in terms of ability 
to predict human response. Therefore, it is useful to consider other animal 
models of human aging and AD, and also to test the potential for combinations of 
antioxidants/ mitochondrial co-factors to improve cognition and reduce Aβ. 
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Specifically, dogs are frequently used to evaluate safety of drugs and in food 
metabolism studies given their substantial similarities to humans. Therefore, 
preclinical studies of mitochondrial function and interventions should be 
completed in an aging canine model of human brain aging and AD to give results 
that can better be translated to humans. 
Targeting Oxidative Stress in a Canine Model of AD 
 
Dogs may be particularly useful in studying human brain aging because 
they naturally develop cognitive decline with age, accumulate oxidative damage 
and Aβ protein [277]. In dog brain, oxidative damage to proteins increases with 
age [278, 279] and is associated with reduced endogenous antioxidant enzyme 
activity or protein levels [278, 280-282]. In several studies, a relation between 
age and increased oxidative damage has been inferred by measuring the amount 
of end products of lipid peroxidation to predict oxidative damage to lipids.  These 
end products including 4-hydroxynonenal [282-285] and malondialdehyde [278]. 
Additionally, we and others have reported evidence of increased oxidative 
damage to DNA or RNA (8OHdG) in aged dog brain [277, 285]. 
Oxidative damage may also be associated with behavioral decline in dogs. 
Rofina and collaborators examined oxidative end products (lipofuscin-like 
pigment and protein carbonyls) in aged companion dog brain and found a 
correlation between increased oxidative end products and severity of behavior 
changes due to cognitive dysfunction [279, 284, 285]. Similarly, in work 
completed by Opii and Head et. al. aging beagles, higher protein oxidative 
damage (3-nitrotyrosine) and lower endogenous antioxidant capacity (superoxide 
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dismutase and glutathione-S-transferase) are associated with poorer prefrontal-
dependent and spatial learning [281]. These correlative studies suggest a link 
between cognition and progressive oxidative damage in the dog, suggesting their 
utility in testing antioxidant treatment strategies.  
To test the hypothesis that reduced oxidative stress leads to cognitive 
benefits, longitudinal studies in aged dogs were completed. In this study, a 
combination of antioxidants and mitochondrial co-factors was provided in food 
[286-290]. 48 aged beagles (between ~8-12 years) were divided into four groups 
that were balanced with respect to baseline cognitive ability, sex and age:  (1) no 
behavioral enrichment/control diet group; (2) behavioral enrichment/control diet; 
(3) no behavioral enrichment/antioxidant diet; and (4) combined behavioral 
enrichment and antioxidant diet. In a subset of experiments, an additional 17 
young beagles (<5 years of age) were included for comparison to aged dogs. 
Young dogs were all placed in the behavioral enrichment condition, with half 
provided with the antioxidant diet (i.e. similar to groups 2 and 4). 
Three unique features of the experiment included: 1) a combination of 
antioxidants and mitochondrial co-factors; 2) incorporation of all antioxidants and 
mitochondrial co-factors into food and; 3) evaluation of dietary treatments in 
combination with behavioral enrichment. An antioxidant-enriched dog diet was 
formulated to include a broad spectrum of antioxidants and two mitochondrial co-
factors [289]. Based on an average weight of 10 kg per animal, the daily doses 
for each compound were 800 IU or 210 mg/day (21 mg/kg/day) of vitamin E, 16 
mg/day (1.6 mg/kg/day) of vitamin C, 52 mg/day (5.2 mg/kg/day) of carnitine and 
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26 mg/day (2.6 mg/kg/day) of lipoic acid. Fruits and vegetables were also 
incorporated at a 1 to 1 exchange ratio for corn, resulting in 1% inclusions 
(dehydrated) of each of the following: spinach flakes, tomato pomace, grape 
pomace, carrot granules and citrus pulp. This was equivalent to raising fruits and 
vegetable intake from 3 servings per day to 5-6 servings per day based upon 
ORAC values [291]. Additionally, vitamin E was increased by ~75% in dogs 
treated with the antioxidant diet [292]. The behavioral enrichment condition 
consisted of additional cognitive experience (20-30 min/day, 5 days/week), an 
enriched sensory environment (housing with a kennel-mate, weekly rotation of 
play toys in kennel) and physical exercise (two 20 min outdoor walks/week) 
[289].  
Dogs were evaluated over a 2.8 year period to evaluate short term and 
chronic treatment effects. Treatment with the antioxidant diet lead to cognitive 
improvements in learning within two weeks, with aged animals showing 
significant improvements in spatial attention (landmark task) [292]. Subsequent 
testing of animals with a more difficult complex learning task (oddity 
discrimination) also revealed benefits of the diet [286]. With antioxidant 
treatment, visual discrimination improved and reversal (frontal function) learning 
ability was maintained over time while untreated animals showed a progressive 
decline [289]. This was despite the fact that for each time point where 
discrimination learning was re-administered, the task was made more difficult 
(harder to distinguish objects) to prevent a practice effect.  Thus the progressive 
increase in error scores over time in untreated dogs reflects both increased task 
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difficulty and possibly, longitudinal aging effects. Interestingly, the dogs fed an 
antioxidant diet benefited from behavioral enrichment, in that cognitive scores of 
aged dogs receiving both treatments were superior to either treatment alone 
[288, 289]. For example, in singly treated animals spatial memory showed a 
trend toward improvement, reaching statistical significance only after long-term 
treatment (>2 years) with a combination of both the antioxidant diet and 
behavioral enrichment [290]. The antioxidant diet selectively repaired an aging 
deficit, in that cognitive scores from young dogs treated with the antioxidant diet 
did not differ from those of young dogs fed control diet [293].    
Neurobiological studies showed reduced oxidative damage and increased 
endogenous antioxidant activity in antioxidant-fed dogs, particularly among 
animals receiving the combination of antioxidants and behavioral enrichment 
[281]. Interestingly, the antioxidant diet increased the levels of glutathione 
suggesting a possible involvement of a possible vitagene network that might 
account for the increased expression of antioxidant molecules and growth 
proteins [294, 295]. Given that the diet provided to the dogs also included 
acetylcarnitine, resulting in increased levels of heme oxygenase (HO-1) also 
support the possibility that vitagene networks are engaged [294]. 
Mitochondrial function was significantly improved in the antioxidant fed 
dogs and not in behaviorally enriched dogs [248]. Interestingly, behavioral 
enrichment but not the antioxidant diet protected against neuron loss in the hilus 
of the dog hippocampus [296]. Further, brain derived neurotrophic factor mRNA 
increased in aged dogs provided with the combination treatment [297]. These 
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results suggest that cognitive benefits of antioxidants can be further enhanced 
with the addition of behavioral enrichment, perhaps due to different yet 
synergistic mechanisms of action in the brain, including reduced oxidative 
damage and maintenance of neuron health.  In addition to brain, however, 
peripheral benefits were also seen, including less cellular degeneration in the 
inner ear [298]. 
Interestingly, in a recent study of aged dogs, the formulation of the diet 
was modified to compare only the mitochondrial co-factors used in this previous 
study and effects on cognition [299]. Aged dogs were treated with lipoic acid, 
ALCAR or the combination and tested with spatial learning and 
discrimination/reversal tasks. When these compounds were included with a 
broader spectrum of antioxidants described above, no cognitive benefits were 
observed when evaluated singly or in combination. Additionally, protein carbonyl 
accumulation in the plasma of treated dogs was increased. Increased oxidative 
damage may reflect either higher doses of the mitochondrial co-factors used in 
this study or increased oxidative stress resulting from not counterbalancing 
mitochondrial cofactors with cellular antioxidants. 
Changes in mitochondrial bioenergetics that occur with age 
 
Through this Calcium mediated mitochondrial cell death mechanism and 
others, mitochondria have been implicated in various age related 
neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, ALS [300]. 
Therefore, scientists have turned their interests to finding novel therapeutic 
approaches in order to target mitochondrial function with the hopes of avoiding 
 73 
the onset and/or progression of diseases where mitochondrial dysfunction is 
present and amendable. However, as scientists discovered approaches that 
were able to target mitochondrial function, a debate ensued as to whether 
mitochondria are a homogenous population across various tissue types. 
With the investigation of mitochondrial targeting therapeutic approaches 
for various disease states, unexpected insights into the nature of mitochondria 
have surfaced. Mitochondrial function does not seem to be consistent across all 
tissue types or even within different regions of a specific cell type, specifically 
synaptic versus non-synaptic mitochondria [301]. Additionally, it is also thought 
that aging further increases these differences [300]. Therefore, to date, the field 
is beginning to probe the idea that mitochondria may not all be alike and may 
react to insults, such as aging or toxins, differentially. Within this article, we will 
review these differences and highlight new data supporting this hypothesis from 
our laboratory.  
Based on the information provided previously, mitochondrial bioenergetics 
and age related changes to these bioenergetics is an important area of research. 
Denham Harman’s work on the Mitochondrial Free Radical Theory of Aging 
(MFRTA) [139, 150, 158-160, 302] is heavily debated, however there are 
specifics that have yet to be disproven. Within MFRTA, Harman acknowledged 
that through the normal function of the electron transport chain, reactive 
electrons are released. These electrons are then able to react with free oxygen, 
generating reactive oxygen species, which can thereby react with nearby 
proteins, nucleic acids, etc. leadings to metabolic mediated oxidative stress. Over 
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time, the oxidative insult perpetuates and mitochondrial and cellular damage can 
occur. After many years, this damage begins to accumulate leading to decreased 
bioenergetics efficiency, increased electron slippage/release and decreased ATP 
production. In cell types with low bioenergetics profiles, this change in 
bioenergetics is not a large concern. However, in cells that have a high energy 
demand such as neurons, decreased ATP production can lead to serious 
detrimental effects which can result in severe functional changes due to 
disruption of cellular homeostasis.  
Age-associated impairments in mitochondrial oxidative phosphorylation 
(OXPHOS) due to oxidative damage has been shown in multiple tissues 
including the brain, muscle, liver and heart [205, 303-306].  However, the 
proteins damaged seem to be very specific and not necessarily the result of a 
complete destruction to all mitochondrial structures. Therefore, specific 
mitochondrial proteins seem to be more vulnerable to age-related metabolic 
mediated oxidative stress. For instance, mitochondria isolated from various 
rodent tissues have shown decreased mitochondrial electron transport chain 
enzymatic activity with age, specifically within complexes I and IV, however 
complexes II and III seemingly remain unaffected [307, 308]. Based on data 
obtained from our laboratory, it has also become apparent that age related 
mitochondrial dysfunction may be the result of a regional specific dysregulation in 
Calcium buffering by the mitochondria [300].  In this specific study, mitochondria 
isolated from aged rat cortex and hippocampus showed increased ROS 
production and decreased Calcium buffering capacity compared to young rats 
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however this was not observed in mitochondria isolated from the cerebellum of 
these animals. This study also found that aged brain mitochondria were able to 
undergo mitochondrial permeability at a lower Calcium threshold than young 
animals with the exception of cerebellar mitochondria where no difference was 
measured.  
It is thought that as oxidative damage and the resulting mitochondrial 
dysfunction increases with age, mitochondria will become more vulnerable to 
insults by environmental toxins, etc. leading to an increase in mitochondrial 
mediated cell death. This rational is supported by the increased prevalence of 
neurodegenerative diseases in the aged population [102]. Additionally, these 
age-related changes in mitochondrial bioenergetics do not seem to occur equally 
in all regions of the central nervous system. Certain regions within the central 
nervous system experience increased mitochondrial dysfunction, increased ROS 
concentrations and decreased Calcium buffering capacity making these tissue 
types more vulnerable to the initiation of mitochondrial mediated cell death 
pathways.  
Mitochondrial differences in the brain versus spinal cord  
 
Back in the early 2000s, our laboratory and others were investigating 
Cyclosporin A for the treatment of injuries to the central nervous system, CNS. At 
the time, Cyclosporin A was a known immunosuppressant however it also had a 
secondary target within the mitochondria. Specifically, it was found to bind a 
protein within the mitochondria called Cyclophilin D, thereby inhibiting the 
mitochondrial permeability transition. In the model of brain injury, this drug 
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provided a means of limiting part of the excitotoxic cell death cascade that occurs 
following injury. However, within these studies it was noticed that the therapeutic 
effect of Cyclosporin A was lost when it was moved from brain injury to a model 
of spinal cord injury.  This work provided evidence that mitochondria in one tissue 
type differs from mitochondria within another tissue [300]. Upon further research, 
it became apparent that these differences could also occur in tissues that were 
histologically similar. For instance, the brain and the spinal cord are one 
continuous structure, thereby sharing similar cell types. However, it has been 
shown that mitochondrial from the brain have different bioenergetics than those 
in the spinal cord.  Later it became apparent that even mitochondria within one 
area of a cell can have a different energetic profiles compared to mitochondria 
within another area of cell. Specifically, our work has shown that neuronal 
mitochondria located in the synapse of neurons have different bioenergetics, 
calcium buffering capacities and respond differently to mitochondrial targeting 
drugs compared to mitochondria found within non-synaptic pools [39, 301, 309-
314]. This data further supports the theory that mitochondrial bioenergetics may 
be location specific. 
From our current understanding, it seems as if there is convincing 
evidence supporting the theory that mitochondria within the spinal cord may have 
significant differences in metabolic profiles than mitochondria within the brain. 
Work from our laboratory and others have found that mitochondria within the 
spinal cord produce more reactive oxygen species and have increased oxidative 
damage compared to age-matched brain mitochondria. Additionally, in normal, 
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non-aged mitochondria obtained from 3 month old rats, spinal cord mitochondria 
have decreased maximum NADH linked mitochondrial respiration. However, in 
this study no difference in FADH2/succinate mediated respiration was 
demonstrated [313]. Additionally, spinal cord mitochondria have a lower calcium 
mediated threshold for the formation of the mitochondrial permeability transition 
pore, which is likely related to increased expression of cyclophilin D compared to 
brain mitochondria. Because of these differences, drugs that inhibit the formation 
of the mitochondrial permeability transition pore such as Cyclosporin A require 
significantly higher concentrations in order to provide the same degree of 
neuroprotection in the spinal cord that is seen in the brain. Although these 
findings were interesting, they lead to more questions. Specifically, does age 
influence the differences seen between mitochondria from the brain versus the 
spinal cord? 
Age related differences between brain and spinal cord mitochondria 
We hypothesized that since age and location of mitochondria both have 
individual effects on mitochondrial bioenergetics, then when combined together 
an even further deviation in mitochondrial function will occur. To test this 
hypothesis we compared mitochondrial bioenergetics within the brain to those 
within the spinal cord in rats at different ages, specifically 3 month compared to 
12-15 month old male Sprague-Dawley rats (9 per age group, tissue from 3
animals pooled for mitochondrial assessments). Within this study we looked at 
differences in the total mitochondrial population within the cortex of the brain and 
cervical, thoracic and lumbar regions of the spinal cord using techniques as 
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described in [39, 300, 301, 313]. Analysis of the NADH-linked maximum 
respiration data using a 2way ANOVA demonstrated a significant age X region 
interaction (F=4.955, p = 0.012) as well as significant effects of age (F=72.69, p < 
0.0001) and region (F=39.46, p < 0.0001). FADH2-linked maximum respiration 
demonstrated significant effects of age (F=31.30, p < 0.0001) and region 
(F=29.68, p < 0.0001) with no significant age X region interaction (F=3.238, p = 
0.050). To further establish age dependent differences, unpaired t-tests were 
performed for each region in young vs aged animals. We determined aged rats 
had a 20 to 50% decrease in NADH mediated respiration within all regions of the 
spinal cord compared to the young cohort (p < 0.05). Aged animals also showed 
a significant decrease in succinate/FADH2 mediated respiration within the 
various regions of the spinal cord (p < 0.05), which was not demonstrated in the 
brain for either NADH or FADH2 mediated respiration (FIGURE 2-1A and 2-1B 
and TABLE 2-1). These findings are very interesting because significant NADH 
mediated inhibition of cortical mitochondria has been documented with age in the 
past however this study did not find the same conclusions [300]. The differences 
observed however may be due to inherent strain differences and/or the ages of 
animals examined in these two studies. We did, however, find a significant 
decrease in both NADH and FADH2 mediated respiration in all the tested areas 
of the spinal cord in the aged animals compared to young. With the results found 
in young animals, mitochondria within the spinal cord seem to have decreased 
bioenergetics, compared to brain mitochondria, which continues to decrease with 
age. This decrease in bioenergetics has the potential of making these areas 
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more vulnerable to insults due to decreased energetic reserves, deceased ATP 
production and decreased capacity for ROS, which would increase the probability 
of a transition to cell death and therefore, increase the possibility of 
neurodegeneration. 
Mitochondrial mediated oxidative stress and mitochondrial dysfunction 
generally occur together however the causation between the two is debated, 
however MFRTA supports the theory that oxidative stress causes mitochondrial 
dysfunction. To further support this hypothesis that the deviations in 
mitochondrial respiration are the result of oxidative stress, we assessed 
mitochondrial ROS production as a function of age across CNS regions using 
methods previously described in [39, 301]. A 2way ANOVA of basal 
mitochondrial ROS production demonstrated a significant age X region 
interaction (F=12.81, p = 0.0002) as well as significant effects of age (F=183.6, p 
< 0.0001) and region (F=16.10, p < 0.0001). Unpaired t-tests revealed that 
mitochondria isolated from aged rats compared to young rats (12 months 
compared to 3 month old Sprague-Dawley rats) had a significant (p < 0.01) 
increase in reactive oxygen species (ROS) production within all regions of the 
CNS, specifically the cortex and the cervical, thoracic and lumbar regions of the 
spinal cord (FIGURE 2-2 and TABLE 2-2). One factor that is ambiguous within 
this study is whether the high ROS production leads to decreased mitochondrial 
bioenergetics or the decreased bioenergetics leads to increased ROS 
production. However, what is known is that this age related increase in ROS can 
eventually lead to cellular dysfunction making aged animals more vulnerable to 
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cellular insults. This increased vulnerability makes the animal more likely to 
experience cellular dysfunction and possibly cellular death within this region.  
With increased production of ROS and decreased mitochondrial 
respiration, mitochondrial and cellular structures become more vulnerable to 
oxidative damage. As previously reported by our group, mitochondrial DNA, 
mtDNA, damage is significantly higher within the spinal cords compared to the 
brain [313]. This increased damage to mtDNA can further perpetuate the 
mitochondrial dysfunction observed since protein structures made within the 
mitochondria have an increased chance of being mutated which can render 
mitochondrial proteins encoded by the mtDNA dysfunctional.  
Summary 
 
Well supported by the literature and the studies conducted in our lab, 
NADH and FADH2 mediated mitochondrial respiration decreases in the cortex 
and within the cervical, thoracic and lumbar regions of the spinal cord as age 
increases. In addition to changes in respiration, we have also observed 
increased mitochondrial ROS production with age in these same regions. Lastly, 
within the spinal cord of aged animals, it seems as in mtDNA damage is 
increased which could be a direct result of the increased mitochondrial ROS 
production. Although more studies may be needed to determine the exact age 
when the mitochondria become less bioenergetically efficient and to determine 
whether ROS or mitochondrial bioenergetics increase first with age leading to the 
other, MFRTA and the previously mentioned studies do give great insight into a 
potential therapeutic target that scientists could exploit in order to improve age 
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related functional decline and thereby improving the quality of life for the older 
population.  
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TABLE 2-1: Mitochondrial Mediated Respiration 
Mean (nmol oxygen/min/mg) + SD 
State III State IV State V State Vsuc 
Young Cortex 94.64 + 4.61 16.09 + 1.42 114.09 + 5.50 125.46 + 1.77 
Young Cervical 70.67 + 7.72 10.73 + 1.88 94.44 + 13.19 100.16 + 14.02 
Young 
Thoracic 
42.32 + 3.99 7.75 + 1.06 81.97 + 2.80 85.60 + 4.36 
Young Lumbar 48.52 + 11.80 7.96 + 0.70 72.24 + 11.29 77.79 + 5.74 
Aged Cortex 85.29 + 14.47 17.87 + 5.67 102.98 + 4.72 118.01 + 11.43 
Aged Cervical 38.06 + 8.52 9.34 + 2.49 45.73 + 9.69 52.44 + 19.15 
Aged Thoracic 26.38 + 8.57 5.58 + 1.82 45.40 + 10.51 58.70 + 13.67 
Aged Lumbar 31.31 + 4.32 5.44 + 1.34 46.29 + 7.20 56.10 + 9.79 
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TABLE 2-2: Tissue Specific ROS Production 
Mean (DCF Flourescence AU/µg) + SD 
Young Cortex 95.88 + 9.24 
Young Cervical 121.95 + 32.61 
Young Thoracic 145.28 + 39.95 
Young Lumbar 144.95 + 61.75 
Aged Cortex 235.30 + 45.52 
Aged Cervical 625.79 + 63.73 
Aged Thoracic 293.04 + 78.52 
Aged Lumbar 485.65 + 52.79 
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FIGURE 2-1 Increased age in rats lead to decreases in (a) NADH and (b) 
FADH2 mediated respiration. 
Total mitochondria were isolated from young (3 month) and aged (12-15 months) 
male Sprague-Dawley rats (9 per age group, tissue from 3 animals pooled for 
final n=3 per group) and oxygen consumption assessed in a sealed, stirred, 
thermostated chamber equipped with a Clark-type electrode and expressed as 
nmol of oxygen consumed per min per mg of mitochondrial protein. Maximum 
NADH-linked (A) and FADH2-linked (B) respiration data were then analyzed 
using 2-way ANOVAs following by unpaired t-tests when warranted to assess 
age effects on mitochondrial bioenergetics. Data are expressed as % of 
respiration measured in young animals, *p < 0.05.   
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FIGURE 2-2: Mitochondrial ROS production increases with age. 
Aged rats had a 200% to 600% increase in ROS production mitochondria 
isolated from the cortex and spinal cord compared to young rats. Total 
mitochondria were isolated from young (3 month) and aged (12-15 months) male 
Sprague-Dawley rats (9 per age group, tissue from 3 animals pooled for final n=3 
per group) and ROS production assessed using the indicator DCF in the 
presence of respiratory substrates. Control wells included FCCP to induce 
minimum ROS production and oligomycin to induce maximum ROS production. 
Wells in which mitochondria were omitted were used for background subtraction. 
Raw data (DCF fluorescence AU/ug) were then analyzed using a 2way ANOVA 
following by unpaired t-tests when warranted to assess age effects on 
FIGURE 2-2 
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mitochondrial basal ROS production. Data are expressed as % of respiration 
demonstrated in young animals, *p < 0.05.   
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CHAPTER 3: TRAUMATIC BRAIN INJURY 
In the United States, the CDC estimates that approximately 1.7 million 
Americans experience a traumatic brain injury (TBI) every year [315]. Expanding 
this scope, it has been further estimated that 57 million people have experienced 
a brain injury worldwide [315, 316]. Even more astounding is that these numbers 
do not account for the population who sustain a TBI, likely more mild in nature, 
and do not seek medical care. With such a large affected population, it is 
estimated that approximately 77 billion dollars are spent annually on direct and 
indirect health related costs in the US alone [316]. Therefore, it becomes obvious 
that there is a great need for pro-regenerative and/or neuroprotective therapeutic 
agents for the treatment of this disease however to date there is still no FDA 
approved drug for its treatment.  Although ample manpower has gone into the 
discovery of drugs to treat TBI, many tribulations have been encountered along 
the way due to the multifaceted complicated set of pathways that are initiated 
following the primary the injury.  
The pathophysiology of TBI 
The pathophysiological nature of TBI is complicated and is thought to 
occur in a biphasic manner. The first phase is termed the primary injury and the 
second phase is termed the secondary injury.  
Primary Injury 
 initial impact is where kinetic energy is transferred into a mechanical 
disruption within the brain causing immediate tissue damage. The extent of 
damage, and therefore the severity of the injury, depends on the nature of the 
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injury as well as the degree of mechanical force transferred to the brain tissue 
when the injury ensues. One complication that physician and researchers 
encounter when attempting to treat this disease is that injuries are generally 
heterogeneous in nature, providing a “significant barrier” for therapeutic 
interventions [317]. According the the Mayo Clinic, injuries may include one or 
more of the following factors:  
1) Tissue damage limited to an acute area directly below the 
point of impact on the skull. This type of injury is often referred to as a 
contusion injury. 
2) Tissue damage at multiple points in the brain due to 
movement of the cerebrum, brain stem, and cerebellum within the 
cranial vault, which is defined as a coup contrecoup injury. 
3) Tearing of cellular structures due to severe rotational 
movement or spinning motion. This type of injury can often include a 
coup contra-coup injury as well as damage to deeper cerebral 
structures. This is often called a rotational injury.  
4) Widespread tissue damage due to a blast from an explosive 
device. This is defined as a blast injury.  
5) Tissue damage can occur as the result of an object 
penetrating the skull such as a bullet or some other rigid structure with 
enough kinetic energy to break the skull. This type of injury can often 
be referred to as a ballistic injury, when referring to a bullet, or produce 
a contusion type of injury as well. 
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6) Changes in vasculature such as bleeding in and/or around
the brain, swelling of the brain and blood clots which disrupt the 
oxygen supply also causing tissue damage. 
7) Lastly, which was not noted by the Mayo Clinic, brain
damage can occur as the result of drowning or any other environment 
where oxygen supply to the brain is diminished. This is defined as an 
anoxic or hypoxic type of TBI. 
These types of primary injuries are most commonly produced by either 
falls, vehicle related-collisions, assault, sports injuries or explosive blast or other 
combat related injuries. 
To date, there are a few known risk factors that increase a person’s 
chances of sustaining a TBI. One of the first risk factors is age including children 
from newborn to 4 years old, young male adults between the ages of 15 to 24, 
and adults ages 75 and older [318]. The rate of TBIs per 100,000 in the US 
population is also greater in males, between 25 to 28 over the past decade 
compared to females which ranges more between 9 and 10.  
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Figure 3.1 Gender is a risk factor for TBI: Based on CDC reports, males have 
double the risk of sustaining a TBI compared to females. [319] 
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Drug usage, nutrition and psychosocial status also are included as risk 
factors for TBI [320]. Additionally, athletes involved in high impact sports, such as 
boxing, football or soccer, and solders involved in military combat have also been 
defined as two groups who are more susceptible to sustaining a TBI. Since this 
phase of the injury is cannot be therapeutically influenced, the best practice to 
avoid the primary injury is through prevention techniques [321]. The CDC 
proposed prevention techniques including: 
1) Using proper restraints for you and your children while
operating or riding in a motor motor vehicle. 
2) Never driving while under the influence of alcohol or drugs.
3) Wear a helmet, or have your children wear helmets, while
a. Riding a bike, motorcycle, snowmobile, scooter, or all-
terrain vehicle; 
b. Playing a contact sport such as football, ice hockey or
boxing; 
c. Using in-line skates or riding a skateboard;
d. Riding a horse; or
e. Sking or snowboarding
4) Making living areas safer for seniors by:
a. Removing tripping hazards;
b. Using nonslip mats on surfaces that become slippery
when wet such as bathroom floors, bathtubs, showers, etc.; 
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c. Installing handrails in stairways; 
d. Proper lighting within the hom 
e. Maintaining a physical activity regiment to provide 
increased body strength and balance. 
5) Making living areas safer for children by: 
a. Using window guards on open windows to avoid them 
falling out of one 
b. Using safety gates at the top and bottom of stairwells.  
6) Having safe shock-absorbent floor surfaces around play 
areas [321]. 
In addition to using proper precautions to help avoid the occurrence of a 
TBI, researchers have also continued to improve upon current helmet designs.  
Researchers have found that a hard shell design alone for helmets will not help 
protect the brain from injury. Not surprisingly, the cushion (foam) within the 
helmet  seems to be of the upmost importance in order to decrease the head 
impact acceleration and therefore the mechanical force that the brain encounters 
[322].  However, as researchers at the Lawrence Livermore National Laboratory 
discovered, there does not seem to be one type of foam that protects against all 
injuries. For instance, dense foams within the helmet seem to protect the brain in 
to a greater extent when high-speed interactions are observed. On the contrary, 
when low speed interactions are encountered, less dense foam seems to 
outperform the higher density foam. Additionally, the thickness of the foam within 
the helmet is also an important factor in that the thicker the foam, the less force 
 94 
the brain will experience during any impact [323]. However, these researchers 
also determined that at high enough speeds, the kinetic energy is too high and 
no thickness or density of the foam could protect against damage to the brain 
[324]. Therefore, although prevention techniques are currently being improved 
upon, mechanical insults to the brain tissue are still able to occur leading to 
necessary progress being made once the injury occurs. 
Even with proper prevention techniques in place, traumatic brain injuries 
are still occurring within the US as an alarming rate. When this injury occurs, as 
mentioned previously, it starts the injury cascade. This cascade is initiated by the 
primary injury leading to tearing of blood vessels, sheering of axons and 
immediate cell death which have all been documented and are dependent on the 
severity of the impact [325]. The initial insult causes cellular membranes around 
the injury to become permeable to various proteins, ions and other molecules 
which is thought to be one factor leading to the initiation the secondary phase of 
the injury [326].  
Following the primary injury, within the first seconds, to minutes, to days 
and now seemingly expanding to months and possibly years later is the second 
phase of this bi-phasic injury cascade. This phase is often called the secondary 
injury cascade and causes delayed non-mechanical tissue damage [327]. This 
tissue occurs due to a complex set of events including alterations of endogenous 
neurochemical mechanisms, ischemic insult, massive edema, increases in 
oxidative stress and mitochondrial dysfunction which all lead to progressive 
damage around the site of the primary injury [109]. It is the tissue that is 
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undergoing this progressive damage that researcher and physicians have the 
greatest interest in when investigating therapeutic interventions following injury. It 
is thought that with proper intervention, improved functional outcomes can be 
obtained due to decreased tissue dysfunction and neurodegeneration. This 
secondary injury cascade will be discussed in more detail later in this chapter. 
Experimental Models of TBI 
 
The heterogeneous nature of clinical TBIs has sparked the invention of 
many experimental injury models [317].  Contusion injury, coup contra-coup, 
rotational injuries, blast injuries, penetrating injuries, anoxic or hypoxic injury, 
plus others, as well as combination injuries, have all been documented in clinical 
setting. When experimentally investigating these injuries, a single model has not 
been shown to be superior so a few of the more commonly used models will be 
discussed. However, a concentration will be placed on the contusion injury 
modeled by the controlled cortical impact since this was the model used for the 
studies in this thesis.  
The experimental injury models can be either static or dynamic. A static 
injury model in one which produces a compression injury and the force applied is 
never removed. Dynamic injury models are the most commonly studied forms of 
injury [328, 329]. These injuries can be the result of an indirect force being 
applied to the brain, an example of this would be an explosion which is modeled 
by the blast wave injury model, or the direct injury model, where there is an 
object which interacts with the head to produce the injury. From here, direct injury 
models can be further classified as penetrating or non-penetrating models of 
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injury. Two well-studied models of dynamic, direct, penetrating injuries are the 
fluid percussion model and the controlled cortical impact model [328].  
Blast Traumatic Brain Injury, mTBI 
The first model discussed will be the blast wave injury model which would 
be considered a dynamic non-penetrating injury. This model has gained more 
interest due to the marked functional changes observed by the men and women 
returning home from the war after encountering a blast or explosion. In this 
experimental design, a stabilized animal is attached to the end of cylindrical 
metal tube that has a closed on the other side. This close end is where a plastic 
explosive or compressed air device is located which can be detonated to produce 
the blast wave. The pathology of this form of injury is still highly debated and 
therefore is being continually investigated. Following the primary insult, shock 
waves from the explosion can pass through the brain tissue leading to minute 
neuroanatomical changes [328]. This blast overpressure causes the transfer of 
kinetic energy into a force on the brain which is thought to induce afferent 
hyperexcitability leading to increase synthesis and release of various 
neurotransmitters [330-332]. Although no apparent mitochondrial dysfunction has 
been documented in this model, neuron swelling, astroglial response and myelin 
debris in the hippocampus have all been observed. Damage to neuronal 
cytoskeletal structures in layers II-IV of the temporal cortex, the cingulate gyrus, 
the piriform cortex, the dentate gryus and CA1 regions of the hippocampus has 
also been seen over 7 days following injury [333]. Increases in oxidative stress, 
alterations of antioxidant defense systems, increased nitric oxide metabolism and 
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cognitive deficits have also been documented in patients who have sustained a 
blast TBI, bTBI. Additionally, compression of blood vessels can also occur 
leading to changes in blood flow to the brain, possibly inducing a hypoxic state.  
As the blast wave encounters the brain tissue, a coup-contracoup injury 
can also occur in which the brain is pushed in the direction of the shock wave 
compressing itself along the backside of the cranial cavity. Based on the law of 
conservation of energy, once the brain impacts the cranial cavity at the site 
opposite to the point of impact, the brain will then move back towards the site of 
injury within the cranial cavity. Therefore, this injury causes a coup and 
contracoup injury which are 180o from one another.  
Fluid Percussion Injury, FPI 
 
The next model of brain injury discussed will be the fluid percussion injury 
model, FPI, which is a direct penetrating injury model. In this model, water 
confined in a tube is impinged by a weight with a specific kinetic energy. This 
generates a pressure pulse in the water. The water is then rapidly injected into 
the cranial cavity, through the Luer cap placed in the skull, providing a 
mechanical force to the brain that is diffuse in nature [334]. Following injury, 
animals experience apnea and the severity of the injury is measured by the 
animals “righting time”. Depending on the location of this injury, either midline or 
lateral, and the severity, this injury does not produce any overt histopathology or 
contusion at the site of injury, however with the lateral fluid percussion, apparent 
cavitation and cell death is markedly observed within the ventricular region out to 
one year post-injury. As a model, FPI produces an injury that is thought to mimic 
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a rotational injury on the brain which can be the result of a clinically traumatic 
event such as a car accident or sports related injury.  
Controlled Cortical Impact, CCI 
The last model discussed, and the most important model related to this 
thesis project, produces a much more focal contusion injury compared to the 
diffuse injury seen with FPI. This is the controlled cortical impact, CCI, which 
uses a rigid impactor which impinges exposed, intact dura producing cortical 
tissue loss, acute subdural hematoma,  axonal injury, concussion, a breakdown 
the of blood brain barrier and coma [329, 335-340]. This experimental models 
dates back to the late 1980s where Dr. James Lighthall produced a novel 
contusion injury model in ferrets. This open-skull midline injury was generated by 
a pneumatic impact device that was attached to a cylinder shaft. The cylinder 
shaft had a 1.25cm diameter aluminum rod at the end, which was the tip that 
interacted with the brain. Dr. Lighthall then drilled a 1.5cm craniotomy in on the 
midline of the skull, between bregma and lambda, to expose the brain tissue. 
Great care was taken to remove the drilled bone flap in order to not damage the 
dura mater. The brain was then impacted at various velocities producing a 
graded injury which became lethal at higher velocities [340].  
Then, in 1991, Dr. Edward Dixon, under the advisement of Dr. Ronald 
Hayes, expanded upon the work from Dr. Lighthall, generating an experimental 
CCI injury model which is most commonly used to study contusion brain injuries 
today. This work from Dr. Dixon was completed in rats and provided a very 
thorough investigation into the neurological, cardiovascular and histopathological 
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changes that occur following a midline contusion injury.  The neurological deficits 
seen were consistent with changes to somatomotor system, showing decreased 
beam balance latencies and increase beam walking latencies which was 
dependent on the depth of the impact. These changes in motor function were 
also further supported with observations of axonal injury in the cerebellar 
peduncles and pontomedullary junction. Changes in mean arterial blood pressure 
were also observed leading to hypotension following a moderate injury (2mm 
cortical deformation) where a severe injury (3mm cortical deformation) produced 
immediate hypertension followed by hypotension. Most importantly noted 
however is that this type of injury paradigm could be graded, which was 
dependent on the extent of cortical deformation during the impact, leading to 
either no overt macroscopic or microscopic changes to the brain when the brain 
was only impacted at a depth of 1mm compared to a brain that received a large 
cortical contusion and intraparenchymal hemorrhage with a 3mm cortical 
defomation [336].    
The work from Dr. Lighthall and Dr. Dixon was further expanded upon 
when Dr. Douglas Smith, in 1995, used this model to injure the left 
parietotemporal cortex in mice. In this study, a 3mm beveled flat-tip metal 
impactor tip was used to impinge the brain at a velocity of 5.7-6m/s. With this 
injury paradigm, decreased cognition was measured at 2 days post-injury with 
the use of the Morris Water Maze. With this cognitive tests, animals are placed in 
a tub of water and tasked to remember visual cues around the room to find a 
platform hidden under the surface of the water. In support of the changes in 
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memory/cognition that was observed, postmortem histological studies from 
48hour post-injured mice revealed substantial cortical loss at the site of the 
impact and cell loss in the CA2, CA3 and CA3a regions of the hippocampus. 
Bilateral degeneration in the gray matter-white matter interface of the corpus 
callosum and reactive gliosis was observed bilaterally in the cortex, hippocampus 
and thalami at 48 hours post-injury. Additionally, a breakdown of the blood brain 
barrier was also documented in the cortex, hippocampus and thalamus [339].  
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Figure 3.2 Injury diagram for the CCI model: The controlled cortical 
impact model of TBI produces a contusion injury that leads to cell death and 
dysfunction acute to the injury. This injured tissue can be found in the cortex, 
hippocampus and corpus callosum on the ipsilateral injured hemisphere as well 
as the corpus callosum on the contralateral hemisphere  [339]. 
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The controlled cortical impact uses a pneumatic piston with a specific 
velocity, depth and dwell time to induce an injury. The severity of the injury can 
be adjusted based on these parameters. This injury provides a non-penetrating 
deformation to the cortex leading to a hematoma that has a similar 
histopathology to a clinical contusion injury, analogous to a lesion due a fall or a 
sports related injury. Immediately following the injury, a bruise occurs which 
begins to undergo progressive neurodegeneration that can continue to extend 
based on the secondary injury cascades for up to years [341].  At this time, 
differences in damage to the blood brain barrier, BBB, and cytoskeletal in the 
cortex and hippocampal formation have all been seen and well documented 
within the secondary injury cascade [342].  Glutamate excitotoxicity, changes in 
calcium homeostasis, increased free radical production and lipid peroxidation, 
mitochondrial dysfunction, inflammation and apoptosis are all hallmarks of this 
injury paradigm and used a potential therapeutic targets following injury [110, 
311, 312, 343-354]. .  
Secondary Injury Cascade 
Following the primary injury is a vast and encompassing secondary injury 
cascade that is initiated at various time point post-injury. This  secondary injury 
cascade arises due to alterations in excitatory amino acids (EAA) such as 
glutamate [309, 355], increases in oxidative stress (ROS) [356-358], the 
disruption of Calcium homeostasis [359, 360], and mitochondrial dysfunction 
[108, 311, 312, 343, 346, 347, 350, 353, 354, 361-364], which can all contribute 
to increased tissue damage at the site of the injury. Scientists believe that by 
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targeting these secondary injury cascades, improved histological and function 
outcomes will follow. 
Although a complete understanding of the secondary injury cascade injury 
is still uncertain, the implications of abnormally high excitatory amino acids, EAA, 
levels around the site of the injury are generally accepted. The most common of 
these EAAs is glutamate. High glutamate levels are thought to be a result of the 
breakdown of the blood-brain barrier, BBB, excessive synaptic release from 
neurons, nearby hyperexcited astrocytes and excitatory amino acids forming 
micropores within the cell membrane [365]. Once in the synaptic cleft, these 
EAAs are able to activate multiple receptors and channels including, AMPA and 
NMDA. Activation of these receptors leads to Calcium influx into the cell. As 
mentioned previously, at low to moderate levels, this intracellular Calcium, 
[Ca2+]i, is used as a potent signaling molecule; important in many pathways such 
as increased metabolism, neurotransmitter release and alterations in 
cytoskeleton. However, following an injury, EAA concentrations around the injury 
site increase to pathogenic levels, leading to drastic increases in Calcium influx 
which has the potential of leading to excitotoxic mediated cell death. The most 
important organelles involved in the rapid buffering of this Calcium, in order to 
avoid neuronal cell damage or death, are the mitochondria, which was discussed 
previously in detail. 
Mitochondria have low-affinity, high capacity Calcium pumps in their inner 
membrane that allow for rapid sequestration of [Ca2+]i. These pumps use 
electrochemical gradients generated by the electron transport chain’s (ETC) 
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translocation of protons across the inner membrane to build a membrane 
potential, ΔΨ. Although the primary usage of ΔΨ is to drive ATP synthesis, it also 
allows for electrogenic movement of [Ca2+]i into the mitochondria. As the 
mitochondria buffer Calcium, a reduction in ΔΨ occurs. The heightened 
intracellular Calcium levels place excessive demand on the mitochondria 
sequestering ability eventually resulting in mitochondrial dysfunction that has 
been documented for up to 48 hours post-injury [110]. It has been shown that 
cortical mitochondria Calcium levels in sham-operated rats range around 
~25nmol Calcium/mg. However, after traumatic brain injury, mitochondrial 
Calcium levels increase nearly 60% to levels hovering ~40nmol Calcium/mg 
[363]. This increase leads to a drastic change to the mitochondrial membrane 
potential eventually causing a detrimental disruption to mitochondrial 
homeostasis. Since [Ca2+]i reach pathogenic levels following injury, extreme ΔΨ 
reduction occurs and consequently ETC mediated ATP synthesis is hindered 
leading to increased ROS production. The dogma is that this ROS can then 
oxidize mitochondrial proteins leading to further mitochondrial dysfunction and 
the eventual initiation of cell death pathways. However, work Opii et al. found that 
even though important proteins, such as PDH, are oxidized, their function is not 
loss [343].  
As pointed out above, the cascade of posttraumatic mitochondrial ROS 
generation and oxygen radical reactions begins in response to rapid elevations in 
intracellular Ca2+ immediately following the primary mechanical injury to the 
brain or spinal cord with the single electron (e-) reduction of an oxygen molecule 
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(O2) to produce superoxide radical (O2•-) which is considered to be a modestly 
reactive primordial radical that can potentially react with other molecules to give 
rise to much more reactive, and thus more potentially damaging radical species. 
The reason that O2•- is only modestly reactive is that it can act as either an 
oxidant by stealing an electron from another oxidizable molecule or it can act as 
a reductant by which it donates it’s unpaired electron to another radical species 
(i.e. an electron-donating antioxidant). 
Although O2•- itself is less reactive than •OH radical, its reaction with nitric 
oxide (•NO) radical forms the highly reactive oxidizing agent, peroxynitrite (PN, 
ONOO-). This reaction (O2•- + •NO → ONOO-) occurs with a very high, 
diffusion-limited rate constant. Subsequently, at physiological pH, ONOO- can 
either undergo protonation to form peroxynitrous acid (ONOOH) or it can react 
with carbon dioxide (CO2) to form nitrosoperoxocarbonate (ONOOCO2). The 
ONOOH can break down to form highly reactive nitrogen dioxide(●NO2) and 
•OH (ONOOH → •NO2 + •OH). Alternatively, the ONOOCO2 can decompose
into •NO2 and carbonate radical (•CO3) (ONOOCO2 → •NO2 + •CO3). 
Increased production of reactive free radicals (i.e. “oxidative stress”) in the 
injured brain has been shown to cause “oxidative damage” to cellular (including 
mitochondrial) lipids and proteins leading to functional compromise and possibly 
cell death in both the microvascular and brain parenchymal cells. The major form 
of radical-induced oxidative damage involves oxidative attack on cell membrane 
polyunsaturated fatty acids triggering the process of lipid peroxidation (LP) which 
has three distinct chemical phases: initiation, propagation and termination. The 
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initiation of LP is triggered when a highly reactive (i.e. electron-seeking) oxygen 
radical (e.g. ●OH, ●NO2, ●CO3) reacts with membrane polyunsaturated fatty 
acids such as arachidonic acid, linoleic acid, eicosapentaenoic acid or 
docosahexaenoic acid resulting in disruptions in membrane integrity. Specifically, 
initiation of LP begins when a highly “electrophilic” radical steals the hydrogen 
electron from an allylic carbon of the peroxidizable polyunsaturated fatty acid. 
The allylic carbon is susceptible to free radical attack because it is surrounded by 
two relatively electronegative double bonds which tend to pull one the carbon 
electron away from the hydrogen electron it is paired with. Consequently, a 
reactive free radical has an easy time pulling the hydrogen electron off of the 
carbon because the commitment of the carbon electron to staying paired with it 
has been weakened by the surrounding double bonds. This reaction results in 
the original radical being quenched while the polyunsaturated fatty acid (L), 
becomes a lipid radical (L•) due to its having lost an electron.  
In the subsequent propagation step, the unstable L• reacts with O2 to form 
a lipid peroxyl radical (LOO•). The LOO• in turn abstracts a hydrogen atom from 
an adjacent polyunsaturated fatty acid yielding a lipid hydroperoxide (LOOH) and 
a second L•, which sets off a series of propagation “chain” reactions. These 
propagation reactions are terminated in the third step when the peroxidizable 
substrate becomes depleted and/or a lipid radical reacts with another radical or 
radical scavenger to yield relatively stable non-radical end products. One of 
those end products that is often used to measure LP is the 3 carbon-containing 
malondialdehyde (MDA) which is mainly a stable non-toxic compound that when 
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measured represents an LP “tombstone”. In contrast, two highly toxic aldehydic 
products of LP are 4-hydroxynonenal (4-HNE) or 2-propenal (acrolein) both of 
which have been well characterized in  experimental brain or spinal cord injury 
models [366-368]. These latter two aldehydic LP end products can covalently 
bind to basic amino acids (e.g. lysine, histidine, arginine, cysteine) in cellular 
proteins, altering their structure and functional properties.  
In addition to LP, free radicals can cause various forms of oxidative 
protein damage. A major mechanism involves carbonylation by reaction of 
various free radicals with susceptible amino acids. Secondly, ●NO2 can nitrate 
the 3 position of tyrosine residues in proteins forming 3-nitrotyrosine (3-NT) 
which is a specific footprint of PN-induced cellular damage. Similarly, lipid 
peroxyl radicals (LOO●) can promote tyrosine nitration by producing initial 
oxidation (loss of an electron) which would enhance the ability of ●NO2 to nitrate 
the phenyl ring [369]. Multiple commercially available polyclonal and monoclonal 
antibodies are available for immunoblot of immunohistochemical measurement of 
proteins that have been nitrated by PN. Thus, in summary, LP can cause cellular 
damage by destroying the integrity of the phospholipid bilayer as well as 
membrane-localized proteins by modification by carbonylation, nitration and/or 
binding of aldehydic LP end products such as 4-HNE or acrolein.  
Mitochondrial oxidative stress and resulting dysfunction plays an 
especially critical role in the post-traumatic cell death cascade in the injured brain 
[359, 360, 370, 371] or spinal cord [372, 373]. The initiator of this mitochondrial 
homeostatic dysfunction involves a rapidly evolving post-injury intracellular 
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accumulation of Ca++ ions which causes the mitochondria to try to buffer 
(sequester) the excess Ca++  which in turn causes mitochondrial respiratory 
dysfunction and lessened oxidative phosphorylation[354, 359, 370, 371] and 
Ca++ buffering capacity [360, 370] and mitochondrial failure due to mitochondrial 
permeability transition (MPT) [108, 364]. In addition to the potential activation of 
mitochondrial caspase-dependent and caspase-independent cell death 
cascades, this mitochondrial failure causes a disruption of synaptic function, and 
indeed synaptic mitochondria are more susceptible than non-synaptic 
mitochondria [354].   
The disruption of respiratory function is preceded by, or at least coincident 
with, an increase in mitochondrial free radical production and/or free radical-
triggered LP-mediated oxidative damage [371-373]. Evidence has accumulated 
which shows that a particularly important oxidant that is being formed by injured 
brain of spinal cord mitochondria is PN [373-378]. The relationship of PN 
generation to mitochondrial dysfunction in the injured spinal cord has been 
recently documented by studies that have shown that the timing of post-SCI 
mitochondrial dysfunction (i.e. respiratory and Ca++ buffering impairment) is 
preceded by an increase in PN-induced 4-HNE (i.e. LP), 3-NT (i.e. protein 
nitration) and 4-HNE and protein carbonyl content in mitochondrial proteins. Nitric 
oxide and a mitochondrial nitric oxide synthase (NOS) isoform (mtNOS) have 
been shown to be present in mitochondria [379, 380]. Exposure of mitochondria 
to Ca++, which is known to cause them to become dysfunctional, leads to PN 
generation which in turn triggers mitochondrial Ca++ release (i.e. limits their 
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Ca++ uptake or buffering capacity) [381]. In vitro application of each of the three 
PN forms, ONOO-, ONOOH and ONOOCO2, have been found to deplete 
mitochondrial antioxidant stores and to cause protein nitration, which is the 
hallmark of PN oxidative damage [382].  The loss of mitochondrial function and 
the increase in oxidative damage markers, including 3-NT, is antagonized by 
early in vivo post-TBI treatment with the PN radical scavenger tempol [376].  
Furthermore, exposure of non-injured mitochondria to PN quickly leads to 
respiratory dysfunction that is antagonized by tempol pretreatment along with a 
reduction in nitration of mitochondrial proteins [383].    
Additionally, the neurotoxic LP end products 4-HNE or acrolein are also 
able to produce a concentration-related attenuation of the respiratory function of 
normal brain or spinal cord mitochondria [384]. In those experiments, acrolein 
was observed to be 10x more potent than 4-HNE. Furthermore, spinal cord 
mitochondria were found to be significantly more susceptible that brain 
mitochondria.  However, scavenging of these carbonyl-containing compounds 
with the carbonyl scavenging compound phenelzine has been shown to 
attenuate mitochondrial respiratory depression along with a reduction in the 
levels of aldehyde-modified mitochondrial proteins [385]. 
As mitochondria remain in this dysfunctional state due to dysregulation of 
Calcium the ETC will reach a point where it can no longer maintain the necessary 
ΔΨ needed to allow Complex V to function properly. As the mitochondria remain 
in a dysfunctional state with a decreased ΔΨ hovering around 100-120mV, which 
is a drastic decrease from the normal membrane potential ranging around 
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180mV, the electron transport systems will begin to slow down or even halt. As 
discussed in Chapter 1, this change in potential allows for an increase in ROS 
production [110]. ANT can then be oxidized resulting in a conformational change 
that promotes cypD binding, along with other accessory proteins. VDAC is then 
able to bind this protein complex forming the mitochondrial permeability transition 
pore, MPTP, which was discussed previously. The MPTP formation exposes the 
inner mitochondrial matrix to the cytosol, allowing for the release of apoptotic 
initiating factors like Cytochrome C, SMAC/diablo and AIF, which all promote cell 
death. Neuroprotective agents that target mitochondrial dynamics and the 
membrane permeability pore formation can improve neuronal function in many 
disease states and therefore is important to consider when studying Traumatic 
Brain Injury. 
Pharmacological Treatments for TBI 
TBI can lead to drastic cognitive and functional deficits for the injured 
person. These deficits can decrease the quality of life for the injured person and 
their family as well as place extreme financial burdens on the individuals 
involved. To date there is still no FDA approved treatment for this disease; 
however, researchers are optimistic that a pharmaceutical intervention can be 
found. Scientists interested in finding a cure for TBI are most interested in the 
tissue where the the secondary injury cascade occurs following the initial injury. 
This is the tissue that is adjacent to the impacted tissue and can undergo a non-
mechanical cell death. Due to the neuroinflammation, the generation of free 
radicals, the accumulation of other reactive species and sustained mitochondrial 
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dysfunction, it is this tissue that is that thought to undergo drastic tissue 
dysfunction and cell death through various apoptotic and necrotic cell death 
pathways. By minimizing this injury cascade it is believed that the injured party 
will experience decreased functional deficits and increased tissue sparing 
providing a neural substrate for rehabilitation.  
Targeting mitochondrial dysfunction 
Some of the most promising neuroprotective agents following TBI are 
drugs that target mitochondrial dysfunction. Within the category of mitochondrial 
targeting drugs, there are multiple classifications. These include uncouplers, 
alternative fuels, antioxidants, oxidative phosphorylation modulators, mPTP 
inhibitors and O2 enhancers. Each of these drugs have specific pathways that 
are independent of one another and some show synergy when paired together. 
When using mitochondrial targeted approached, the time of delivery seems to be 
a critical factor. Mitochondrial targeting drugs seem to work best when delivered 
within the first hour or two of injury, however some seem to show positive effects 
when the therapeutic window is extended even further [110].  
One way to avoid mitochondrial dysfunction and the resulting cell death is 
by decreasing mitochondrial calcium buffering. Researchers have found that 
weak lipophilic acids that act like mitochondrial uncouplers, such as carbonyl 
cyanide 4-triflouromethoxy phenylhydrazone (FCCP) and 2,4-dinitrophenol 
(DNP), can produce positive therapeutic effects in animal studies of TBI. Acting 
as uncouplers are weak lipophilic acids that are able to deplete the membrane 
potential and thereby decrease the electromotive force by which calcium enter 
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the mitochondria. With decreased calcium uptake, markers of oxidative stress 
decreased as well leading to improved cortical sparing of up to 12% and 
enhanced cognition measured with the Morris Water Maze test when compared 
to vehicle treated animals [350, 363]. Although this technique has shown much 
promise, the dose response is steep providing an extra burden if it were to be 
used clinically.  
TBI induced oxidative stress occurs leading to oxidative modifications on 
various proteins rendering them dysfunctional. Oxidative stress with Pyruvate 
Dehydrogenase (PDH) has been documented following injury however the 
function of PDH does not seem to decrease with this increased oxidation [343]. 
This leads to the question as to where the mitochondrial dysfunction is 
originating. Additionally, glucose mediated depression has been seen in both 
animal and humans following TBI which is dependent on the injury severity [386, 
387]. Therefore, with metabolic enzymatic dysfunction and decreased metabolic 
substrates, a state of acute metabolic crisis has been shown to occur [388].  
 Alternative biofuels like ketones and beta-Hydroxybutyric acid 
(BHB), which are substrates that easily feed into the ETC without the contribution 
PDH or GDH, become a promising area of research [389]. For this reason, the 
use of ketone bodies in various animal models have been shown to decrease the 
production of free radicals through increases in glutathione production as well as 
increase the expression of various endogenous mitochondrial uncoupling 
proteins [361, 389, 390]. A study from Davis et. al. showed that with a moderate 
contusion injury in rats, treatment with D-beta-hydroxybuterate can decrease 
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markers of oxidative stress and increase mitochondrial oxidative phosphorylation 
following injury [361]. With these marked improved mitochondrial bioenergetics, 
cortical sparing and functional recovery has been seen as well.  [391, 392].  
Another important secondary injury mechanism that seems to show 
therapeutic effects when targeted following a TBI are those which up-regulate 
endogenous antioxidant activities. As mentioned previously, GSH/Glutathione is 
an endogenous antioxidant which is located in the mitochondria and converts the 
H2O2 generated by mnSOD to H2O. Present at mM levels, it is known to be the 
most abundant antioxidant found within the cell. Previous reports have shown 
that targeting GSH using a modified molecule of gamma-glutamylcysteine 
reduces markers of oxidative damage following TBI [393, 394]. Similarly, studies 
have also shown that n-acetyl cysteine, NAC, administration, the non-amide form 
of NACA, can increase brain GSH levels, improve mitochondrial function, reduce 
BBB permeability, and decrease brain edema following TBI [395-397]. NAC has 
also been shown to be effective in reducing free radical dependent 
cerebrovascular responsiveness in fluid percussion model of TBI which are likely 
the result of NAC’s ability to improve free radical scavenging mechanisms [398-
400]. Additionally, NAC has also been shown to be an effective compound in CCI 
by inhibiting cerebral inflammatory responses [401] and, when used in 
combination with minocycline, it has been shown to improve cognition and 
memory function following TBI [402, 403]. Most recently, NAC treatment has 
been evaluated in U.S. service members deployed to Iraq who had been 
exposed to a blast induced mild traumatic brain injury (mTBI). The initial report 
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indicates significantly improved behavioral outcome measures when patients 
were treated with NAC for 7 days compared to the placebo treatment [398, 404]. 
The Authors reported that if NAC treatment were received within 24 hrs of blast 
injury, members had significantly better chances of symptom resolution which 
included dizziness, hearing loss, headache, memory loss, sleep disturbances, 
and neurocognitive dysfunction. However, given the limited CNS bioavailability of 
NAC due to its limited BBB, cellular and, most importantly, mitochondrial 
permeability, the potential benefit of GSH as a therapeutic target has most likely 
been underestimated and has not reached its full potential. This justifies the 
foundation for a clinical trial that is currently underway to utilize the membrane 
transporter inhibitor probenecid to improve bioavailability of NAC following TBI in 
pediatric patients (Pro-Nac clinical trial, ClinicalTrials.gov ID NCT1322009).  
Building upon this, researchers have now started to investigate the use of 
NACA, the novel amide form of NAC which has increased bioavailability and 
ability to cross cellular and mitochondrial membranes. NAC is negatively charged 
at physiological pH, and mostly lipid insoluble in vivo, whereas the chemical 
derivative NACA is neutral and has high lipid solubility under physiological 
conditions [405, 406]. Although the literature on NACA is still somewhat limited it 
has been shown to increase tissue sparing and functional recovery following a 
CNS injury when compared to NAC and vehicle treated animals. These results 
were seen in both models of TBI and Spinal Cord Injury and have been attributed 
to the increased mitochondrial function and decreased oxidative stress which 
were both observed [344, 407-409]. 
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Interventions with multiple targets 
Lastly, it is thought that due to the complicated nature of the secondary 
injury cascade, the best pharmaceutical interventions will target multiple steps in 
this cascade. Cyclosporin A, CSA, is a drug that has been investigated for the 
use for a use in TBI and has shown great promise. CSA had multiple indications, 
including immune suppression, inhibition of mPTP formation and indirect 
antioxidant properties. In its action of targeting mPTP, CSA binds Cyclophilin D, 
CypD. Once CSA binds CypD, it is not able to contribute to the structure of the 
megapore leading to non-functionality thus preventing Calcium overload induced 
MPT. As an indirect antioxidant, CSA is not able to directly scavenger reactive 
radicals or aldehydes. Rather, CSA inhibition of MPT in TBI models secondarily 
lessens mitochondrial free radical formation and decreases the further 
accumulation of 4-HNE and 3-NT together with a histological neuroprotection in 
terms of decreased lesion volume with a therapeutic window as long as 8 hours 
[110, 360, 410-413]. This effect is totally unrelated to immunosuppression since 
the non-immunosuppressive cyclosporin A analog, NIM811, is able to duplicate 
the posttraumatic mitochondrial and neuroprotective effects [410, 414]. A phase 
2 dose escalation and safety study in 40 severe TBI patients has suggested that 
CSA treatment initiated within the first 8 hours and continued for 3 days may 
improve their functional recovery [415].  However, additional clinical trials are 
needed to determine the reliability of this effect.   
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CHAPTER 4: PIOGLITAZONE AS A TARGET FOR TBI INDUCED 
MITOCHONDRIAL DYSFUNCTION 
 
Traumatic brain injury (TBI) is a serious healthcare problem resulting in 
health, emotional, behavioral and financial complications [315]. The discovery of 
effective pharmacological agents is necessary to help this ailing population. Alas, 
there are no approved pharmacological treatments for TBI so progress in this 
area is vital. Appropriately aligned, this study will investigate the mechanism of 
neuroprotection offered by pioglitazone, an FDA approved pharmacological 
agent, and the importance of mitoNEET within this mechanism. This study will 
also help advance the field of traumatic brain injury by investigating the 
importance of mitochondrial bioenergetics to neuronal loss following TBI, while 
possibly uncovering a novel neuroprotective therapeutic target, mitoNEET.  
Complications that arise from TBI are multifaceted and originate from a 
mechanical insult. This insult leads to tearing of blood vessels, axonal shearing 
and cellular death, resulting in increased membrane permeability and the 
initiation of multiple signaling cascades [325]. Since the initial insult cannot be 
reversed, it is this secondary injury cascade where drug interventions can be 
targeted and advantageous. Some well accepted occurrences in the secondary 
injury cascade are alterations in excitatory amino acids (EAA) [309, 355], 
disruption of Calcium homeostasis [350, 359, 416], and mitochondrial dysfunction 
[108, 110, 313, 346, 347, 354, 359-361, 364, 416-420]. The implications of 
abnormally high excitatory amino acids, EAA, levels around the site of the injury 
are generally accepted. These EAAs activate multiple receptors and channels, 
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such as the NMDA receptor [421, 422]. Activation of these receptors leads to 
Calcium influx into neurons. At low to moderate levels, this intracellular Calcium 
concentration, [Ca2+]i, is used as a potent signaling molecule; however, following 
an injury, EAA concentrations drastically elevate Calcium levels leading to an 
overwhelming influx of Calcium and consequential neuronal cell death [423]. One 
of the most important organelles involved in the rapid buffering of this Calcium is 
the mitochondria. 
Mitochondria and TBI Link: Mitochondria have low-affinity, high capacity 
Calcium uniporters in their inner membrane that allow for rapid sequestration of 
[Ca2+]i. These uniporters “piggyback” off the membrane potential, ΔΨ, generated 
by the electron transport chain’s (ETC) translocation of protons across the inner 
membrane. As the mitochondria buffer Calcium, a reduction in ΔΨ occurs. 
Following injury, [Ca2+]i rapidly increases and mitochondria work feverishly to 
buffer it leading to decreased ΔΨ and decreased ETC mediated ATP synthesis. 
This mechanism continues until ΔΨ is depleted. At this point, mitochondria 
become dysfunctional and cell death pathways are initiated. Mitochondrial 
dysfunction related to excitotoxicity may be a therapeutic target for future drug 
interventions. Following a CNS (central nervous system) injury excitotoxic event, 
mitochondrial uncouplers have been studied to inhibit mitochondrial Calcium 
uptake through the reduction of ΔΨ. These uncouplers have been shown to be 
neuroprotective due to their ability to modulate mitochondrial dysfunction [350, 
363, 420, 424]. Recent studies have also shown that post-injury treatment of 
pioglitazone is able to attenuate mitochondrial dysfunction and increase cortical 
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sparing, however the exact target of pioglitazone within this mechanism is still 
unknown. 
PPAR, PPAR agonists and TBI: Peroxisome Proliferator Activated 
Receptors (PPARs) are Nuclear Receptor proteins that can heterodimerize in a 
ligand-dependent and -independent manner to regulate gene expression of 
multiple molecular processes. There has been 3 PPARs identified including α, δ/ 
β or and γ [425-429]. PPAR-γ the most widely studied subtype in the area of 
CNS injury due to its well-established role in the regulation of adipogenesis, 
glucose homeostasis, cellular differentiation, apoptosis and modulation of 
inflammation resulting from chronic and acute neurological insult. One class of 
drugs which have shown much promise as neuroprotective agents are 
thiazolidinedione which are anti-diabetic drugs used for the treatment of type 2 
diabetes. This class of drugs were generated for their ability to activate various 
Peroxisome Proliferating Activating Receptor isoforms [427, 428].  One of the 
isoforms in this class of drugs that has drawn much attention due to its ability to 
provide neuroprotection in models of CNS injury is pioglitazone [347, 430]. 
Originally, the mechanism of neuroprotection for this drug was thought to be 
through the modulation of PPARγ, however recent data analyzing PPARγ 
activation, as well as pioglitazone binding affinities for a specific mitochondrial 
membrane protein, may prove that this initial hypothesis needs reconsideration. 
Data has suggested that the therapeutic effects of pioglitazone may be more 
complex than just activation of PPAR. Not only has pioglitazone been shown to 
decrease inflammation it has also been shown to decrease oxidative damage, 
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attenuate mitochondrial dysfunction and reduce cell death following CNS injury, 
pathways which seem to be slightly more encompassing and on a quicker 
timeline than what could be attributed solely as PPARγ activation [311, 347, 430, 
431]. To further support this, a study by Thai et al. used PPAR antagonists to 
show that the neuroprotective effects seen with pioglitazone were independent of 
PPARγ. Additionally, a study by Bieganski et. al. showed that pioglitazone bound 
to mitoNEET, a mitochondrial membrane protein with an unknown role in the cell 
[432]. Lasly, a recent study by Zuris et al. showed that pioglitazone binding to 
mitoNEET was able to inhibit [2Fe2S] cluster transfer upon binding however the 
role of such a mechanism in providing therapy in CNS injury is unknown [433]. 
The combination of this data has stemmed ample research from our lab showing 
that pioglitazone is unable to increase mitochondrial bioenergetics in transgenic 
mice who lack mitoNEET and that pioglitazone loses some of its neuroprotection 
following injury in these animals as well.  
mitoNEET: mitoNEET was discovered in 2004 by Colca et. al. in the brain, 
liver and skeletal muscles of rodents [434]. This discovery was a result of a 
pioglitazone pull-down assay that bound to the novel m-17 kDa mitochondrial 
membrane protein, which was later termed mitoNEET [434]. The exact role of 
mitoNEET still remains unclear. However, it is known that mitoNEET knockout 
mice experience reduced oxidative capacity hinting to an importance in 
mitochondrial mediated respiration [435, 436]. A recent publication also found 
that mitoNEET binds Glutamate Dehydrogenase I allowing for direct control over 
the Krebs cycle and therefore control over mitochondrial respiration [83]. 
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Therefore, I propose mitoNEET to be important for mitochondrial homeostasis 
and therefore a crucial therapeutic target for pioglitazone mediated 
neuroprotection. 
Results  
Pioglitazone is able to increase mitochondrial respiration in a biphasic 
manner following calcium insult.  
The mitochondrial effects of pioglitazone have been debated in the 
literature [347, 430, 437]. Pioglitazone has been shown to interact with multiple 
proteins at the cytosolic, nuclear and mitochondrial level [431, 432, 434, 437, 
438]. In order to study the importance of mitochondria bioenergetics in 
pioglitazone mediated neuroprotection, we isolated mitochondria, removing any 
interactions due to cytosolic or nuclear proteins such as the PPARs. This allows 
for insight into what exactly is occurring in the mitochondrial level. Previous 
results from Murphy et. al. have shown that micromolar concentrations of 
pioglitazone are able to decrease mitochondrial respiration [437]. However, 
results from Sauerbeck et al show that lower concentrations, nanomolar to 
micromolar range, of pioglitazone can increase mitochondrial respiration in 
isolated mitochondria [347]. In order to determine where this discrepancy arose, 
cortical mitochondria were isolated from naive CD57/BL6 mice, insulted with 
Calcium (150nm/mg) and then treated with various concentrations of 
pioglitazone. Mitochondrial bioenergetics were analyzed (Figure 4.1). This 
calcium insult provides a similar effect to that seen within the excitotoxicity 
mechanism following a TBI. 50nM pioglitazone was able to increase 
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mitochondrial respiration 12.7% compared to naïve non-insulted mitochondria 
and 32.8% compared to vehicle treated calcium insulted mitochondria. Also, a 
biphasic effect was seen where lower dosages of pioglitazone (0.05uM) provided 
increased mitochondrial bioenergetics and higher concentrations provided 
decreased mitochondrial bioenergetics. This data supports what has been 
published in the literature where lower concentrations of pioglitazone increased 
mitochondrial respiration and higher concentrations decreased mitochondrial 
respiration.  
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Figure 4.1 Pioglitazone Dose Response: Pioglitazone is able to increase state 
V mediated maximal mitochondrial respiration in isolated from wild-type C57BL/6 
mice cortex insulted with 150nm/mg of calcium. One-way ANOVA, Compared 
Drug Treated to Ca + Vehicle, Bonferroni Post-Hoc – protects from a type I 
error (Detecting an effect that is not present), N=3, SEM 
Naïve	
with	
No	
Calcium
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Pioglitazone loses its neuroprotective effects in mitoNEET KO animals. 
As mentioned previously, mitoNEET is a novel mitochondrial membrane 
protein which has been shown to modulate mitochondrial respiration. 
Pioglitazone has also been shown to bind mitoNEET however the importance of 
this interaction in pioglitazone’s neuroprotective effects remains unknown. 
Therefore, we wanted to preform a similar test to what was performed in 
mitochondria isolated from wild-type mice however use mitoNEET null mice 
instead. The mitoNEET null mice were generated by Dr. Stewart Ross at the 
university of Kentucky and used previously Western blot was performed in WT 
versus mitoNEET null cortical homogenate to confirm the presence, or lack, of 
mitoNEET [435] (Figure 4.2). As shown in figure 1, calcium is able to decrease 
mitochondrial respiration in wild-type mitochondria and pioglitazone is able to 
reverse these inhibitory effect. However, in mitochondria isolated from the 
cortical tissue of mitoNEET null mice, calcium (150nm/mg of protein) had little 
effect on mitochondrial respiration and the use of pioglitazone provided no 
increased respiration (Figure 4.3). In order to further understand this 
phenomenon, we evaluated the membrane potential using TMRE and Ca5 
indicators and there was no differences observered, data not shown. Combined, 
these results show that mitoNEET is important in calcium mediated decreases in 
mitochondrial bioenergetics and that mitoNEET is necessary for pioglitazone 
mediated increased respiration following an insult from Calcium. 
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Figure 4.2 WT versus mitoNEET null protein expression: Western blot 
analysis of mitoNEET expression in WT versus mitoNEET null animals.  
KO WT KO WT 
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Figure 4.3 Pioglitazone dose response in mitoNEET null mice: In 
mitochondria isolated from the cortical tissue of mitoNEET null mice, calcium 
insult (150nm/mg protein) has no significant effect and pioglitazone is unable to 
increase state V mediated maximal mitochondrial respiration. One-way ANOVA, 
Compared Drug Treated to Ca + Vehicle, Bonferroni Post-Hoc, N=3, SEM 
Naïve	with	
No	Calcium 
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Work from Sullivan et. al. and many others have shown that mitochondrial 
dysfunction is progressive over the first 24 to 48hrs following a control cortical 
impact and that amelioration of this mitochondrial dysfunction can improve 
neurological function and cortical sparing. This mitochondrial dysfunction can be 
targeted with various therapeutic interventions in order to improve tissue and 
functional outcomes following an injury. Pioglitazone is one drug that has been 
shown to both target mitochondrial dysfunction and improve tissue and functional 
outcome. However, the question that arises when studying pioglitazone mediated 
neuroprotection following a traumatic brain injury is ‘what is its mechanism?’. 
This is a difficult question to answer because pioglitazone has been shown to 
interact with multiple proteins within the cell. In the past, much interest has been 
placed on pioglitazone interaction with various isoforms of PPAR however one 
specific protein that is starting to gain some interest in the literature is mitoNEET. 
This protein is found within the mitochondria giving it direct localization to 
improve mitochondrial bioenergetics. In order to test the importance of mitoNEET 
in pioglitazone’s ability to increase mitochondrial bioenergetics following injury, 
mitoNEET null and wild-type mice were injured and received one IP injection of 
pioglitazone at 12 hours post-injury. The animals were sacrificed and cortical 
mitochondria were isolated at 13 hours post-injury. Mitochondria isolated from 
mice treated with pioglitazone had a 54% increase in mitochondrial bioenergetics 
compared to vehicle treated wild-type mice. On the contrary, mitoNEET knockout 
mice experienced no increase in mitochondrial bioenergetics compared to 
vehicle treated animals of the same genotype. This data provides support that 
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the ability of pioglitazone to improve mitochondrial dysfunction following 
traumatic brain injury is directly dependent on the presence of mitoNEET.  
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Figure 4.4 Pioglitazone response in WT verus mitoNEET Null mice: FCCP 
mediated, maximal mitochondrial oxygen consumption rate, in wild-type and 
mitoNEET null mice (n=3) who received pioglitazone (1 IP injection, 10mg/kg) at 
12hours post-injury with isolations at 13hours post-injury. Mitochondria from wild-
type mice treated with pioglitazone had significantly increased bioenergetics 
compared to mitoNEET null mice. Data represents means + SEM, *p=0.0322 
wild-type compared to mitoNEET null mice. 
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Pioglitazone treatment following TBI is able to increase cortical sparing 
however the effect is diminished when mitoNEET is removed.  
As mentioned previously, research has found that pioglitazone is able to 
alter mitochondrial bioenergetics and improve neuroprotection [347, 430]. Many 
pharmacological treatments that target mitochondrial dysfunction have also 
shown promising neuroprotective effects following an injury to the CNS [361, 
439-444]. To test whether the change in mitochondrial bioenergetics lead to 
increased cortical sparing following a brain injury, adult wild-type and mitoNEET 
null mice (n=6) received a moderate contusion injury and then received either 
vehicle (DMSO) or 10mg/kg of pioglitazone through IP injection at 15min and 
then daily for the first 7 days post-injury. Cortical tissue sparing was accessed at 
14 days post-injury and pioglitazone was found to be neuroprotective following 
TBI in wild-type (+/+) but not mitoNEET null (-/-) mice (n=6, p=0.0049). As shown 
in Figure 3, pioglitazone treatment significantly increases tissue sparing in wild-
type (+/+) mice but this effect was lost in mitoNEET null (-/-) mice. The effects of 
pioglitazone that are seen in the mitoNEET mice are likely due to other 
neuroprotective effects mediated at the cytosolic and/or nuclear level. It is also 
important to note that no significant differences were measured between vehicle-
treated animals of either genotype, showing that the removal of mitoNEET from 
the mitochondrial membrane did not increase the animals’ susceptibility to injury. 
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Figure 4.5: Pioglitazone is neuroprotective following TBI in wild-type (+/+) 
but not mitoNEET null (-/-). 
In this study, mice (n=6 per group) were injured (1.0 mm, severe) followed by 
pioglitazone injections (10mg/kg) at 15min, and 24hours post injury with cortical 
tissue sparing was assessed at 7 days. Pioglitazone treatment significantly 
increases tissue sparing in wild-type (+/+) but not mitoNEET null (-/-) mice. 
Additionally, no significant differences were measured between vehicle treated 
animals of any genotype. One-way ANOVA, Compared Drug Treated to 
Vehicle within same genotype, Bonferroni Post-Hoc, n=6, p=0.0049, mean 
+/- SEM 
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mitoNEET binding with a mitoNEET specific ligand, NL-1, increases cortical 
sparing and improves functional outcome following a TBI. 
Due to the slight trend of neuroprotection seen in mitoNEET null mice who 
were treated with pioglitazone, we decided to probe the importance of targeting 
mitoNEET specifically, with a mitoNEET ligand. In regards to this non-significant, 
off-target effect seen with pioglitazone, it is likely due to interactions at the 
cytosolic level, quit possibly with PPAR. We know that this effect is due to 
cytosolic contributions because we do not see increases in isolated mitochondrial 
respiration in mitoNEET KO mitochondria however do see an effect in wild-type 
mitochondria. Therefore, we moved our studies forward hypothesizing that NL-1 
would provide the same degree of neuroprotection which was seen with 
pioglitazone, however render no trends towards neuroprotection in the mitoNEET 
null mitochondria. Therefore, collaborators synthesized a compound that binds to 
mitoNEET called NL-1. Pharmacodynamic studies have shown that this drug is 
very similar to pioglitazone, retaining the traditional glitazones structure, binding 
to mitoNEET with equal affinity as pioglitazone, however lacks the PPAR binding 
region.  Following a severe injury, either WT or mitoNEET null mice received 
either an IP injection of 10mg/kg NL-1 or vehicle (DMSO) at 15 minutes and then 
daily for the first 7 days post-injury. At 7 days post-injury, animals were sacrificed 
and tissue sparing was calculated. As seen in Figure 4.6, NL-1 administration 
following injury significantly increases (p=0.033, n=16) cortical sparing by 37% 
compared to vehicle treated animals.  
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Figure 4.6: NL-1 administration increases cortical tissue sparing after TBI. 
CD57bl6 WT or mitoNEET null mice received the mitoNEET ligand, NL-1, (n=16, 
IP injection, 10mg/kg, at 15min and then daily for the first 7 days post-injury) 
following a moderate injury (1.0mm) had a significant increase in cortical sparing 
at 37% compared to vehicle treated mice (n =16) at 7 days, an effect that was 
lost in the mitoNEET null animals. One-way ANOVA, Compared Drug Treated 
to Vehicle within same genotype, Bonferroni Post-Hoc, n=16, p=0.0222, 
mean +/- SEM  
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Figure 4.7 Qualitative Images of NL-1 Cortical Sparing: Representative 
figures of the cortical sparing seen in WT animals treated with NL-1 compared to 
either vehicle treated or drug treated without mitoNEET’s presence.  
 
  
WT Animals KO Animals 
Vehicle 
NL-1 
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The neuroprotective effects seen with NL-1 lead us to believe that 
treatment with NL-1 could also increase functional recovery following injury. With 
the model of injury used in this study, animals experience damage to regions of 
the motor cortex leading to motor deficits. To test these deficits, animals are 
trained before their TBI surgery to traverse various sized beams. Following injury, 
the animals are then placed on the various sized beams and foot faults are 
measured as an indication of deficits to the corticospinal tracts. Therefore, the 
animals were trained to traverse the beams and then provided a severe injury to 
both wild-type and mitoNEET null mice. We treated them with either vehicle or 
10mg/kg of NL-1 at 15 minutes’ post-injury and then daily for the first 7 days. 
Foot faults on the beam were tested at 1 hour, 1 day, 3 days and 5 days post-
injury. Injections on behavioral test days were provided following the behavioral 
tests in order to avoid any confounding stresses. The wild-type mice treated with 
NL-1 had a significant increase in functional recovery at day 5 compared to 
vehicle treated, which is an effect that was not seen in the mitoNEET null mice.  
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Figure 4.8: Wild-type mice treated with NL-1 had a significant increase in 
functional recovery, an effect lost in the mitoNEET null mice. Wild-type and 
mitoNEET null mice were trained on the beam walk test and then received a 
severe CCI injury 24 hours later. They were given 8 IP injections of 10mg/kg of 
NL-1 at 15 minutes and then every 24 hours thereafter for the first 7 days post-
injury. At 1 hours, 1day, 3 days and 5 days post-injury, the beam walk test was 
performed and foot faults were measured. Wild-type mice treated with NL-1 had 
improved performance on this test compared to vehicle treated mice. This effect 
was lost in mitoNEET null mice. Two-way ANOVA, Compared Drug Treated to 
Vehicle within same genotype, Bonferroni Post-Hoc, n=16, p=0.0168, mean 
+/- SEM  
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mitoNEET is able to interact with GDH providing insight to a possible 
neuroprotective mechanism.  
Following a brain injury, a dysregulation of excitatory amino acids occurs, 
specifically related to Glutamate. This eventually leads to the initiation of 
excitotoxicity through pathogenic influxes of calcium. Mitochondria are the first 
line of defense in order to rapidly buffer high intracellular calcium levels. As they 
continue to buffer Calcium in a process mediated by the mitochondrial calcium 
uniporter, the membrane potential, generated by the electron transport chain, 
becomes depleted. The current theory is that as Calcium levels reach high 
enough level, reactive oxygen species and reactive nitrogen species (ROS and 
RNS specifically) production increases leading to the damage of proteins within 
the mitochondria. However, work published by Pandya, show that with increased 
calcium insult in isolated mitochondria did not lead to increased oxidative stress. 
Additionally, calcium insult leads to decreased state III respiration, which hints to 
an inhibition that is mediated either at Complex I or upstream. According to this 
2013 paper however, neither Complex I nor PDH activity were inhibited by 
calcium load hinting at another possible mechanism [362]. After observing 
decreased calcium inhibited respiration in the mitoNEET null mice, we became 
interested in a possible mechanism. Work from Roberts observed that mitoNEET 
was able to interact with GDH, which was observed during a pull-down assay 
[83]. Additionally, work from Cole found that GDH expression increases following 
TBI, which was proposed to be due to a lack of BCAA [445]. However, I 
hypothesize that decreased mitoNEET activity leads to inhibition of GDH 
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following TBI, which leads to compensatory increased expression. I propose that 
this effect would be reversed following treatment with either NL-1 or pioglitazone.  
Discussion 
The mechanism of pioglitazone mediated neuroprotection has been highly 
debated for years. Historically, the effect of this glitazones has been thought to 
be through its interactions with PPAR-γ. However, many research groups have 
found pioglitazone retains its therapeutic effects in the presence of PPAR 
inhibitors. Additionally, researchers have found that pioglitazone is able to target 
mitochondrial bioenergetics and we have found that it can increase mitochondrial 
bioenergetics in pure isolated mitochondria, removing any effect from the cytosol 
or nucleus. Therefore, with this study, we attempted to understand the 
importance of mitoNEET within the mechanism of neuroprotection provided by 
pioglitazone following a control cortical impact injury. 
 One topic that has been highly debated regarding pioglitazone is whether 
it increases or decreased mitochondrial bioenergetics. In a previous study 
completed my Murphy et. al. mitochondrial bioenergetics were decreased with 
permeabilized cells were incubated with micromolar concentrations of 
pioglitazone [437]. However, research from Sauerbeck et. al. found that 
pioglitazone is able to increase mitochondrial bioenergetics when isolated 
mitochondria were incubated with nanomolar concentrations of pioglitazone 
[347]. Results from this study provide possible insight into where this discrepancy 
may be arising in that pioglitazone has a biphasic effect which increased 
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mitochondrial bioenergetics at low concentrations but can become toxic to 
mitochondria when concentrations become too high.  
 Building upon the importance of dosage when working with pioglitazone, 
the next important topic to discuss is the mechanism of neuroprotection. In the 
literature, pioglitazone is described as a PPAR agonist that provides 
neuroprotection through changes in gene expression of a plethora of important 
proteins such a cytokines and various endogenous antioxidants. These changes 
are extremely important when treating traumatic brain injury and should not be 
disregarded. However, interestingly enough, the improvements of mitochondrial 
dysfunction that have been seen following an injury to the brain occur on a 
timescale much more rapid than the effects seen with changes in gene 
expression. As seen with the previous data, animals treated with pioglitazone at 
12 hours post-injury and sacrificed 1 hour later had increased mitochondrial 
function compared to vehicle treated animals. Since the drug was only introduced 
one hour before the mitochondria were isolated, the effects are thought to be 
based on direct interactions and not through changes in gene expression. 
 This observation raises the question, if pioglitazone is not providing 
neuroprotection through changes in gene expression, then what is pioglitazone 
interacting with directly? From this study it seems as if the answer to this 
question lies within mitoNEET. From the data we see that pioglitazone is able to 
increase mitochondrial bioenergetics by over 54% in wild-type mice who express 
mitoNEET in their mitochondria however lose its ability to increase mitochondrial 
bioenergetics in mitoNEET null (-/-) mice. To further support this, wild-type mice 
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that were injured with a moderate CCI injury had a 64% increase in tissue 
sparing compared to mitoNEET null (-/-) mice. This provides evidence that 
mitoNEET is crucial for pioglitazone mediated neuroprotection. 
In order to further test that hypothesis that binding mitoNEET with a 
mitoNEET ligand is indeed able to increase mitochondrial bioenergetics, NL-1 
was synthesized as a truncated glitazones, retaining a structure similar to 
pioglitazone which allows it to bind mitoNEET but not interact with the PPAR 
isoforms. This drug was not only found to provide a 37% increase in cortical 
sparing but was able to improved motor function in wild-type mice, which was not 
seen in mitoNEET null (-/-) mice.  
 The data provided from this study provides strong evidence that 
pioglitazone mediated neuroprotection following a contusion injury in rodent 
models is able to provide increase tissue sparing and improved functional 
outcome is dependent on interactions with mitoNEET. This data also supports 
mitoNEET as a potential therapeutic target for brain injury as well as other 
neurodegenerative diseases where mitochondrial dysfunction is prevalent.  
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CHAPTER 5: METHODS USED FOR THESIS WORK 
 
Animals: All of the studies performed were approved by the University of 
Kentucky Institutional Animal Care and Usage Committee. All experiments were 
conducted using either adult (male Sprague-Dawley rats (Harlan, Indianapolis, 
IN) weighing 300-350g (chapter 2) or adult (~8-10 week old) male and females 
adult wild-type (C57BL/6) or mitoNEET null mice with an average mass of 30 
grams. Studies with wild-type (WT) and mitoNEET -/- (KO) mice were the same 
mice described in [435] which are bred and housed in the SCoBIRC transgenic 
animal core. The rats were housed 3 per cage and the mice were house 5 per 
cage. Both sets of animals were maintained in a 12-hr light/12hr dark cycle and 
fed a balanced diet ad libitum.  
 
mitoNEET Null Colony: Genotyping of these animals has been done by our 
laboratory and wild-type littermates will be used as controls. These animals have 
been backcrossed into the C57BL/6 strain of mice (minimum of 30 generations) 
to account for differential strain sensitivity to neuronal insult and injury. C57BL/6 
mice are an inbred strain, maintained in a barrier-reared environment, widely 
used in TBI research and as genetic background strains in transgenic models. 
 
Controlled Cortical Impact Brain Injury: All surgical procedures were 
performed as previously described [110, 346, 350, 354, 361, 363, 364, 416, 418, 
444] and were classified as severe (1.0 mm (mice) deep contusion at 3.5 
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meters/second for 500ms). Prior to injury, animals were anesthetized using 2% 
isofluorane, weighed and their head was shaved to remove hair at the site of the 
surgery. Animals were then placed in a Kopf stereotaxic frame (David Kopf 
Instruments, Tujunga, CA) for proper positioning under a pneumatic head 
impactor (Precision Science Instruments) and body temperature was maintained 
at 37oC with the use of a isothermal pad. A 5mm craniotomy was drilled lateral to 
the central fissure on the left side of the skull centered between lambda and 
bregma, with much care taken to not disrupt the dura. Injury groups then 
received a unilateral injury directly to the surface of the brain. Sham animals 
received a 5.0mm craniotomy but did not receive an impact to the brain. 
Following the injury, a hardened circular piece of dental acrylic made the night 
before, and secured with sterile surgical adhesive over the craniotomy. The 
incision was then closed with medical grade sutures.  
 After the surgery sites were closed on all animals, the isofluorane was 
shut off and the animals were removed from the stereotaxic frame. They were 
then placed in a clean cage that was temperature controlled at 37oC with a 
heating pad until the animals were mobile and fully responsive. 
To investigate the neuroprotective effects of either pioglitazone or NL-1 
after TBI, animals were given a CCI in the manner described above and then 
given an IP injection of either pioglitazone or NL-1. Both drugs were solubilized in 
vehicle (100% Ethanol, 1uL 38% HCl, and 25uL of 0.9% saline for pioglitazone 
and 100% DMSO for NL-1) before injection. All drugs were made at an 
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appropriate concentration in order to inject ~100uL per animals and exact 
adjustments for weight were made before the injection was given.  
 
 
TABLE 5.1 Dosage Paradigm for Animals 
Desired Dosage For Animal Concentration of Drug 
1mg/kg 0.3mg/ml 
10mg/kg 3mg/ml 
20mg/kg 6mg/ml 
40mg/kg 12mg/ml 
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Mitochondrial isolation: Mitochondria were isolated using previously employed 
differential mitochondrial isolation methods [347, 362, 446]. Animals were 
sacrificed by asphyxiation with CO2 and then rapidly decapitated. This CO2 
asphyxiation method is the standard euthanasia method used. The animal’s 
consciousness is quickly removed allowing for the rapid removal of the brain 
without any confounding factors that other methods would pose, such as the use 
of FatalPlus. The brain is then washed with ice-cold (around 4oC) mitochondrial 
isolation buffer with EGTA (MIB+EGTA) made-up of 215 mM Mannitol, 75 mM 
Sucrose, 0.1% BSA, 1 mM EGTA, and 20 mM HEPES at pH 7.2. This step 
removes excess blood and debris, while chilling the brain rapidly. The used of 
MIB+ETGA at this point is a crucial step as EGTA is used to chelate free calcium 
released during the homogenization process. Cortical tissue, either total or a 
5mm punch if the brains were injured, were then homogenized in a Potter-
Elvejhem manual homogenizer with 3mL of MIB+EGTA. Once the tissue was 
fully homogenized, the samples were spun via centrifugation at 1300 × G for 
3 min.  
Following the last spin, the supernatant is placed in a fresh tube and the 
pellet is re-suspended in MIB+EGTA. The samples are then spun again at 
1300 × G for 3 min. This step allows for the separation of heavy cellular debris 
such as the plasma membrane, from smaller intercellular organelles, etc. The 
supernatant from the first and second spins were collected in separate tubes and 
spun at 13,000 × G for 10 min. This spin allows for the removal of light-weight 
objects such as proteins, RNA, etc. The pellets from both tubes are then 
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combined, resuspended in 500 μl MIB+EGTA and placed in a nitrogen bomb at 
1,200 psi for 10 min. The pressure in the nitrogen bomb is rapidly released after 
10 min in order to pop the synaptosomes and release synaptic mitochondria.  
  The samples are then placed as the top layer on a Ficoll separation 
column which consisted of a 10% Ficoll layer (bottom) and a 7.5% Ficoll layer 
(top). The Ficoll column with sample carefully placed on top is centrifuged at 
32,000 × G for 30 min at 4 °C. Following the Ficoll purification, the mitochondrial 
pellet, bottom layer, is re-suspended in mitochondrial isolation buffer without 
EGTA (MIB-EGTA) and centrifuged at 10,000 × G for 10 min at 4 °C in order to 
remove residual Ficoll and EGTA from the purified mitochondrial sample. The 
final mitochondrial pellet is re-suspended in MIB-EGTA to yield a final 
concentration of approximately 10 mg/ml. These samples are stored immediately 
on ice. Protein concentrations for each sample is determined with all the samples 
on the same plate using the BCA protein assay kit and measuring absorbance at 
560 nm with a Biotek Synergy HT plate reader (Winooski, VT). 
Measurement of mitochondrial bioenergetics: Oxytherm 
 
As mentioned in Chapter 1, and seen in Figures 1.10 and 1.11, the 
Oxytherm which uses a Clark Electrode, is historically used for mitochondrial 
bioenergetics assays. Before the mitochondrial samples are evaluated, the 
electrode is built in the manner described in Chapter 1. The Oxytherm is then 
calibrated at 37oC, measuring 100% oxygen, 0% oxygen in the presence of 
Sodium Borohydride (Sigma 213462-25G) and then 100% oxygen again. Once 
calibrated, 250uL of Respiration Buffer (RB) composed of 215 mM mannitol, 
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75 mM sucrose, 0.1% BSA, 20 mM HEPES, 2 mM MgCl, 2.5 mM KH2PO4 at 
pH 7.2, is added to the chamber along with 50ug of mitochondrial protein and the 
Oxytherm program, Oxy32, is started to read oxygen changes. 
 Substrates and inhibitors are then added allowing us insight into the 
functionality of the proteins within the Electron Transport System.  
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TABLE 5.2 Mitochondrial Bioenergetics Overview 
Targeted 
State of 
Respiration 
Substrate or 
Inhibitor Added 
Amount 
Added Concentration 
Rational of 
Addition 
State I  Mitochondria ~5ul 10ug/ul No Substrate 
added 
State II Pyruvate/Malate 2.5ul 5mM/2.5mM Added to “charge” 
the membrane. 
Pyr and Mal will 
start the Krebs 
Cycle allowing for 
the production of 
NADH. These are 
then fed into the 
ETS, building the 
proton-motive 
force however 
this force cannot 
be converted into 
energy (ATP) due 
to a lack of ADP.  
State IIIADP ADP 1.25ul x 2 150uM The presence of 
ADP allows ATP 
Synthase to 
convert the 
proton-motive 
force (Membrane 
Potential) built by 
the addition of 
Pyr/Mal into ATP. 
With differential 
mitochondria, 
ATPases will use 
the ATP as it is 
generated leading 
to a depletion of 
Oxygen. In 
isolated 
mitochondria, the 
ATP synthase will 
convert all the 
ADP to ATP and 
the oxygen 
consumption will 
plateau. A second 
amount of ADP is 
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added again in 
order to get 
maximal State III 
respiration. 
State IV Oligomycin 0.5ul 1uM As mentioned in 
Chapter 1, 
Oligomycin is an 
ATP Synthase 
inhibitor. It binds 
the Oligomycin 
Sensitive 
Conferring 
Protein (OSCP), 
consequently 
inhibiting State III 
respiration. This 
allows the proton-
motive force to 
build back up and 
any oxygen 
consumption 
measured here is 
a result of proton 
leak across the 
inner membrane. 
State V FCCP 
/Uncoupler 
0.5ul 1uM FCCP is a weak 
lipophilic acid 
which acts as a 
membrane 
uncoupler. It 
binds protons in 
the IMS and 
translocates them 
to the matrix. The 
rate of oxygen 
consumed here 
provides the 
maximal 
mitochondrial 
respiration.  
State 
VSuccinate 
Rotenone + 
Succiate 
0.1ul + 
5ul 
1mM + 10mM Rotenone is 
added to inhibit 
Complex I, as 
discussed in 
Chapter 1. Once 
Complex I is 
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inhibited, 
succinate is able 
to feed electrons 
into the ETC 
through Complex 
II. The rate of 
oxygen 
consumption here 
provides 
information about 
State III Complex 
II mediated 
respiration 
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A representative figure of an Oxytherm plot is as follows:  
 
 
 
  
 
 
Figure 5.1 A representative figure of healthy mitochondria respiring 
during a coupling experiment: Oxygen consumption within healthy 
mitochondria.  
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Measurement of mitochondrial bioenergetics: Seahorse 
 
Measurements of mitochondrial bioenergetics in isolated mitochondrial 
were completed using a Seahorse XF24 Flux Analyzer as published previously 
using slight modifications [447]. Stock mitochondrial substrates of 500 mM 
pyruvate, 250 mM malate, 30 mM ADP, 1 mg/ml oligomycin-A, 1 mM FCCP, 
1 mM rotenone and 1 M succinate were prepared and the pH was adjusted to 
pH 7.2. The day before the planned experiment, a 24 well dual-analyte solid state 
bio-sensor cartridge was hydrated with Seahorse XF Calibrant (pH 7.4) and 
incubated in a non-CO2 incubator at 37 °C.  
On the experiment day, the bio-sensor cartridge ports A through D were 
loaded with 75ul of the appropriate mitochondrial substrates or inhibitors (Port A 
= 8 x, Port B = 9 x, Port C = 10 x, and Port D = 11 x concentration made from 
stocks and RB), and injected into the assay plate according to protocol procedure 
to reach the final concentration of the compound (1 ×) in each well. The amount 
of substrates/inhibitors loaded for each port is based upon the initial 525 μl RB 
volume in the mitochondrial plate as follows: Port A – 75 μl (mixture of pyruvate, 
malate and ADP), Port B – 75 μl (Oligomycin A), Port C – 75 μl (FCCP), and Port 
D – 75 μl (rotenone and succinate). Once the bio-sensor cartridge was loaded 
with all of the experimental reagents it was placed into the Seahorse XF24 Flux 
Analyzer for automated calibration. 
During the calibration phase, the Seahorse Standard XF24e flux assay 
plates were utilized for mitochondrial analysis. Isolated mitochondria (7μg) from 
every experimental group were analyzed together on a single plate. 
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Mitochondrial samples were re-suspended in 50 μl RB and added in 
experimental wells whereas background control wells contained 50 μl of RB 
without mitochondria. Once every well was loaded, it was centrifuged for 4 
minutes at 3,000 rpm room temperature. Following the centrifugation of the 
plates, 475 μl (37 °C) of pre-warmed RB was gently added to each well for a final 
volume of 525 μl per well. Plates were then placed into the calibrated Seahorse 
XF24 flux analyzer for mitochondrial bioenergetics analysis after the sensor 
cartridge calibration was concluded. 
An optimized protocol was utilized for the analysis of bioenergetics 
function in purified mitochondria using the Seahorse Biosciences XF24 Flux 
Analyzer. The protocol contains sequential and/or cyclic steps of a cartridge 
probe calibration, mixing substrates in the assay system, a delay for some time, 
injections of substrates/inhibitors and then measurement of the oxygen 
consumption rates (OCR) as elaborated upon previously [447].  
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TABLE 5.3 Protocol for mitochondrial coupling studies  
Step Time Elapsed 
Time 
Procedure Reason Potential 
Issues 
Calibration -30 
minutes 
 Calibrate 
Biosensors 
Calibration of 
the 
biosensors, 
measuring 
standard 
Oxygen and 
pH 
 
Insert 
microplate 
0 
minutes 
0 
minutes 
   
Equilibration 
 
12 
minutes 
12 
minutes 
2 minutes 
Mix x 3 
 
Allows 
samples in 
microplate to 
adjust to 
temperature 
changes. 
Consists of 2 
minute mix 
and a 2 
minute wait 
which is 
repeated 3 
times. 
 
2 minutes 
Wait x 3 
 
Basal 
Respiration 
 
1 
minutes 
13 
minutes 
Mix Measures the 
State I 
respiration. 
No 
substrates, 
only 
mitochondria 
 
1:30 
minutes 
 
14:30 
minutes 
Wait  
2:00 
minutes 
16:30 
minutes 
Measure  
5mM 
Pyruvate 
2.5mM 
Malate 
1.0mM ADP 
~30 
seconds 
17 
minutes 
Inject Port 
A 
This step 
measures 
State IIIP/M 
mitochondrial 
respiration. It 
will produce 
the electron 
rich NADH 
molecules 
leading to a 
charged inner 
mitochondrial 
When 
running this 
step, it is 
crucial to go 
back to the 
raw O2 
levels to 
assure that 
you have 
not depleted 
the oxygen 
stores. This 
25 
seconds 
17:25 
minutes 
Mix 
0 
seconds 
17:25 
minutes 
Wait 
2:00 
minutes 
19:25 
minutes 
Measure 
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membrane 
through 
Complex I 
while 
providing the 
ADP 
necessary to 
allow ATP 
Synthase to 
make ATP 
will lead to 
errors in 
your 
calculated 
OCR values 
Mix 1 1 
minute 
20:25 
minutes 
Mix Helps to re-
equilibrate 
the system to 
prepare for 
the next 
substrate 
Sensors 
needs to re-
equilibrate 
to ambient 
O2 in order 
to read 
effectively. If 
this step is 
skipped, 
sensor can 
drop below 
its threshold 
of reading 
O2 
1uM 
Oligomycin 
~30 
seconds 
20:55 
minutes 
Inject Port 
B 
This step 
measures the 
State IV 
respiration. 
Any oxygen 
consumption 
here is the 
result of 
proton leak 
across the 
membrane 
One has to 
assure that 
the O2 
consumption 
has 
plateaued 
before using 
the values to 
calculate 
your OCR 
25 
seconds 
21:20 
minutes 
Mix 
0 
seconds 
21:20 
minutes 
Wait 
4:00 
minutes 
25:20 
minutes 
Measure 
Mix 2 1 minute 26:20 
minutes 
Mix Same as  
Mix 1 
 
4uM FCCP ~30 
seconds 
26:50 
minutes 
Inject Port 
C 
This step 
measures the 
State V 
respiration. 
This is the 
measurement 
of O2 
consumption 
when it is a 
Similar issue 
seen here 
as seen with 
the injection 
of Port A. 
Make sure 
you have 
not depleted 
oxygen 
10 
seconds 
27:00 
minutes 
Mix 
0 
seconds 
27:00 
minutes 
Wait 
4:00 
minutes 
31:00 
minutes 
Measure 
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uncoupled 
from ATP 
production 
and is 
defined as 
the Maximal 
Mitochondrial 
Respiration 
levels when 
your OCR is 
calculated. 
Mix 3 1 minute 32:00 
minutes 
Mix Same as  
Mix 1 
 
0.1uM 
Rotenone  
10mM 
Succinate 
~30 
seconds 
32:30 
minutes 
Inject Port 
D 
This step 
measures 
State Vsucc 
mitochondrial 
respiration. It 
will produce 
the electron 
rich FADH2 
molecules 
leading to 
activation of 
the ETS 
through 
Complex II 
while 
inhibiting 
Complex I 
with 
Rotenone 
 
25 
seconds 
32:55 
minutes 
Mix  
0 
seconds 
32:55 
minutes 
Wait  
4:00 
minutes 
36:55 
minutes 
Measure  
 
 
  
 156 
Mitochondrial oxygen consumption rates (OCR) rates were recorded in the 
absence or the presence of various mitochondrial substrates/inhibitors which 
were added from port A to port D. The data files collected from each experiment 
were analyzed and reported as percent OCR (% OCR) using GraphPad Prism 6 
software package (GraphPad Software, Inc. La Jolla, CA). 
Reactive Oxygen Species:  
Mitochondrial ROS production was measured using 25uM 2’-7’-
dichlorodihydro-fluorescein diacetate (DCF) purchased from Molecular Probes 
(Eugene, OR) (excitation 485nm, emission 528nm) in the Biotek Synergy HT 
plate reader as described by [300, 301, 313, 418]. 25ug of isolated total 
mitochondria were added to the a 96 well plate with 100uL of a mixture of RB, 
5mM pyruvate, 2.5mM malate. Plate was warmed to 37oC within the plate reader. 
DCF was added and the plate was incubated for 15 minutes. ROS production 
was then calculated as the maximum DCF fluorescence expressed in arbitrary 
fluorescence units. ROS production in the presence of oligomycin, which will 
produce the maximal ROS production, and FCCP, which will produce the least 
amount of ROS production, was also determined to assure that the 
measurements were within the range of the ROS indicator.   
Histological Analysis:  
Animals were anesthetized using FatalPlus and immediately perfused with 
saline followed by 4% paraformaldehyde. The brains were removed and placed 
in 4% paraformaldehyde and 30% sucrose solution in PBS for 24hrs. After 24hrs, 
the brains were transferred to a 30% sucrose PBS buffer solution without 
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paraformaldehyde. 35uM coronal sections were cut with a freezing microtome 
throughout the rostral caudal extent of the damaged cortex. Sections were 
stained with cresyl violet and subjected to image analysis for lesion volume 
assessment. Quantitative assessment of cortical damage employed a blinded 
unbiased stereological protocol using the cavalieri method as previously 
described. All slides were assessed blindly with respect to treatment group using 
Image J for simple ROI analysis of cortical sparing. 
Adjusted Neurological Severity Score: 
Injured wild-type or mitoNEET null mice had functional recovery tested 
using the adjusted neurological severity score (aNSS). This 14-point test 
measures coordinated motor function and balance as a measurement of motor 
function/recovery following injury. One day prior to injury, all animals were trained 
to traverse elevated beams of 3, 2, 1, and 0.5 cm width and a 0.5 cm diameter 
rod. At 1 hour, 24 hours, 3 day and 5 days post-injury, mice were allowed to 
traverse the beams and points were deducted for footfalls, hanging upside-down, 
an unwillingness to traverse the beam or falling off the beam. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Heather Marie Yonutas 2016 
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CHAPTER 6: SUMMARY AND CONCLUSIONS 
With over 150 years of research into mitochondria, it is now well-accepted 
that these once ill-defined bioplasts are crucial for cellular homeostasis. Their 
role within the cell transcends mere ATP production. As more than the 
proclaimed cellular “Power Plants”, these organelles are also important in 
calcium cycling, the generation of reactive oxygen and nitrogen species and play 
an integral role in apoptotic and necrotic cell mediated death pathways. Because 
of their importance in overall cellular homeostasis, mitochondrial dysfunction has 
been linked to many diseased states including Diabetes, Parkinson’s Disease, 
Alzheimer’s Disease, Amyotrophic Lateral Sclerosis and, most important to this 
dissertation, Traumatic Brain Injury. Mitochondria function has also been found to 
be altered in models of aging, hinting to a possible mechanism as to 
neurodegenerative diseases which generally appear in aged population.  
Mitochondria are essential for appropriate metabolism and energy flow 
within neurons but they have also been found to contribute to metabolic mediated 
oxidative stress and for the initiation of cell death. Because of this, mitochondria 
have been proposed as a therapeutic target in models of aging and Alzheimer’s 
Disease, AD. With mitochondria being a key player in metabolism, dietary 
interventions and supplementations with various antioxidants and mitochondrial 
co-factors have been proposed to target mitochondrial dysfunction in order to 
avoid age and AD related deficits, however the results from these studies have 
been controversial.  
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Oxidative damage seems to be a consistent feature seen in models of 
aging [156-159]. The brain is particularly vulnerable to oxidative damage as a 
result of it consuming approximately 20% of the body’s total oxygen, having a 
high content of polyunsaturated fatty acids and lower levels of endogenous 
antioxidant activity relative to other tissue [104-106]. Normal metabolic processes 
result in the release of reactive oxygen species (ROS), which in turn can lead to 
oxidative damage to proteins, lipids, DNA and RNA [156]. Since mitochondrial 
are also a primary production site for ROS [163], these organelles become 
particularly vulnerable to oxidative damage [164]. It has been hypothesized that 
the combination of mitochondrial dysfunction and production of ROS may be a 
key contributor to the deleterious effects of aging on the brain [14, 167, 173-179]. 
In addition to playing a role to the deficits seen with aging, mitochondria 
dysfunction is also thought to be hallmark feature with this secondary injury 
cascade in TBI, in which a similar mechanism has been proposed. 
Similar to aging models, traumatic brain injury is another state that seems 
to be plagued with mitochondrial dysfunction. Due to the heterogeneous nature 
of this disease, experimental modeling has been challenging leading to the 
invention of numerous injury paradigms in order to encompass a full range of 
what is seen clinically. The rodent model of TBI that shows the most apparent 
mitochondrial dysfunction is the controlled cortical impact. This is likely a result 
of the focal nature of the injury which allows scientists to isolate tissue only 
undergoing the secondary injury cascade. It is this tissue, which surrounds the 
impact site and is defined as the penumbra and core tissue, that has been 
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highly investigated for therapeutic interventions in an attempt to avoid the non-
mechanical tissue damage that occurs following the primary injury.  
The current dogma within the TBI literature is that following injury, 
excitatory amino acids are released into the extracellular space in a 
dysregulated manner. This leads to excitation of nearby neurons causing 
pathogenic influxes of calcium. Mitochondria buffer this calcium leading to intra-
mitochondrial changes in the redox potential and consequently the initiation of 
oxidative stress. This oxidative stress is thought to lead to lipid peroxidation and 
protein damage, similar to what has been proposed in aging models. This 
oxidative stress was traditionally thought to be irreversible however work within 
this dissertation project proposes a mechanism of mitochondrial dysfunction that 
is enzymatically regulated and not due to vast oxidative damage, as originally 
hypothesized [327].  
After over 15 years, mitochondrial studies in the field of TBI have 
concluded a well-accepted time course of mitochondrial dysfunction. Following a 
focal injury significant dysfunction is seen at 1 hour post-injury and persists out to 
48 hours, peaking around 12 to 24 hours [311, 348, 350, 363].  Still till today, the 
mechanism behind this dysfunction is debated. As mentioned previously, the 
current dogma proposes a mechanism which leads to irreversible oxidative 
damage. However, as seen in Figure 4.4, pioglitazone, a drug which has been 
shown to improve mitochondrial dysfunction, is able to improve mitochondrial 
function when given at 12 hours post-injury, a time-point linked to maximal 
mitochondrial dysfunction. In addition to pioglitazone, the use of an alternative 
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biofuel called beta-hydroxybuterate, which is able to feed directly into Complex I, 
effectively skipping any metabolic processes upstream up of Complex I, is also 
able to increase mitochondrial function when given ex vivo.  
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Figure 6.1 BHB intervention following injury can improve mitochondrial 
respiration: In this experiment, BHB was given at 24 hours ex vivo in 
mitochondria. BHB was able to increase mitochondrial respiration showing that 
mitochondria are not completely damaged, rather inhibited at a point upstream 
of Complex I.  
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 In healthy, uninjured, cortical tissue, Pyruvate Dehydrogenase, PDH, is 
traditionally thought to be the gatekeeper of mitochondrial respiration [448]. 
Therefore, it was only reasonable to hypothesize the the limiting step that occurs 
upstream of Complex I leading to inhibited respiration following injury would be 
PDH. However, as seen by Opii et. al., PDH activity does not significantly 
decrease following injury [343].  
 If not PDH, then what? Well, insight into this question may have surfaced 
in 2004 when Colca et al discovered a novel mitochondrial protein which is now 
hypothesized to be a Redox sensitive switch which is able to modulate 
mitochondrial respiration [434, 449-452]. Work from Roberts et. al. has found 
that mitoNEET is able to increase Glutatmate Dehydrogenase activity [83]. 
With compelling evidence showing mitoNEET as a redox switch and 
showing mitoNEETs direct positive effects on GDH activity, it proposes a theory 
in that GDH mediates mitochondrial respiration through mitoNEET activity. This 
activity is then inhibited during high oxidative states, such as during calcium 
cycling and following injury to the cortical tissue, leading to decreased 
substrates feeding into the electron transport chain and therefore inhibiting state 
III mediated respiration as seen with this research. When using a mitoNEET 
ligand, such as NL-1 or pioglitazone, mitoNEET activity is increased during this 
inhibitory state leading to increase mitochondrial respiration resulting in 
increased cortical sparing and functional recovery.  
From an evolutionary perspective, GDH is a highly modulated enzyme 
that has been previously linked to mitochondrial function through the production 
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of NADH and α-ketogluterate from glutatmate and NAD+. It is thought that this 
protein is an evolutionary byproduct from protozoa, which used this enzyme as a 
sensor in its antenna in order to sense its environment and avoid encounters to 
dangerous environments [453-456]. This information leads to a model as seen 
below: 
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Figure 6.2 Thesis Overview: This diagram proposes the mechanism which is hypothesized for 
mitoNEET.  mitoNEET targeting pharmacological treatments such at pioglitazone or NL-1 are able to 
activate mitoNEET, which leads to Glutamate Dehydrogenase (GDH) activity. Under normal, homeostatic 
conditions, mitoNEET activates GDH. Following a redox change within mitochondria, mitoNEET loses its 
activity leading to an inhibition on GDH and therefore decreased mitochondrial respiration. 
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Future work within this project is ample. At this point, an in depth analysis 
into GDH activity following injury needs to be completed, since the current 
research related to GDH activity following TBI is limited and possibly nonexistent. 
One will need to the hypothesis that pioglitazone’s ability to improve functional 
recovery and increase tissue sparing following moderate CCI is dependent upon 
GDH activity, which is modulated through mitoNEET. To further expand this 
study, one will need to test whether NL-1, the mitoNEET specific ligand, can 
reproduce the same effects as pioglitazone. The rationale behind this is that our 
data supports the hypothesis that pioglitazone can significantly increase 
mitochondrial bioenergetics following TBI resulting in increased tissue sparing 
but does not provide the same degree of neuroprotection in mitoNEET -/- mice. 
The literature also shows that pioglitazone binds mitoNEET, that pioglitazone 
confers neuroprotection in mice after TBI at 1.0 and 10mg/kg and that GDH is 
activated by interactions with mitoNEET. I have also demonstrated that the 
mitoNEET ligand (NL-1) can confer neuroprotection following TBI. These data 
drive the novel hypothesis that pioglitazone neuroprotection following TBI is 
dependent upon its interactions with mitoNEET.  
 The experimental designs for these studies should assess GDH activity 
following injury in addition to neuroprotection, through tissue sparing and 
behavioral outcomes, following moderate CCI in mice administered the optimal 
dose of a known GDH activator and/or inhibitor. Adult wild-type (+/+) and 
mitoNEET null (-/-) male mice, should be subjected to either a sham surgery or 
moderate TBI and either sacrificed at 24 hours post-injury for GDH activity 
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studies or allowed to survive for 30 days, with naïve mice included for behavioral 
outcome measures, depending on the cohort. Animals should all receive 
intraperitoneal (i.p.) injections of vehicle or the 10mg/kg pioglitazone or NL-1 or 
the ideal dosage of GDH activator and inhibitor at 15 minutes post-injury, in 
accordance with their grouping. Changes in cortical and hippocampal 
morphology should be assessed longitudinally (days 7, 14 and 28 post-injury) 
using parametric T2 weighted imaging and apparent diffusion weighted 
coefficients from DTI in addition to employing unbiased stereology at 30 days 
post-injury. The extent of cortical sparing should be measured in a blinded 
fashion using the variations in signal intensities at the region of interest, ROI. 
These ROI measurements will be hand drawn and calculated with ImageJ. 
Behavioral measures should include motor and cognitive function to assess the 
degree of functional recovery as a result of treatment, employing both the 
Adjusted Neurological Severity Score (aNSS) and Morris Water Maze (MWM). 
Recovery of motor function will be assessed using the NSS at 1 hr, 24 hr, 72 hr, 
and 120hrs after CCI or sham injury.  
 Additionally, since GDH is tightly linked to insulin production, which has 
not been investigated within this paradigm. However, in a study completed by 
Davis, it was found that insulin injections at 3 hours post-injury lead to rapid 
death in a rodent model of CCI injury and did not increase cortical sparing or 
functional recovery following injury. It is well accepted that metabolic dysfunction 
occurs following injury and therefore further research into important metabolic 
signaling molecules, like insulin, should be further investigated as well.  
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 Lastly, and seemingly most important to this study, is that further studies 
need to completed in order to investigate the hypothesis that mitoNEET is a 
redox sensitive mitochondrial protein that is able to modulate mitochondrial 
function (“switching” them on and off) during times that redox potential has 
shifted to a potentially pathogenic state. We currently understand that following 
TBI, calcium dysregulation occurs leading to changes in the redox potential of 
mitochondria. We also know that mitoNEET is able to inhibit mitochondrial 
respiration. Research from this study showed the mitoNEET null mitochondrial 
did not experience the same extent of mitochondrial respiration depression 
when calcium was added ex vivo, compared to mitoNEET containing 
mitochondrial. Therefore, mechanistic studies using mitochondria need to be 
further investigated to determine if mitoNEET is indeed the “switch” that we think 
it is.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Heather Marie Yonutas 2016 
 169 
REFERENCES 
 
 
1. Chance, B., et al., Basic principles of tissue oxygen determination from 
mitochondrial signals. Adv Exp Med Biol, 1973. 37A: p. 277-92. 
2. Chance, B., H. Sies, and A. Boveris, Hydroperoxide metabolism in 
mammalian organs. Physiol Rev, 1979. 59(3): p. 527-605. 
3. Chance, B. and L. Smith, Respiratory pigments of Rhodospirillum rubrum. 
Nature, 1955. 175(4462): p. 803-6. 
4. Chance, B. and G.R. Williams, Respiratory enzymes in oxidative 
phosphorylation. IV. The respiratory chain. J Biol Chem, 1955. 217(1): p. 
429-38. 
5. Chance, B. and G.R. Williams, Respiratory enzymes in oxidative 
phosphorylation. III. The steady state. J Biol Chem, 1955. 217(1): p. 409-
27. 
6. Chance, B. and G.R. Williams, Respiratory enzymes in oxidative 
phosphorylation. II. Difference spectra. J Biol Chem, 1955. 217(1): p. 395-
407. 
7. Chance, B. and G.R. Williams, Respiratory enzymes in oxidative 
phosphorylation. I. Kinetics of oxygen utilization. J Biol Chem, 1955. 
217(1): p. 383-93. 
8. Chance, B., et al., Respiratory enzymes in oxidative phosphorylation. V. A 
mechanism for oxidative phosphorylation. J Biol Chem, 1955. 217(1): p. 
439-51. 
9. Ernster, L. and G. Schatz, Mitochondria: a historical review. J Cell Biol, 
1981. 91(3 Pt 2): p. 227s-255s. 
10. Sapp, J., Evolution by Association : A History of Symbiosis. 1994, USA: 
Oxford University Press. 272. 
11. Henle, J., Allgemeine Anatomie. Leipzig, 1841. 
12. van der Giezen, M., Mitochondria and the Rise of Eukaryotes. BioScience, 
2011. 61(8): p. 594-601. 
13. Scheffler, I.E., Mitochondria. Second Edition ed. 2008: John Wiley & Sons, 
Inc. 
14. Wallace, D.C., Mitochondrial genetics: a paradigm for aging and 
degenerative diseases? . Science, 1992. 256: p. 628-632. 
15. Wallace, D.C., Mitochondrial DNA mutations in disease and aging. 
Environ Mol Mutagen, 2010. 51(5): p. 440-50. 
16. Wallace, D.C., Why do we still have a maternally inherited mitochondrial 
DNA? Insights from evolutionary medicine. Annu Rev Biochem, 2007. 76: 
p. 781-821. 
17. Lehninger, A.L., The mitochondrion; molecular basis of structure and 
function. 1965, New York,: W. A. Benjamin. xx, 263 p. 
18. Gourdin, M.D., P., Impact of Ischemia on Cellular Metabolism, in Artery 
Bypass, W. Aronow, Editor. 2013. 
 170 
19. Bergman, J., ATP: The Perfect Energy Currency for the Cell. Creation 
Research Society Quarterly Journal, 1999. 36(1). 
20. Kalckar, H.M., Aspects of the biological function of phosphate in 
enzymatic syntheses. Nature, 1947. 159(4057): p. 143-7. 
21. Kalckar, H.M., The enzymatic synthesis of purine ribosides. J Biol Chem, 
1947. 167(2): p. 477-86. 
22. Kalckar, H.M., Differential spectrophotometry of purine compounds by 
means of specific enzymes; studies of the enzymes of purine metabolism. 
J Biol Chem, 1947. 167(2): p. 461-75. 
23. Kalckar, H.M., Differential spectrophotometry of purine compounds by 
means of specific enzymes; determination of adenine compounds. J Biol 
Chem, 1947. 167(2): p. 445-59. 
24. Kalckar, H.M., Differential spectrophotometry of purine compounds by 
means of specific enzymes; determination of hydroxypurine compounds. J 
Biol Chem, 1947. 167(2): p. 429-43. 
25. Kalckar, H.M., The biological synthesis of purine compounds. Symp Soc 
Exp Biol, 1947(1): p. 38-55. 
26. Claude, A., The Constitution of Mitochondria and Microsomes, and the 
Distribution of Nucleic Acid in the Cytoplasm of a Leukemic Cell. J Exp 
Med, 1944. 80(1): p. 19-29. 
27. Claude, A. and E.F. Fullam, An Electron Microscope Study of Isolated 
Mitochondria : Method and Preliminary Results. J Exp Med, 1945. 81(1): 
p. 51-62. 
28. Claude, A., Fractionation of mammalian liver cells by differential 
centrifugation; experimental procedures and results. J Exp Med, 1946. 84: 
p. 61-89. 
29. Claude, A., Fractionation of mammalian liver cells by differential 
centrifugation; problems, methods, and preparation of extract. J Exp Med, 
1946. 84: p. 51-9. 
30. Claude, A., Fractionation of Mammalian Liver Cells by Differential 
Centrifugation : Ii. Experimental Procedures and Results. J Exp Med, 
1946. 84(1): p. 61-89. 
31. Claude, A., Fractionation of Mammalian Liver Cells by Differential 
Centrifugation : I. Problems, Methods, and Preparation of Extract. J Exp 
Med, 1946. 84(1): p. 51-9. 
32. Kennedy, E.P. and A.L. Lehninger, Oxidation of fatty acids and 
tricarboxylic acid cycle intermediates by isolated rat liver mitochondria. J 
Biol Chem, 1949. 179(2): p. 957-72. 
33. Kennedy, E.P. and A.L. Lehninger, The products of oxidation of fatty acids 
by isolated rat liver mitochondria. J Biol Chem, 1950. 185(1): p. 275-85. 
34. Lehninger, A.L., On the activation of fatty acid oxidation. J Biol Chem, 
1945. 161: p. 437-51. 
35. Lehninger, A.L., Fatty acid oxidation and the Krebs trocarboxylic acid 
cycle. J Biol Chem, 1945. 161: p. 413. 
36. Lehninger, A.L., The oxidation of higher fatty acids in heart muscle 
suspensions. J Biol Chem, 1946. 165(1): p. 131-45. 
 171 
37. Lehninger, A.L., A quantitative study of the products of fatty acid oxidation 
in liver suspensions. J Biol Chem, 1946. 164: p. 291-306. 
38. Lehninger, A.L., The synthesis and properties of the acyl phosphates of 
some higher fatty acids. J Biol Chem, 1946. 162: p. 333-42. 
39. Brown, M.R., et al., Nitrogen disruption of synaptoneurosomes: an 
alternative method to isolate brain mitochondria. J Neurosci Methods, 
2004. 137(2): p. 299-303. 
40. Nicholls, D.G. and S.J. Ferguson, Bioenergetics3. 2002, London: 
Academic Press. 
41. Slater, E.C. and K.W. Cleland, The calcium content of isolated heart-
muscle sarcosomes. Biochem J, 1953. 54(3): p. xxii. 
42. Robinson, J., D., Oxidative Phosphorylyation: Chemical-Coupling 
Hypothesis. 1997, New York: Springer. 
43. Slater, E.C., Mechanism of oxidative phosphorylation. Annu Rev Biochem, 
1977. 46: p. 1015-26. 
44. Williams, R.J., The history of proton-driven ATP formation. Biosci Rep, 
1993. 13(4): p. 191-212. 
45. Mitchell, P., Chemiosmotic coupling in oxidative and photosynthetic 
phosphorylation. Biol Rev Camb Philos Soc, 1966. 41(3): p. 445-502. 
46. Mitchell, P., Aspects of the chemiosmotic hypothesis. Biochem J, 1970. 
116(4): p. 5P-6P. 
47. Mitchell, P., Chemiosmotic coupling in energy transduction: a logical 
development of biochemical knowledge. J Bioenerg, 1972. 3(1): p. 5-24. 
48. Mitchell, P., A chemiosmotic molecular mechanism for proton-
translocating adenosine triphosphatases. FEBS Lett, 1974. 43(2): p. 189-
94. 
49. Mitchell, P. and J. Moyle, Chemiosmotic hypothesis of oxidative 
phosphorylation. Nature, 1967. 213(5072): p. 137-9. 
50. Campbell, A.K., Intracellular Calcium. 2014: Wiley. 
51. Raaflaub, J., [Swelling of isolated mitochondria of the liver and their 
susceptibility to physicochemical influences]. Helv Physiol Pharmacol 
Acta, 1953. 11(2): p. 142-56. 
52. Raaflaub, J., [Mechanism of adenosinetriphosphate as cofactor of isolated 
mitochondria]. Helv Physiol Pharmacol Acta, 1953. 11(2): p. 157-65. 
53. Crofts, A.R. and J.B. Chappell, Calcium Ion Accumulation and Volume 
Changes of Isolated Liver Mitochondria. Reversal of Calcium Ion-Induced 
Swelling. Biochem J, 1965. 95: p. 387-92. 
54. Chappell, J.B. and A.R. Crofts, Calcium Ion Accumulation and Volume 
Changes of Isolated Liver Mitochondria. Calcium Ion-Induced Swelling. 
Biochem J, 1965. 95: p. 378-86. 
55. Azzi, A. and G.F. Azzone, Swelling and shrinkage phenomena in liver 
mitochondria. II. Low amplitude swelling-shrinkage cycles. Biochim 
Biophys Acta, 1965. 105(2): p. 265-78. 
56. Azzi, A. and G.F. Azzone, Swelling and shrinkage phenomena in liver 
mitochondria. I. Large amplitude swelling induced by inorganic phosphate 
and by ATP. Biochim Biophys Acta, 1965. 105(2): p. 253-64. 
 172 
57. Zborowski, J. and L. Wojtczak, Induction of Swelling of Liver Mitochondria 
by Fatty Acids of Various Chain Length. Biochim Biophys Acta, 1963. 70: 
p. 596-8. 
58. Wojtczak, L. and A.L. Lehninger, Formation and disappearance of an 
endogenous uncoupling factor during swelling and contraction of 
mitochondria. Biochim Biophys Acta, 1961. 51: p. 442-56. 
59. Lehninger, A.L. and M. Schneider, Mitochondrial swelling induced by 
glutathione. J Biophys Biochem Cytol, 1959. 5(1): p. 109-16. 
60. Lehninger, A.L. and L.F. Remmert, An endogenous uncoupling and 
swelling agent in liver mitochondria and its enzymic formation. J Biol 
Chem, 1959. 234: p. 2459-64. 
61. Lehninger, A.L., Reversal of thyroxine-induced swelling of rat liver 
mitochondria by adenosine triphosphate. J Biol Chem, 1959. 234(8): p. 
2187-95. 
62. Lehninger, A.L., Reversal of various types of mitochondrial swelling by 
adenosine triphosphate. J Biol Chem, 1959. 234: p. 2465-71. 
63. Tapley, D.F., The effect of thyroxine and other substances on the swelling 
of isolated rat liver mitochondria. J Biol Chem, 1956. 222(1): p. 325-39. 
64. Hunter, F.E., Jr. and L. Ford, Inactivation of oxidative and phosphorylative 
systems in mitochondria by preincubation with phosphate and other ions. 
J Biol Chem, 1955. 216(1): p. 357-69. 
65. Haworth, R.A. and D.R. Hunter, The Ca2+-induced membrane transition in 
mitochondria. II. Nature of the Ca2+ trigger site. Arch Biochem Biophys, 
1979. 195(2): p. 460-7. 
66. Hunter, D.R. and R.A. Haworth, The Ca2+-induced membrane transition in 
mitochondria. I. The protective mechanisms. Arch Biochem Biophys, 
1979. 195(2): p. 453-9. 
67. Hunter, D.R. and R.A. Haworth, The Ca2+-induced membrane transition in 
mitochondria. III. Transitional Ca2+ release. Arch Biochem Biophys, 1979. 
195(2): p. 468-77. 
68. Hunter, D.R., R.A. Haworth, and J.H. Southard, Relationship between 
configuration, function, and permeability in calcium-treated mitochondria. J 
Biol Chem, 1976. 251(16): p. 5069-77. 
69. Bernardi, P., The mitochondrial permeability transition pore: a mystery 
solved? Front Physiol, 2013. 4: p. 95. 
70. Halestrap, A.P. and A.M. Davidson, Inhibition of Ca2(+)-induced large-
amplitude swelling of liver and heart mitochondria by cyclosporin is 
probably caused by the inhibitor binding to mitochondrial-matrix peptidyl-
prolyl cis-trans isomerase and preventing it interacting with the adenine 
nucleotide translocase. Biochem J, 1990. 268(1): p. 153-60. 
71. Davidson, A.M. and A.P. Halestrap, Partial inhibition by cyclosporin A of 
the swelling of liver mitochondria in vivo and in vitro induced by sub-
micromolar [Ca2+], but not by butyrate. Evidence for two distinct swelling 
mechanisms. Biochem J, 1990. 268(1): p. 147-52. 
 173 
72. Broekemeier, K.M. and D.R. Pfeiffer, Cyclosporin A-sensitive and 
insensitive mechanisms produce the permeability transition in 
mitochondria. Biochem Biophys Res Commun, 1989. 163(1): p. 561-6. 
73. Broekemeier, K.M., M.E. Dempsey, and D.R. Pfeiffer, Cyclosporin A is a 
potent inhibitor of the inner membrane permeability transition in liver 
mitochondria. J Biol Chem, 1989. 264(14): p. 7826-30. 
74. Crompton, M., H. Ellinger, and A. Costi, Inhibition by cyclosporin A of a 
Ca2+-dependent pore in heart mitochondria activated by inorganic 
phosphate and oxidative stress. Biochem J, 1988. 255(1): p. 357-60. 
75. Fournier, N., G. Ducet, and A. Crevat, Action of cyclosporine on 
mitochondrial calcium fluxes. J Bioenerg Biomembr, 1987. 19(3): p. 297-
303. 
76. Magistretti, P.J. and L. Pellerin, Cellular mechanisms of brain energy 
metabolism and their relevance to functional brain imaging. Philos Trans R 
Soc Lond B Biol Sci, 1999. 354(1387): p. 1155-63. 
77. Magistretti, P.J. and L. Pellerin, Astrocytes Couple Synaptic Activity to 
Glucose Utilization in the Brain. News Physiol Sci, 1999. 14: p. 177-182. 
78. Pellerin, L., et al., Evidence supporting the existence of an activity-
dependent astrocyte-neuron lactate shuttle. Dev Neurosci, 1998. 20(4-5): 
p. 291-9. 
79. Pellerin, L. and P.J. Magistretti, How to balance the brain energy budget 
while spending glucose differently. J Physiol, 2003. 546(Pt 2): p. 325. 
80. Pellerin, L. and P.J. Magistretti, Food for thought: challenging the dogmas. 
J Cereb Blood Flow Metab, 2003. 23(11): p. 1282-6. 
81. Ebert, D., R.G. Haller, and M.E. Walton, Energy contribution of octanoate 
to intact rat brain metabolism measured by 13C nuclear magnetic 
resonance spectroscopy. J Neurosci, 2003. 23(13): p. 5928-35. 
82. Alberts, B.J., A.; Lewis, J.; et al., Molecular Biology of the Cell. 4th edition. 
2002, New York: Garland Science. 
83. Roberts, M.E., et al., Identification of disulfide bond formation between 
MitoNEET and glutamate dehydrogenase 1. Biochemistry, 2013. 52(50): 
p. 8969-71. 
84. Guenebaut, V., et al., Three-dimensional structure of NADH-
dehydrogenase from Neurospora crassa by electron microscopy and 
conical tilt reconstruction. J Mol Biol, 1997. 265(4): p. 409-18. 
85. Fato, R., et al., Differential effects of mitochondrial Complex I inhibitors on 
production of reactive oxygen species. Biochim Biophys Acta, 2009. 
1787(5): p. 384-92. 
86. Efremov, R.G., R. Baradaran, and L.A. Sazanov, The architecture of 
respiratory complex I. Nature, 2010. 465(7297): p. 441-5. 
87. Efremov, R.G. and L.A. Sazanov, Structure of the membrane domain of 
respiratory complex I. Nature, 2011. 476(7361): p. 414-20. 
88. Efremov, R.G. and L.A. Sazanov, Respiratory complex I: 'steam engine' of 
the cell? Curr Opin Struct Biol, 2011. 21(4): p. 532-40. 
 174 
89. Sazanov, L.A. and P. Hinchliffe, Structure of the hydrophilic domain of 
respiratory complex I from Thermus thermophilus. Science, 2006. 
311(5766): p. 1430-6. 
90. Sazanov, L.A., et al., A long road towards the structure of respiratory 
complex I, a giant molecular proton pump. Biochem Soc Trans, 2013. 
41(5): p. 1265-71. 
91. Baradaran, R., et al., Crystal structure of the entire respiratory complex I. 
Nature, 2013. 494(7438): p. 443-8. 
92. Pramanik, K.C., S.R. Boreddy, and S.K. Srivastava, Role of mitochondrial 
electron transport chain complexes in capsaicin mediated oxidative stress 
leading to apoptosis in pancreatic cancer cells. PLoS One, 2011. 6(5): p. 
e20151. 
93. Okun, J.G., P. Lummen, and U. Brandt, Three classes of inhibitors share a 
common binding domain in mitochondrial complex I (NADH:ubiquinone 
oxidoreductase). J Biol Chem, 1999. 274(5): p. 2625-30. 
94. Raha, S. and B.H. Robinson, Mitochondria, oxygen free radicals, disease 
and ageing. Trends Biochem Sci, 2000. 25(10): p. 502-8. 
95. Cecchini, G., Function and structure of complex II of the respiratory chain. 
Annu Rev Biochem, 2003. 72: p. 77-109. 
96. Stowe, D.F. and A.K. Camara, Mitochondrial reactive oxygen species 
production in excitable cells: modulators of mitochondrial and cell function. 
Antioxid Redox Signal, 2009. 11(6): p. 1373-414. 
97. Li, Y., et al., Cytochrome c oxidase subunit IV is essential for assembly 
and respiratory function of the enzyme complex. J Bioenerg Biomembr, 
2006. 38(5-6): p. 283-91. 
98. Jonckheere, A.I., J.A. Smeitink, and R.J. Rodenburg, Mitochondrial ATP 
synthase: architecture, function and pathology. J Inherit Metab Dis, 2012. 
35(2): p. 211-25. 
99. Birkenhager, R., et al., F0 complex of the Escherichia coli ATP synthase. 
Not all monomers of the subunit c oligomer are involved in F1 interaction. 
Eur J Biochem, 1999. 264(2): p. 385-96. 
100. Nicholls, D.G., and Ferguson, S. J., Bioenergetics 3. Biochemistry 
(Moscow), 2004. 69(7): p. 819. 
101. Symersky, J., et al., Oligomycin frames a common drug-binding site in the 
ATP synthase. Proc Natl Acad Sci U S A, 2012. 109(35): p. 13961-5. 
102. Moreira, P.I., et al., Mitochondria: a therapeutic target in 
neurodegeneration. Biochim Biophys Acta, 2010. 1802(1): p. 212-20. 
103. Jastroch, M., et al., Mitochondrial proton and electron leaks. Essays 
Biochem, 2010. 47: p. 53-67. 
104. Shulman, R.G., et al., Energetic basis of brain activity: implications for 
neuroimaging. Trends Neurosci, 2004. 27(8): p. 489-95. 
105. Halliwell, B., & Gutteridge, J.M.C., Oxygen radicals in the nervous system. 
Trends in Neuroscience, 1985. 8: p. 22-26. 
106. Floyd, R.A. and K. Hensley, Oxidative stress in brain aging. Implications 
for therapeutics of neurodegenerative diseases. Neurobiol Aging, 2002. 
23(5): p. 795-807. 
 175 
107. Buono, M.J. and F.W. Kolkhorst, Estimating ATP resynthesis during a 
marathon run: a method to introduce metabolism. Advances in Physiology 
Education, 2001. 25: p. 70-71. 
108. Sullivan, P.G., et al., Mitochondrial permeability transition in CNS trauma: 
cause or effect of neuronal cell death? J Neurosci Res, 2005. 79(1-2): p. 
231-9. 
109. Yi, J.H. and A.S. Hazell, Excitotoxic mechanisms and the role of astrocytic 
glutamate transporters in traumatic brain injury. Neurochem Int, 2006. 
48(5): p. 394-403. 
110. Sullivan, P.G., A.H. Sebastian, and E.D. Hall, Therapeutic window 
analysis of the neuroprotective effects of cyclosporine A after traumatic 
brain injury. J Neurotrauma, 2011. 28(2): p. 311-8. 
111. Belzacq, A.S., et al., The adenine nucleotide translocator in apoptosis. 
Biochimie, 2002. 84(2-3): p. 167-76. 
112. Halestrap, A.P., Calcium, mitochondria and reperfusion injury: a pore way 
to die. Biochem Soc Trans, 2006. 34(Pt 2): p. 232-7. 
113. Varanyuwatana, P. and A.P. Halestrap, The roles of phosphate and the 
phosphate carrier in the mitochondrial permeability transition pore. 
Mitochondrion, 2012. 12(1): p. 120-5. 
114. Wiley, S.E., et al., The outer mitochondrial membrane protein mitoNEET 
contains a novel redox-active 2Fe-2S cluster. J Biol Chem, 2007. 282(33): 
p. 23745-9. 
115. Landry, A.P., Z. Cheng, and H. Ding, Reduction of mitochondrial protein 
mitoNEET [2Fe-2S] clusters by human glutathione reductase. Free Radic 
Biol Med, 2015. 81: p. 119-27. 
116. Walker, D.A., The Principle of Oxygen Measurement, in The Use of the 
Oxygen Electrode & Fluorescence Probes in Simple Measurements of 
Photosynthesis. 1987, Oxygraph Ltd. 
117. Hedden, T. and J.D. Gabrieli, Insights into the ageing mind: a view from 
cognitive neuroscience. Nat Rev Neurosci, 2004. 5(2): p. 87-96. 
118. Fjell, A.M. and K.B. Walhovd, Structural brain changes in aging: courses, 
causes and cognitive consequences. Rev Neurosci, 2010. 21(3): p. 187-
221. 
119. Vanguilder, H.D. and W.M. Freeman, The hippocampal neuroproteome 
with aging and cognitive decline: past progress and future directions. Front 
Aging Neurosci, 2011. 3: p. 8. 
120. Sonntag, W.E., et al., Pleiotropic effects of growth hormone and insulin-
like growth factor (IGF)-1 on biological aging: inferences from moderate 
caloric-restricted animals. J Gerontol A Biol Sci Med Sci, 1999. 54(12): p. 
B521-38. 
121. Fields, R.D., Neuroscience. Change in the brain's white matter. Science, 
2010. 330(6005): p. 768-9. 
122. Calabrese, V., et al., Nitric oxide and cellular stress response in brain 
aging and neurodegenerative disorders: the role of vitagenes. In Vivo, 
2004. 18(3): p. 245-67. 
 176 
123. Paz Gavilan, M., et al., Cellular environment facilitates protein 
accumulation in aged rat hippocampus. Neurobiol Aging, 2006. 27(7): p. 
973-82. 
124. Poon, H.F., et al., Proteomics analysis provides insight into caloric 
restriction mediated oxidation and expression of brain proteins associated 
with age-related impaired cellular processes: Mitochondrial dysfunction, 
glutamate dysregulation and impaired protein synthesis. Neurobiol Aging, 
2006. 27(7): p. 1020-34. 
125. Rowe, W.B., et al., Hippocampal expression analyses reveal selective 
association of immediate-early, neuroenergetic, and myelinogenic 
pathways with cognitive impairment in aged rats. J Neurosci, 2007. 
27(12): p. 3098-110. 
126. Freeman, W.M., et al., Cognitive performance and age-related changes in 
the hippocampal proteome. Neuroscience, 2009. 159(1): p. 183-95. 
127. Pawlowski, T.L., et al., Hippocampal gene expression changes during 
age-related cognitive decline. Brain Res, 2009. 1256: p. 101-10. 
128. Erickson, K.I., et al., Brain-derived neurotrophic factor is associated with 
age-related decline in hippocampal volume. J Neurosci, 2010. 30(15): p. 
5368-75. 
129. Glover, A., et al., Diagnoses, problems and healthcare interventions 
amongst older people with an unscheduled hospital admission who have 
concurrent mental health problems: a prevalence study. BMC Geriatr, 
2014. 14(1): p. 43. 
130. Welmer, A.K., et al., Walking Speed, Processing Speed, and Dementia: A 
Population-Based Longitudinal Study. J Gerontol A Biol Sci Med Sci, 
2014. 
131. Curtis, R.G., T.D. Windsor, and A. Soubelet, The relationship between 
Big-5 personality traits and cognitive ability in older adults - a review. 
Neuropsychol Dev Cogn B Aging Neuropsychol Cogn, 2014. 
132. Nilsson, J., et al., White matter and cognitive decline in aging: a focus on 
processing speed and variability. J Int Neuropsychol Soc, 2014. 20(3): p. 
262-7. 
133. Serper, M., et al., Health Literacy, Cognitive Ability, and Functional Health 
Status among Older Adults. Health Serv Res, 2014. 
134. Glisky, E.L., Changes in Cognitive Function in Human Aging, in Brain 
Aging: Models, Methods, and Mechanisms, D.R. Riddle, Editor. 2007: 
Boca Raton (FL). 
135. Schaffer, S., et al., Effects of Polyphenols on Brain Ageing and 
Alzheimer's Disease: Focus on Mitochondria. Molecular Neurobiology, 
2012. 46(1): p. 161-178. 
136. Rygiel, K.A., J.P. Grady, and D.M. Turnbull, Respiratory chain deficiency 
in aged spinal motor neurons. Neurobiol Aging, 2014. 
137. Gheorghe, M., et al., Major aging-associated RNA expressions change at 
two distinct age-positions. BMC Genomics, 2014. 15(1): p. 132. 
 177 
138. Mosconi, L., Glucose metabolism in normal aging and Alzheimer's 
disease: Methodological and physiological considerations for PET studies. 
Clin Transl Imaging, 2013. 1(4). 
139. Harman, D., Aging: a theory based on free radical and radiation chemistry. 
J Gerontol, 1956. 11(3): p. 298-300. 
140. Mecocci, P., et al., Oxidative damage to mitochondrial DNA shows marked 
age-dependent increases in human brain. Ann Neurol, 1993. 34(4): p. 
609-16. 
141. Smith, C.D., et al., Excess brain protein oxidation and enzyme dysfunction 
in normal aging and in Alzheimer disease. Proc Natl Acad Sci U S A, 
1991. 88(23): p. 10540-3. 
142. Montine, T.J., Neely, M.D., Quinn, J.F., Beal, M.F., Markesbery, W.R., 
Roberts, L.J., and Morrow, J.D., Lipid peroxidation in aging brain and 
Alzheimer's disease. Free Radical Biology & Medicine, 2002. 33(5): p. 
620-626. 
143. Stadtman, E.R., Protein oxidation and aging. Science, 1992. 257: p. 1220-
1224. 
144. Stadtman, E.R. and B.S. Berlett, Reactive oxygen-mediated protein 
oxidation in aging and disease. Chem Res Toxicol, 1997. 10(5): p. 485-94. 
145. Berlett, B.S. and E.R. Stadtman, Protein oxidation in aging, disease, and 
oxidative stress. JBC, 1997. 272(33): p. 20313-6. 
146. Cini, M., and Moretti, A., Studies on lipid peroxidation and protein 
oxidation in the aging brain. Neurobiology of Aging, 1995. 16(1): p. 53-57. 
147. Markesbery, W.R. and M.A. Lovell, Four-hydroxynonenal, a product of 
lipid peroxidation, is increased in the brain in Alzheimer's disease. 
Neurobiol Aging, 1998. 19(1): p. 33-6. 
148. Liang, W.S., et al., Alzheimer's disease is associated with reduced 
expression of energy metabolism genes in posterior cingulate neurons. 
Proc Natl Acad Sci U S A, 2008. 105(11): p. 4441-6. 
149. Valla, J., J.D. Berndt, and F. Gonzalez-Lima, Energy hypometabolism in 
posterior cingulate cortex of Alzheimer's patients: superficial laminar 
cytochrome oxidase associated with disease duration. J Neurosci, 2001. 
21(13): p. 4923-30. 
150. Harman, D., Aging : a theory based on free radical and radiation 
chemistry. 1955, University of California Radiation Laboratory: Berkeley, 
CA. 
151. Jensen, P.K., Antimycin-insensitive oxidation of succinate and reduced 
nicotinamide-adenine dinucleotide in electron-transport particles. II. 
Steroid effects. Biochim Biophys Acta, 1966. 122(2): p. 167-74. 
152. Loschen, G., L. Flohe, and B. Chance, Respiratory chain linked H(2)O(2) 
production in pigeon heart mitochondria. FEBS Lett, 1971. 18(2): p. 261-
264. 
153. Boveris, A. and B. Chance, The mitochondrial generation of hydrogen 
peroxide. General properties and effect of hyperbaric oxygen. Biochem J, 
1973. 134(3): p. 707-16. 
 178 
154. Murphy, M.P., How mitochondria produce reactive oxygen species. 
Biochem J, 2009. 417(1): p. 1-13. 
155. Karnati, S., et al., Mammalian SOD2 is exclusively located in mitochondria 
and not present in peroxisomes. Histochem Cell Biol, 2013. 140(2): p. 
105-17. 
156. Poon, H.F., et al., Free radicals and brain aging. Clin Geriatr Med, 2004. 
20(2): p. 329-59. 
157. Liu, J. and A. Mori, Stress, aging, and brain oxidative damage. 
Neurochem Res, 1999. 24(11): p. 1479-97. 
158. Ames, B.N., Shigenaga, M.K., Oxidants are a major contributor to aging. 
Annals of the New York Academy of Sciences, 1992. 663: p. 85-96. 
159. Ames, B.N., Shigenaga, M.K., and Hagen, T.M., Oxidants, antioxidants, 
and the degenerative diseases of aging. Proc. Natl. Acad. Sci. USA, 1993. 
90: p. 7915-7922. 
160. Harman, D., The biologic clock: the mitochondria? J Am Geriatr Soc, 
1972. 20(4): p. 145-7. 
161. Gilmer, L.K., et al., Age-related changes in mitochondrial respiration and 
oxidative damage in the cerebral cortex of the Fischer 344 rat. Mech 
Ageing Dev, 2010. 131(2): p. 133-43. 
162. Barja, G., Mitochondrial oxygen consumption and reactive oxygen species 
production are independently modulated: implications for aging studies. 
Rejuvenation Res, 2007. 10(2): p. 215-24. 
163. Perez-Campo, R., et al., The rate of free radical production as a 
determinant of the rate of aging: evidence from the comparative approach. 
J Comp Physiol [B], 1998. 168(3): p. 149-58. 
164. Liu, J., et al., Delaying brain mitochondrial decay and aging with 
mitochondrial antioxidants and metabolites. Ann N Y Acad Sci, 2002. 959: 
p. 133-66. 
165. Ochoa, J.J., et al., Age-related changes in brain mitochondrial DNA 
deletion and oxidative stress are differentially modulated by dietary fat 
type and coenzyme Q(1)(0). Free Radic Biol Med, 2011. 50(9): p. 1053-
64. 
166. Cassarino, D.S. and J.P. Bennett, Jr., An evaluation of the role of 
mitochondria in neurodegenerative diseases: mitochondrial mutations and 
oxidative pathology, protective nuclear responses, and cell death in 
neurodegeneration. Brain Res Brain Res Rev, 1999. 29(1): p. 1-25. 
167. Shigenaga, M.K., Hagen, T.M., Ames, B.N., Oxidative damage and 
mitochondrial decay in aging. Proc. Natl. Acad. Sci. USA, 1994. 91: p. 
10771-10778. 
168. Ojaimi, J., et al., Mitochondrial respiratory chain activity in the human brain 
as a function of age. Mech Ageing Dev, 1999. 111(1): p. 39-47. 
169. Yan, L.-J., Levine, R.L., and Sohal, R.S., Oxidative damage during aging 
targets mitochondrial aconitase. Proc. Natl. Acad. Sci., USA, 1997. 94: p. 
11168-11172. 
 179 
170. Michikawa, Y., Mazzucchelli, F., Bresolin, N., Scarlato, G., and Attardi, G., 
Aging-dependent large accumulation of point mutations in the human 
mtDNA control region for replication. Science, 1999. 286: p. 774-779. 
171. Stuart, J.A., et al., A midlife crisis for the mitochondrial free radical theory 
of aging. Longev Healthspan, 2014. 3(1): p. 4. 
172. Indo, H.P., et al., Evidence of ROS generation by mitochondria in cells 
with impaired electron transport chain and mitochondrial DNA damage. 
Mitochondrion, 2007. 7(1-2): p. 106-18. 
173. Mori, A., et al., Oxidative damage in the senescence-accelerated mouse. 
Ann N Y Acad Sci, 1998. 854: p. 239-50. 
174. Nakahara, H., et al., Mitochondrial dysfunction in the senescence 
accelerated mouse (SAM). Free Radic Biol Med, 1998. 24(1): p. 85-92. 
175. Mecocci, P., U. MacGarvey, and M.F. Beal, Oxidative damage to 
mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol, 1994. 
36(5): p. 747-51. 
176. Wei, Y.H., Oxidative stress and mitochondrial DNA mutations in human 
aging. Proceedings of the Society for Experimental Biology and Medicine, 
1998. 217(1): p. 53-63. 
177. Hirai, K., et al., Mitochondrial abnormalities in Alzheimer's disease. J 
Neurosci, 2001. 21(9): p. 3017-23. 
178. Miquel, J., Economos, A.C., Fleming, J., Johnson, J.E., Jr., Mitochondrial 
role in cell aging. Experimental Gerontology, 1980. 15: p. 575-591. 
179. Haripriya, D., et al., Age-dependent alterations in mitochondrial enzymes 
in cortex, striatum and hippocampus of rat brain -- potential role of L-
Carnitine. Biogerontology, 2004. 5(5): p. 355-64. 
180. Harman, D., Alzheimer's disease pathogenesis: role of aging. Ann N Y 
Acad Sci, 2006. 1067: p. 454-60. 
181. Markesbery, W.R., Oxidative stress hypothesis in Alzheimer's disease. 
Free Radic Biol Med, 1997. 23(1): p. 134-47. 
182. Pratico, D. and N. Delanty, Oxidative injury in diseases of the central 
nervous system: focus on Alzheimer's disease. Am J Med, 2000. 109(7): 
p. 577-85. 
183. Behl, C., Alzheimer's disease and oxidative stress:  Implications for novel 
therapeutic approaches. Progress in Neurobiology, 1999. 57: p. 301-323. 
184. Martin, S.B., et al., Coenzyme Q10 and cognition in atorvastatin treated 
dogs. Neurosci Lett, 2011. 501(2): p. 92-5. 
185. Mirra, S.S., The CERAD neuropathology protocol and consensus 
recommendations for the postmortem diagnosis of Alzheimer's disease: a 
commentary. Neurobiol Aging, 1997. 18(4 Suppl): p. S91-4. 
186. Butterfield, D.A. and J. Kanski, Brain protein oxidation in age-related 
neurodegenerative disorders that are associated with aggregated proteins. 
Mech Ageing Dev, 2001. 122(9): p. 945-62. 
187. Smith, M.A., Richey Harris, P.L., Sayre, L.M., Beckman, J.S. and Perry, 
G., Widespread peroxynitrite-mediated damage in Alzheimer's disease. J. 
Neurosci., 1997. 17: p. 2653-2657. 
 180 
188. Su, J.H., Deng, G. and Cotman, C.W., Neuronal DNA damage precedes 
tangle formation and is associated with up-regulation of nitrotyrosine in 
Alzheimer's Disease brain. Brain Research, 1997. 774: p. 193-199. 
189. Hensley, K., et al., Brain regional correspondence between Alzheimer's 
disease histopathology and biomarkers of protein oxidation. J. 
Neurochem., 1995. 65: p. 2146-2156. 
190. Lyras, L., Cairns, N.J., Jenner, A., Jenner, P., and Halliwell, B., An 
assessment of oxidative damage to proteins, lipids and DNA in brain from 
patients with Alzheimer's disease. Journal of Neurochemistry, 1997. 68: p. 
2061-2069. 
191. Aksenov, M.Y., et al., Protein oxidation in the brain in Alzheimer's disease. 
Neuroscience, 2001. 103(2): p. 373-83. 
192. Castegna, A., et al., Proteomic identification of oxidatively modified 
proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine 
synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic Biol 
Med, 2002. 33(4): p. 562-71. 
193. Castegna, A., et al., Proteomic identification of oxidatively modified 
proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase-related 
protein 2, alpha-enolase and heat shock cognate 71. J Neurochem, 2002. 
82(6): p. 1524-32. 
194. Palmer, A.M., and Burns, M.A., Selective increase in lipid peroxidation in 
the inferior temporal cortex in Alzheimer's disease. Brain Research, 1994. 
645(1-2): p. 338-342. 
195. Sayre, L.M., Zelasko, D.A., Harris, P.L.R., Perry, G., Salomon, R.G., and 
Smith, M.A., 4-Hydroxynonenal-derived advanced lipid peroxidation end 
products are increased in Alzheimer's disease. Journal of Neurochemistry, 
1997. 68: p. 2092-2097. 
196. Pratico, D., Lee, M.Y.,  Trojanowski, J.Q.,  Rokach, J., and Fitzgerald, G. 
A., Increased F2-isoprostanes in Alzheimer's disease: evidence for 
enhanced lipid peroxidation in vivo. Faseb Journal, 1998. 12(15): p. 1777-
1783. 
197. Pratico, D., et al., Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: 
correlation of a noninvasive index of lipid peroxidation with disease 
severity. Ann Neurol, 2000. 48(5): p. 809-12. 
198. Lovell, M.A. and W.R. Markesbery, Oxidative DNA damage in mild 
cognitive impairment and late-stage Alzheimer's disease. Nucleic Acids 
Res, 2007. 35(22): p. 7497-504. 
199. Lovell, M.A., Gabbita, S.P., and Markesbery, W.R., Increased DNA 
oxidation and decreased levels of repair products in Alzheimer's disease 
ventricular CSF. Journal of Neurochemistry, 1999. 72: p. 771-776. 
200. Gabbita, S.P., Lovell, M.A., and Markesbery, W.R., Increased nuclear 
DNA oxidation in the brain in Alzheimer's disease. Journal of 
Neurochemistry, 1998. 71: p. 2034-2040. 
201. Lovell, M.A. and W.R. Markesbery, Oxidatively modified RNA in mild 
cognitive impairment. Neurobiol Dis, 2008. 29(2): p. 169-75. 
 181 
202. Nunomura, A., Perry, G., Pappolla, M.A., Wade, R., Hirai, K., Chiba, S., 
and Smith, M.A., RNA oxidation is a prominent feature of vulnerable 
neurons in Alzheimer's disease. The Journal of Neuroscience., 1999. 
19(6): p. 1959-1964. 
203. Pappolla, M.A., et al., Immunohistochemical evidence of oxidative 
[corrected] stress in Alzheimer's disease. Am J Pathol, 1992. 140(3): p. 
621-8. 
204. Butterfield, D.A., Proteomics: a new approach to investigate oxidative 
stress in Alzheimer's disease brain. Brain Res., 2004. 1000(1-2): p. 1-7. 
205. Gibson, G.E., K.F. Sheu, and J.P. Blass, Abnormalities of mitochondrial 
enzymes in Alzheimer disease. J Neural Transm, 1998. 105(8-9): p. 855-
70. 
206. Bosetti, F., et al., Cytochrome c oxidase and mitochondrial F1F0-ATPase 
(ATP synthase) activities in platelets and brain from patients with 
Alzheimer's disease. Neurobiol Aging, 2002. 23(3): p. 371-6. 
207. Coskun, P.E., M.F. Beal, and D.C. Wallace, Alzheimer's brains harbor 
somatic mtDNA control-region mutations that suppress mitochondrial 
transcription and replication. Proc Natl Acad Sci U S A, 2004. 101(29): p. 
10726-31. 
208. Supnet, C. and I. Bezprozvanny, Neuronal calcium signaling, 
mitochondrial dysfunction, and Alzheimer's disease. J Alzheimers Dis, 
2010. 20 Suppl 2: p. S487-98. 
209. Mocchegiani, E., et al., Vitamin E-gene interactions in aging and 
inflammatory age-related diseases: Implications for treatment. A 
systematic review. Ageing Res Rev, 2014. 14C: p. 81-101. 
210. Engelhart, M.J., , Geerlings, M.I., Ruitenberg, A., van Swieten, J.C., 
Hofman, A., Witteman, J.C., Breteler, M.M., Dietary intake of antioxidants 
and risk of Alzheimer disease. JAMA., 2002. 287(24): p. 3223-3229. 
211. Morris, M.C., Evans, D.A., Bienias, J.L., Tangney, C.C., Wilson, R.S., 
Vitamin E and cognitive decline in older persons. Arch Neurol, 2002. 59: p. 
1125-1132. 
212. Maxwell, C.J., et al., Supplemental use of antioxidant vitamins and 
subsequent risk of cognitive decline and dementia. Dement Geriatr Cogn 
Disord, 2005. 20(1): p. 45-51. 
213. Luchsinger, J.A., et al., Antioxidant vitamin intake and risk of Alzheimer 
disease. Arch Neurol, 2003. 60(2): p. 203-8. 
214. Masaki, K.H., Losonczy, K.G., Izmirlian, G., Foley, D.J., Ross, G.W., 
Petrovitch, H., Havlik, R., and White, L.R., Association of vitamin E and C 
supplement use with cogntive function and dementia in elderly men. 
Neurology, 2000. 54: p. 1265-1272. 
215. Kang, J.H., et al., A randomized trial of vitamin E supplementation and 
cognitive function in women. Arch Intern Med, 2006. 166(22): p. 2462-8. 
216. Fillenbaum, G.G., et al., Dementia and Alzheimer's disease in community-
dwelling elders taking vitamin C and/or vitamin E. Ann Pharmacother, 
2005. 39(12): p. 2009-14. 
 182 
217. Rizvi, S., et al., The Role of Vitamin E in Human Health and Some 
Diseases. Sultan Qaboos Univ Med J, 2014. 14(2): p. e157-e165. 
218. Ernst, I.M., et al., Vitamin E supplementation and lifespan in model 
organisms. Ageing Res Rev, 2013. 12(1): p. 365-75. 
219. Enesco, H.E. and C. Verdone-Smith, alpha-Tocopherol increases lifespan 
in the rotifer Philodina. Exp Gerontol, 1980. 15(5): p. 335-8. 
220. Lam, Y.T., R. Stocker, and I.W. Dawes, The lipophilic antioxidants alpha-
tocopherol and coenzyme Q10 reduce the replicative lifespan of 
Saccharomyces cerevisiae. Free Radic Biol Med, 2010. 49(2): p. 237-44. 
221. Minogue, P.J. and J.N. Thomas, An alpha-tocopherol dose response 
study in Paramecium tetraurelia. Mech Ageing Dev, 2004. 125(1): p. 21-
30. 
222. Sawada, M. and H.E. Enesco, Vitamin E extends lifespan in the short-
lived rotifer Asplanchna brightwelli. Exp Gerontol, 1984. 19(3): p. 179-83. 
223. Thomas, J. and D. Nyberg, Vitamin E supplementation and intense 
selection increase clonal life span in Paramecium tetraurelia. Exp 
Gerontol, 1988. 23(6): p. 501-12. 
224. Miquel, J., R. Binnard, and W.H. Howard, Effects of dI-alpha-tocopherol in 
life span of Drosophila melanogaster. Gerontologist, 1973. 13: p. 37. 
225. Bahadorani, S., et al., The effects of vitamin supplementation on 
Drosophila life span under normoxia and under oxidative stress. J 
Gerontol A Biol Sci Med Sci, 2008. 63(1): p. 35-42. 
226. Arnold, W.H., et al., Comparative study of in vitro caries-like lesions and 
natural caries lesions at crown margins. J Prosthodont, 2007. 16(6): p. 
445-51. 
227. Porta, E.A., N.S. Joun, and R.T. Nitta, Effects of the type of dietary fat at 
two levels of vitamin E in Wistar male rats during development and aging. 
I. Life span, serum biochemical parameters and pathological changes. 
Mech Ageing Dev, 1980. 13(1): p. 1-39. 
228. Blackett, A.D. and D.A. Hall, Tissue vitamin E levels and lipofuscin 
accumulation with age in the mouse. J Gerontol, 1981. 36(5): p. 529-33. 
229. Blackett, A.D. and D.A. Hall, Vitamin E--its significance in mouse ageing. 
Age Ageing, 1981. 10(3): p. 191-5. 
230. Blackett, A.D. and D.A. Hall, The effects of vitamin E on mouse fitness 
and survival. Gerontology, 1981. 27(3): p. 133-9. 
231. Selman, C., et al., Lifelong alpha-tocopherol supplementation increases 
the median life span of C57BL/6 mice in the cold but has only minor 
effects on oxidative damage. Rejuvenation Res, 2008. 11(1): p. 83-96. 
232. Sano, M., Ernesto, C., Thomas, R.G., Klauber, M.R., Schafer, K., 
Grundman, M., Woodbury, P., Growdon, J., Cotman, C.W., Pfeiffer, E., 
Schneider, L.S. and Thal, L.J., A controlled trial of selegiline, alpha-
tocopherol, or both as treatment for Alzheimer's disease. The New 
England Journal of Medicine, 1997. 336: p. 1216-1222. 
233. Petersen, R.C., et al., Vitamin E and donepezil for the treatment of mild 
cognitive impairment. N Engl J Med, 2005. 352(23): p. 2379-88. 
 183 
234. Chambial, S., et al., Vitamin C in Disease Prevention and Cure: An 
Overview. Indian J Clin Biochem, 2013. 28(4): p. 314-328. 
235. Niki, E., et al., Interaction among vitamin C, vitamin E, and beta-carotene. 
Am J Clin Nutr, 1995. 62(6 Suppl): p. 1322S-1326S. 
236. Wilson, M.K., et al., Review of high-dose intravenous vitamin C as an 
anticancer agent. Asia Pac J Clin Oncol, 2014. 10(1): p. 22-37. 
237. Kara, Y., et al., Acetylsalicylic acid and ascorbic acid combination 
improves cognition; Via antioxidant effect or increased expression of 
NMDARs and nAChRs? Environ Toxicol Pharmacol, 2014. 37(3): p. 916-
927. 
238. Kook, S.Y., et al., High-dose of vitamin C supplementation reduces 
amyloid plaque burden and ameliorates pathological changes in the brain 
of 5XFAD mice. Cell Death Dis, 2014. 5: p. e1083. 
239. Rafnsson, S.B., V. Dilis, and A. Trichopoulou, Antioxidant nutrients and 
age-related cognitive decline: a systematic review of population-based 
cohort studies. Eur J Nutr, 2013. 52(6): p. 1553-67. 
240. von Arnim, C.A., et al., Dietary antioxidants and dementia in a population-
based case-control study among older people in South Germany. J 
Alzheimers Dis, 2012. 31(4): p. 717-24. 
241. Sandhir, R., et al., Coenzyme Q10 treatment ameliorates cognitive deficits 
by modulating mitochondrial functions in surgically induced menopause. 
Neurochem Int, 2014. 
242. Spindler, M., M.F. Beal, and C. Henchcliffe, Coenzyme Q10 effects in 
neurodegenerative disease. Neuropsychiatr Dis Treat, 2009. 5: p. 597-
610. 
243. Potgieter, M., E. Pretorius, and M.S. Pepper, Primary and secondary 
coenzyme Q10 deficiency: the role of therapeutic supplementation. Nutr 
Rev, 2013. 71(3): p. 180-8. 
244. Won, R., K.H. Lee, and B.H. Lee, Coenzyme Q10 protects neurons 
against neurotoxicity in hippocampal slice culture. Neuroreport, 2011. 
22(14): p. 721-6. 
245. Shetty, R.A., M.J. Forster, and N. Sumien, Coenzyme Q(10) 
supplementation reverses age-related impairments in spatial learning and 
lowers protein oxidation. Age (Dordr), 2013. 35(5): p. 1821-34. 
246. Coppadoro, A., et al., Plasma levels of Coenzyme Q10 are reduced in 
critically ill patients as compared to healthy volunteers and correlate with 
age. Critical Care, 2012. 16(Suppl 1): p. 154. 
247. Turunen, M., J. Olsson, and G. Dallner, Metabolism and function of 
coenzyme Q. Biochim Biophys Acta, 2004. 1660(1-2): p. 171-99. 
248. Head, E., et al., Effects of age, dietary, and behavioral enrichment on 
brain mitochondria in a canine model of human aging. Exp Neurol, 2009. 
249. Kamat, C.D., et al., Antioxidants in central nervous system diseases: 
preclinical promise and translational challenges. J Alzheimers Dis, 2008. 
15(3): p. 473-93. 
 184 
250. Pratico, D., Evidence of oxidative stress in Alzheimer's disease brain and 
antioxidant therapy: lights and shadows. Ann N Y Acad Sci, 2008. 1147: p. 
70-8. 
251. Bickford, P.C., et al., Antioxidant-rich diets improve cerebellar physiology 
and motor learning in aged rats. Brain Res, 2000. 866(1-2): p. 211-7. 
252. Joseph, J.A., Denisova, N., Villalobos-Molina, R., Erat, S. and Strain, J., 
Oxidative stress and age-related neuronal deficits. Molecular and 
Chemical Neuropathology, 1996. 28: p. 35-40. 
253. Joseph, J.A., et al., Oxidative stress protection and vulnerability in aging: 
putative nutritional implications for intervention. Mech Ageing Dev, 2000. 
116(2-3): p. 141-53. 
254. Lau, F.C., B. Shukitt-Hale, and J.A. Joseph, The beneficial effects of fruit 
polyphenols on brain aging. Neurobiol Aging, 2005. 26 Suppl 1: p. 128-
32. 
255. Cole, G.M., et al., NSAID and antioxidant prevention of Alzheimer's 
disease: lessons from in vitro and animal models. Ann N Y Acad Sci, 
2004. 1035: p. 68-84. 
256. Crouch, P.J., et al., Mitochondria in aging and Alzheimer's disease. 
Rejuvenation Res, 2007. 10(3): p. 349-57. 
257. Hensley, K., et al., Analysis of Postmortem Ventricular Cerebrospinal Fluid 
from Patients with and without Dementia Indicates Association of Vitamin 
E with Neuritic Plaques and Specific Measures of Cognitive Performance. 
J Alzheimers Dis, 2011. 24(4): p. 767-74. 
258. Morris, M.C. and C.C. Tangney, A potential design flaw of randomized 
trials of vitamin supplements. JAMA, 2011. 305(13): p. 1348-9. 
259. Zandi, P.P., Anthony, J.C., Khachaturian, A.S., Stone, S.V., Gustafson, D., 
Tschanz, J.T., Norton,C., Welsh-Bohmer, K.A., Breitner, J.C.; Cache 
County Study Group., Reduced risk of Alzheimer disease in users of 
antioxidant vitamin supplements: the Cache County Study. Arch Neurol., 
2004. 61(1): p. 82-88. 
260. Barberger-Gateau, P., et al., Dietary patterns and risk of dementia: the 
Three-City cohort study. Neurology, 2007. 69(20): p. 1921-30. 
261. Morris, M.C., et al., Dietary intake of antioxidant nutrients and the risk of 
incident Alzheimer disease in a biracial community study. Jama, 2002. 
287(24): p. 3230-7. 
262. Chandra, R.K., Effect of vitamin and trace-element supplementation on 
cognitive function in elderly subjects. Nutrition, 2001. 17: p. 709-712. 
263. Liu, J., D.W. Killilea, and B.N. Ames, Age-associated mitochondrial 
oxidative decay: improvement of carnitine acetyltransferase substrate-
binding affinity and activity in brain by feeding old rats acetyl-L- carnitine 
and/or R-alpha -lipoic acid. Proc Natl Acad Sci U S A, 2002. 99(4): p. 
1876-81. 
264. Rai, G., Wright, G., Scott, L., Beston, B., Rest, J., and Exton-Smith, A.N., 
Double-blind, placebo controlled study of acetyl-l-carnitine in patients with 
Alzheimer's dementia. Curr Med Res Opin, 1990. 11(10): p. 638-647. 
 185 
265. Pettegrew, J.W., et al., Clinical and neurochemical effects of acetyl-L-
carnitine in Alzheimer's disease. Neurobiol Aging, 1995. 16(1): p. 1-4. 
266. Spagnoli, A., et al., Long-term acetyl-L-carnitine treatment in Alzheimer's 
disease. Neurology, 1991. 41(11): p. 1726-32. 
267. Bonavita, E., Study of the efficacy and tolerability of L-acetylcarnitine 
therapy in the senile brain. Int. J. Clin. Pharm, Ther. & Toxicol., 1986. 
24(9): p. 511-516. 
268. Thal, L.J., et al., A 1-year controlled trial of acetyl-l-carnitine in early-onset 
AD. Neurology, 2000. 55(6): p. 805-10. 
269. Brooks, J.O., 3rd, et al., Acetyl L-carnitine slows decline in younger 
patients with Alzheimer's disease: a reanalysis of a double-blind, placebo-
controlled study using the trilinear approach. Int Psychogeriatr, 1998. 
10(2): p. 193-203. 
270. Thal, L.J., et al., A 1-year multicenter placebo-controlled study of acetyl-L-
carnitine in patients with Alzheimer's disease. Neurology, 1996. 47(3): p. 
705-11. 
271. Montgomery, S.A., L.J. Thal, and R. Amrein, Meta-analysis of double blind 
randomized controlled clinical trials of acetyl-L-carnitine versus placebo in 
the treatment of mild cognitive impairment and mild Alzheimer's disease. 
Int Clin Psychopharmacol, 2003. 18(2): p. 61-71. 
272. Bianchetti, A., R. Rozzini, and M. Trabucchi, Effects of acetyl-L-carnitine in 
Alzheimer's disease patients unresponsive to acetylcholinesterase 
inhibitors. Curr Med Res Opin, 2003. 19(4): p. 350-3. 
273. Hager, K., et al., Alpha-lipoic acid as a new treatment option for Azheimer 
type dementia. Arch Gerontol Geriatr, 2001. 32(3): p. 275-282. 
274. Hager, K., et al., Alpha-lipoic acid as a new treatment option for 
Alzheimer's disease--a 48 months follow-up analysis. J Neural Transm 
Suppl, 2007(72): p. 189-93. 
275. Williams, J.W., et al. Preventing Alzheimer's Disease and Cognitive 
Decline. Evidence Report/Technology Assessment No. 193 (Prepared by 
the Duke Evidence-based Practice Center under Contract No. HHSA 290-
2007-10066-I.). in AHRQ Publication No. 10-E005. 2010. Rockville, MD: 
Agency for Healthcare Research and Quality. 
276. Shen, L. and H.F. Ji, Insights into the disappointing clinical trials of 
antioxidants in neurodegenerative diseases. J Alzheimers Dis. 19(4): p. 
1141-2. 
277. Cotman, C.W. and E. Head, The canine (dog) model of human aging and 
disease: dietary, environmental and immunotherapy approaches. J 
Alzheimers Dis, 2008. 15(4): p. 685-707. 
278. Head, E., et al., Oxidative Damage Increases with Age in a Canine Model 
of Human Brain Aging. Journal of Neurochemistry, 2002. 82: p. 375-381. 
279. Skoumalova, A., et al., The role of free radicals in canine counterpart of 
senile dementia of the Alzheimer type. Exp Gerontol, 2003. 38: p. 711-
719. 
 186 
280. Kiatipattanasakul, W., et al., Immunohistochemical detection of anti-
oxidative stress enzymes in the dog brain. Neuropathology, 1997. 17: p. 
307-312. 
281. Opii, W.O., et al., Proteomic identification of brain proteins in the canine 
model of human aging following a long-term treatment with antioxidants 
and a program of behavioral enrichment: relevance to Alzheimer's 
disease. Neurobiol Aging, 2008. 29(1): p. 51-70. 
282. Hwang, I.K., et al., Differences in Lipid Peroxidation and Cu,Zn-
Superoxide Dismutase in the Hippocampal CA1 Region Between Adult 
and Aged Dogs. J Vet Med Sci, 2008. 70(3): p. 273-7. 
283. Papaioannou, N., Tooten, P.C.J., van Ederen, A.M., Bohl, J.R.E., Rofina, 
J., Tsangaris, T., Gruys, E., Immunohistochemical investigation of the 
brain of aged dogs. I. Detection of neurofibrillary tangles and of 4-
hydroxynonenal protein, an oxidative damage product, in senile plaques. 
Amyloid: J. Protein Folding Disord., 2001. 8: p. 11-21. 
284. Rofina, J.E., et al., Histochemical accumulation of oxidative damage 
products is associated with Alzheimer-like pathology in the canine. 
Amyloid, 2004. 11(2): p. 90-100. 
285. Rofina, J.E., et al., Cognitive disturbances in old dogs suffering from the 
canine counterpart of Alzheimer's disease. Brain Res, 2006. 1069(1): p. 
216-26. 
286. Cotman, C.W., et al., Brain Aging in the Canine: A Diet Enriched in 
Antioxidants Reduces Cognitive Dysfunction. Neurobiology of Aging, 
2002. 23(5): p. 809-818. 
287. Milgram, N.W., et al., Dietary enrichment counteracts age-associated 
cognitive dysfunction in canines. Neurobiol Aging, 2002. 23(5): p. 737-45. 
288. Milgram, N.W., Head, E., Zicker, S.C., Ikeda-Douglas, C., Murphey, H., 
Muggenberg, B.A., Siwak, C.T., Dwight, Tapp. P., Lowry, S.R., Cotman. 
C,W., Long-term treatment with antioxidants and a program of behavioral 
enrichment reduces age-dependent impairment in discrimination and 
reversal learning in beagle dogs. Exp Gerontol., 2004. 39(5): p. 753-765. 
289. Milgram, N.W., et al., Learning ability in aged beagle dogs is preserved by 
behavioral enrichment and dietary fortification: a two-year longitudinal 
study. Neurobiol Aging, 2005. 26(1): p. 77-90. 
290. Nippak, P.M., et al., Enhanced spatial ability in aged dogs following dietary 
and behavioural enrichment. Neurobiol Learn Mem, 2007. 87(4): p. 610-
23. 
291. Zicker, S.C., Cognitive and behavioral assessment in dogs and pet food 
market applications. Prog Neuropsychopharmacol Biol Psychiatry, 2005. 
29(3): p. 455-9. 
292. Milgram, N.W., et al., Landmark discrimination learning in the dog:  effects 
of age, an antioxidant fortified diet, and cognitive strategy. Neuroscience 
and Biobehavioral Reviews, 2002. 26(6): p. 679-695. 
293. Siwak, C.T., et al., Chronic antioxidant and mitochondrial cofactor 
administration improves discrimination learning in aged but not young 
dogs. Prog Neuropsychopharmacol Biol Psychiatry, 2005. 29(3): p. 461-9. 
 187 
294. Calabrese, V., et al., Cellular stress responses, mitostress and carnitine 
insufficiencies as critical determinants in aging and neurodegenerative 
disorders: role of hormesis and vitagenes. Neurochem Res, 2010. 35(12): 
p. 1880-915. 
295. Calabrese, V., et al., Cellular stress responses, the hormesis paradigm, 
and vitagenes: novel targets for therapeutic intervention in 
neurodegenerative disorders. Antioxid Redox Signal, 2010. 13(11): p. 
1763-811. 
296. Siwak-Tapp, C.T., et al., Region specific neuron loss in the aged canine 
hippocampus is reduced by enrichment. Neurobiol Aging, 2008. 29(1): p. 
39-50. 
297. Fahnestock, M., et al., BDNF increases with behavioral enrichment and an 
antioxidant diet in the aged dog. Neurobiol Aging, 2010. 
298. Le, T. and E.M. Keithley, Effects of antioxidants on the aging inner ear. 
Hear Res, 2007. 226(1-2): p. 194-202. 
299. Christie, L.A., et al., Short-term supplementation with acetyl-L-carnitine 
and lipoic acid alters plasma protein carbonyl levels but does not improve 
cognition in aged beagles. Exp Gerontol, 2009. 44(12): p. 752-9. 
300. Brown, M.R., J.W. Geddes, and P.G. Sullivan, Brain region-specific, age-
related, alterations in mitochondrial responses to elevated calcium. J 
Bioenerg Biomembr, 2004. 36(4): p. 401-6. 
301. Brown, M.R., P.G. Sullivan, and J.W. Geddes, Synaptic mitochondria are 
more susceptible to Ca2+overload than nonsynaptic mitochondria. J Biol 
Chem, 2006. 281(17): p. 11658-68. 
302. Brody, H., et al., Clinical, morphologic, and neurochemical aspects in the 
aging central nervous system. Aging. 1975, New York: Raven Press. xi, 
221 p. 
303. Hansford, R.G., Lipid oxidation by heart mitochondria from young adult 
and senescent rats. Biochem J, 1978. 170(2): p. 285-95. 
304. Paradies, G., F.M. Ruggiero, and P. Dinoi, The influence of 
hypothyroidism on the transport of phosphate and on the lipid composition 
in rat-liver mitochondria. Biochim Biophys Acta, 1991. 1070(1): p. 180-6. 
305. Paradies, G. and F.M. Ruggiero, Effect of aging on the activity of the 
phosphate carrier and on the lipid composition in rat liver mitochondria. 
Arch Biochem Biophys, 1991. 284(2): p. 332-7. 
306. Shigenaga, M.K., T.M. Hagen, and B.N. Ames, Oxidative damage and 
mitochondrial decay in aging. Proc Natl Acad Sci U S A, 1994. 91(23): p. 
10771-8. 
307. Navarro, A. and A. Boveris, Rat brain and liver mitochondria develop 
oxidative stress and lose enzymatic activities on aging. Am J Physiol 
Regul Integr Comp Physiol, 2004. 287(5): p. R1244-9. 
308. Navarro, A. and A. Boveris, The mitochondrial energy transduction system 
and the aging process. Am J Physiol Cell Physiol, 2007. 292(2): p. C670-
86. 
309. Yamamoto, T., et al., CSF and ECF glutamate concentrations in head 
injured patients. Acta Neurochir Suppl, 1999. 75: p. 17-9. 
 188 
310. Patel, S.P., et al., Differential effects of the mitochondrial uncoupling 
agent, 2,4-dinitrophenol, or the nitroxide antioxidant, Tempol, on synaptic 
or nonsynaptic mitochondria after spinal cord injury. J Neurosci Res, 2009. 
87(1): p. 130-40. 
311. Singh, I.N., et al., Time course of post-traumatic mitochondrial oxidative 
damage and dysfunction in a mouse model of focal traumatic brain injury: 
implications for neuroprotective therapy. J Cereb Blood Flow Metab, 2006. 
26(11): p. 1407-18. 
312. Hall, E.D., et al., Spatial and temporal characteristics of 
neurodegeneration after controlled cortical impact in mice: more than a 
focal brain injury. J Neurotrauma, 2005. 22(2): p. 252-65. 
313. Sullivan, P.G., et al., Intrinsic differences in brain and spinal cord 
mitochondria: Implication for therapeutic interventions. J Comp Neurol, 
2004. 474(4): p. 524-34. 
314. Naga, K.K., P.G. Sullivan, and J.W. Geddes, High cyclophilin D content of 
synaptic mitochondria results in increased vulnerability to permeability 
transition. J Neurosci, 2007. 27(28): p. 7469-75. 
315. Centers for Disease Control and Prevention, N.C.f.I.P.a.C. Traumatic 
Brain Injury Pubications, Reports and Fact Sheets. 2015; Available from: 
http://www.cdc.gov/TraumaticBrainInjury/factsheets_reports.html. 
316. Norris, J. Traumatic Brain Injury Research Advances with $18.8M NIH 
Award. 2013; Available from: 
https://www.ucsf.edu/news/2013/10/109851/traumatic-brain-injury-
research-advances-188-million-nih-award-administered-ucsf. 
317. Saatman, K.E., et al., Classification of traumatic brain injury for targeted 
therapies. J Neurotrauma, 2008. 25(7): p. 719-38. 
318. Staff, M.C. Traumatic Brain Injury. 2014; Available from: 
http://www.mayoclinic.org/diseases-conditions/traumatic-brain-
injury/basics/risk-factors/con-20029302. 
319. Centers for Disease Control and Prevention, N.C.f.I.P.a.C. Rates of TBI-
related Deaths by Sex - United States, 2001-2010. 2014; Available from: 
http://www.cdc.gov/traumaticbraininjury/data/rates_deaths_bysex.html. 
320. Gribkoff, V.K., E.A. Jonas, and J.M. Hardwick, The Functions, Disease-
Related Dysfunctions, and Therapeutic Targeting of Neuronal 
Mitochondria. 2015: Wiley. 
321. Centers for Disease Control and Prevention, N.C.f.I.P.a.C. What Can I do 
to Help Prevent Traumatic Brain Injury? 2013; Available from: 
http://www.cdc.gov/traumaticbraininjury/prevention.html. 
322. Blackman, E. Helmet Protection against Traumatic Brain Injury: A Physics 
Perspective. 2008; Available from: 
http://www.pas.rochester.edu/~blackman/ur10helmets.pdf. 
323. King, M.M., W., A Simple Way to Better Protect Soldiers against Head 
Trauma. Science and Technology Review, ed. L.L.N. Laboratory. Vol. 
April/May. 2012. 14-16. 
324. Wampler, S.P. LLNL researchers find way to mitigate traumatic brain 
injury in study for Joint IED Defeat Organization. 2011; Available from: 
 189 
https://www.llnl.gov/news/llnl-researchers-find-way-mitigate-traumatic-
brain-injury-study-joint-ied-defeat-organization. 
325. LaPlaca, M.C., et al., CNS injury biomechanics and experimental models. 
Prog Brain Res, 2007. 161: p. 13-26. 
326. Tate, C.C., A.J. Garcia, and M.C. LaPlaca, Plasma fibronectin is 
neuroprotective following traumatic brain injury. Exp Neurol, 2007. 207(1): 
p. 13-22. 
327. Werner, C. and K. Engelhard, Pathophysiology of traumatic brain injury. Br 
J Anaesth, 2007. 99(1): p. 4-9. 
328. Cernak, I., Animal models of head trauma. NeuroRx, 2005. 2(3): p. 410-
22. 
329. Xiong, Y., A. Mahmood, and M. Chopp, Animal models of traumatic brain 
injury. Nat Rev Neurosci, 2013. 14(2): p. 128-42. 
330. Cernak, I., et al., Ultrastructural and functional characteristics of blast 
injury-induced neurotrauma. J Trauma, 2001. 50(4): p. 695-706. 
331. Cernak, I., et al., Cognitive deficits following blast injury-induced 
neurotrauma: possible involvement of nitric oxide. Brain Inj, 2001. 15(7): p. 
593-612. 
332. Cernak, I., et al., Involvement of the central nervous system in the general 
response to pulmonary blast injury. J Trauma, 1996. 40(3 Suppl): p. S100-
4. 
333. Saljo, A., et al., Blast exposure causes redistribution of phosphorylated 
neurofilament subunits in neurons of the adult rat brain. J Neurotrauma, 
2000. 17(8): p. 719-26. 
334. Dixon, C.E., et al., A fluid percussion model of experimental brain injury in 
the rat. J Neurosurg, 1987. 67(1): p. 110-9. 
335. Povlishock, J.T., et al., Workshop on animal models of traumatic brain 
injury. J Neurotrauma, 1994. 11(6): p. 723-32. 
336. Dixon, C.E., et al., A controlled cortical impact model of traumatic brain 
injury in the rat. J Neurosci Methods, 1991. 39(3): p. 253-62. 
337. Lighthall, J.W., H.G. Goshgarian, and C.R. Pinderski, Characterization of 
axonal injury produced by controlled cortical impact. J Neurotrauma, 1990. 
7(2): p. 65-76. 
338. Morales, D.M., et al., Experimental models of traumatic brain injury: do we 
really need to build a better mousetrap? Neuroscience, 2005. 136(4): p. 
971-89. 
339. Smith, D.H., et al., A model of parasagittal controlled cortical impact in the 
mouse: cognitive and histopathologic effects. J Neurotrauma, 1995. 12(2): 
p. 169-78. 
340. Lighthall, J.W., Controlled cortical impact: a new experimental brain injury 
model. J Neurotrauma, 1988. 5(1): p. 1-15. 
341. Kumar, A., et al., Traumatic brain injury in aged animals increases lesion 
size and chronically alters microglial/macrophage classical and alternative 
activation states. Neurobiol Aging, 2013. 34(5): p. 1397-411. 
342. Brustovetsky, N. and J.M. Dubinsky, Dual responses of CNS mitochondria 
to elevated calcium. J Neurosci, 2000. 20(1): p. 103-13. 
 190 
343. Opii, W.O., et al., Proteomic identification of oxidized mitochondrial 
proteins following experimental traumatic brain injury. J Neurotrauma, 
2007. 24(5): p. 772-89. 
344. Pandya, J.D., et al., N-acetylcysteine amide confers neuroprotection, 
improves bioenergetics and behavioral outcome following TBI. Exp 
Neurol, 2014. 257: p. 106-13. 
345. Sauerbeck, A., et al., Traumatic brain injury and trichloroethylene 
exposure interact and produce functional, histological, and mitochondrial 
deficits. Exp Neurol, 2012. 234(1): p. 85-94. 
346. Readnower, R.D., et al., Post-injury administration of the mitochondrial 
permeability transition pore inhibitor, NIM811, is neuroprotective and 
improves cognition after traumatic brain injury in rats. J Neurotrauma, 
2011. 28(9): p. 1845-53. 
347. Sauerbeck, A., et al., Pioglitazone attenuates mitochondrial dysfunction, 
cognitive impairment, cortical tissue loss, and inflammation following 
traumatic brain injury. Exp Neurol, 2011. 227(1): p. 128-35. 
348. Gilmer, L.K., et al., Early mitochondrial dysfunction after cortical contusion 
injury. J Neurotrauma, 2009. 26(8): p. 1271-80. 
349. Hall, E.D., et al., Evolution of post-traumatic neurodegeneration after 
controlled cortical impact traumatic brain injury in mice and rats as 
assessed by the de Olmos silver and fluorojade staining methods. J 
Neurotrauma, 2008. 25(3): p. 235-47. 
350. Pandya, J.D., et al., Post-Injury Administration of Mitochondrial 
Uncouplers Increases Tissue Sparing and Improves Behavioral Outcome 
following Traumatic Brain Injury in Rodents. J Neurotrauma, 2007. 24(5): 
p. 798-811. 
351. Singh, I.N., P.G. Sullivan, and E.D. Hall, Peroxynitrite-mediated oxidative 
damage to brain mitochondria: Protective effects of peroxynitrite 
scavengers. J Neurosci Res, 2007. 85(10): p. 2216-23. 
352. Maalouf, M., et al., Ketones inhibit mitochondrial production of reactive 
oxygen species production following glutamate excitotoxicity by increasing 
NADH oxidation. Neuroscience, 2007. 145(1): p. 256-64. 
353. Lifshitz, J., et al., Mitochondrial damage and dysfunction in traumatic brain 
injury. Mitochondrion, 2004. 4(5-6): p. 705-13. 
354. Sullivan, P.G., et al., Traumatic brain injury alters synaptic homeostasis: 
implications for impaired mitochondrial and transport function. J 
Neurotrauma, 1998. 15(10): p. 789-98. 
355. Rose, M.E., et al., Regulation of interstitial excitatory amino acid 
concentrations after cortical contusion injury. Brain Res, 2002. 943(1): p. 
15-22. 
356. Marklund, N., et al., Free radical scavenger posttreatment improves 
functional and morphological outcome after fluid percussion injury in the 
rat. J Neurotrauma, 2001. 18(8): p. 821-32. 
357. Hall, E.D., et al., Peroxynitrite-mediated protein nitration and lipid 
peroxidation in a mouse model of traumatic brain injury. J Neurotrauma, 
2004. 21(1): p. 9-20. 
 191 
358. Tavazzi, B., et al., Cerebral oxidative stress and depression of energy 
metabolism correlate with severity of diffuse brain injury in rats. 
Neurosurgery, 2005. 56(3): p. 582-9; discussion 582-9. 
359. Xiong, Y., et al., Mitochondrial dysfunction and calcium perturbation 
induced by traumatic brain injury. J Neurotrauma, 1997. 14(1): p. 23-34. 
360. Sullivan, P.G., M.B. Thompson, and S.W. Scheff, Cyclosporin A 
attenuates acute mitochondrial dysfunction following traumatic brain injury. 
Exp Neurol, 1999. 160(1): p. 226-34. 
361. Davis, L.M., et al., Fasting is neuroprotective following traumatic brain 
injury. J Neurosci Res, 2008. 86(8): p. 1812-22. 
362. Pandya, J.D., V.N. Nukala, and P.G. Sullivan, Concentration dependent 
effect of calcium on brain mitochondrial bioenergetics and oxidative stress 
parameters. Front Neuroenergetics, 2013. 5: p. 10. 
363. Pandya, J.D., J.R. Pauly, and P.G. Sullivan, The optimal dosage and 
window of opportunity to maintain mitochondrial homeostasis following 
traumatic brain injury using the uncoupler FCCP. Exp Neurol, 2009. 
218(2): p. 381-9. 
364. Sullivan, P.G., et al., Cytochrome c release and caspase activation after 
traumatic brain injury. Brain Res, 2002. 949(1-2): p. 88-96. 
365. Bullock, R., et al., Factors affecting excitatory amino acid release following 
severe human head injury. J Neurosurg, 1998. 89(4): p. 507-18. 
366. Hall, E.D., R.A. Vaishnav, and A.G. Mustafa, Antioxidant therapies for 
traumatic brain injury. Neurotherapeutics, 2010. 7(1): p. 51-61. 
367. Hamann, K. and R. Shi, Acrolein scavenging: a potential novel mechanism 
of attenuating oxidative stress following spinal cord injury. J Neurochem, 
2009. 111(6): p. 1348-56. 
368. Bains, M. and E.D. Hall, Antioxidant therapies in traumatic brain and 
spinal cord injury. Biochim Biophys Acta, 2012. 1822(5): p. 675-84. 
369. Mustafa, A.G., et al., Mitochondrial protection after traumatic brain injury 
by scavenging lipid peroxyl radicals. J Neurochem, 2010. 114(1): p. 271-
80. 
370. Lifshitz, J., et al., Structural and functional damage sustained by 
mitochondria after traumatic brain injury in the rat: evidence for 
differentially sensitive populations in the cortex and hippocampus. J Cereb 
Blood Flow Metab, 2003. 23(2): p. 219-31. 
371. Singh, I.N., et al., Time course of post-traumatic mitochondrial oxidative 
damage and dysfunction in a mouse model of focal traumatic brain injury: 
implications for neuroprotective therapy. J Cereb Blood Flow Metab, 2006. 
26: p. 1407-1418. 
372. Azbill, R.D., et al., Impaired mitochondrial function, oxidative stress and 
altered antioxidant enzyme activities following traumatic spinal cord injury. 
Brain Res, 1997. 765(2): p. 283-90. 
373. Sullivan, P.G., et al., Temporal characterization of mitochondrial 
bioenergetics after spinal cord injury. J Neurotrauma, 2007. 24(6): p. 991-
9. 
 192 
374. Bao, F. and D. Liu, Peroxynitrite generated in the rat spinal cord induces 
neuron death and neurological deficits. Neuroscience, 2002. 115(3): p. 
839-49. 
375. Bao, F. and D. Liu, Peroxynitrite generated in the rat spinal cord induces 
apoptotic cell death and activates caspase-3. Neuroscience, 2003. 116(1): 
p. 59-70. 
376. Deng, Y., et al., Temporal relationship of peroxynitrite-induced oxidative 
damage, calpain-mediated cytoskeletal degradation and 
neurodegeneration after traumatic brain injury. Exp Neurol, 2007. 205(1): 
p. 154-65. 
377. Xiong, Y. and E.D. Hall, Pharmacological evidence for a role of 
peroxynitrite in the pathophysiology of spinal cord injury. Exp Neurol, 
2009. 216: p. 105-114. 
378. Xiong, Y., A.G. Rabchevsky, and E.D. Hall, Role of peroxynitrite in 
secondary oxidative damage after spinal cord injury. J Neurochem, 2007. 
100(3): p. 639-49. 
379. Lopez-Figueroa, M.O., et al., Direct evidence of nitric oxide presence 
within mitochondria. Biochem Biophys Res Commun, 2000. 272(1): p. 
129-33. 
380. Zanella, B., et al., Mitochondrial nitric oxide localization in H9c2 cells 
revealed by confocal microscopy. Biochem Biophys Res Commun, 2002. 
290(3): p. 1010-4. 
381. Bringold, U., P. Ghafourifar, and C. Richter, Peroxynitrite formed by 
mitochondrial NO synthase promotes mitochondrial Ca2+ release. Free 
Radic Biol Med, 2000. 29(3-4): p. 343-8. 
382. Valdez, L.B., et al., Reactions of peroxynitrite in the mitochondrial matrix. 
Free Radic Biol Med, 2000. 29(3-4): p. 349-56. 
383. Xiong, Y., I.N. Singh, and E.D. Hall, Tempol protection of spinal cord 
mitochondria from peroxynitrite-induced oxidative damage. Free Radic 
Res, 2009. 43(6): p. 604-12. 
384. Vaishnav, R.A., et al., Lipid peroxidation-derived reactive aldehydes 
directly and differentially impair spinal cord and brain mitochondrial 
function. J Neurotrauma, 2010. 27(7): p. 1311-20. 
385. Singh, I.N., et al., Phenelzine mitochondrial functional preservation and 
neuroprotection after traumatic brain injury related to scavenging of the 
lipid peroxidation-derived aldehyde 4-hydroxy-2-nonenal. J Cereb Blood 
Flow Metab, 2013. 33(4): p. 593-9. 
386. Yoshino, A., et al., Dynamic changes in local cerebral glucose utilization 
following cerebral conclusion in rats: evidence of a hyper- and subsequent 
hypometabolic state. Brain Res, 1991. 561(1): p. 106-19. 
387. Bergsneider, M., et al., Cerebral hyperglycolysis following severe 
traumatic brain injury in humans: a positron emission tomography study. J 
Neurosurg, 1997. 86(2): p. 241-51. 
388. Wright, M.J., et al., Early metabolic crisis-related brain atrophy and 
cognition in traumatic brain injury. Brain Imaging Behav, 2013. 7(3): p. 
307-15. 
 193 
389. Sullivan, P.G., et al., The ketogenic diet increases mitochondrial 
uncoupling protein levels and activity. Ann Neurol, 2004. 55(4): p. 576-80. 
390. Ziegler, D.R., et al., Ketogenic diet increases glutathione peroxidase 
activity in rat hippocampus. Neurochem Res, 2003. 28(12): p. 1793-7. 
391. Prins, M.L., L.S. Fujima, and D.A. Hovda, Age-dependent reduction of 
cortical contusion volume by ketones after traumatic brain injury. J 
Neurosci Res, 2005. 82(3): p. 413-20. 
392. Appelberg, K.S., D.A. Hovda, and M.L. Prins, The effects of a ketogenic 
diet on behavioral outcome after controlled cortical impact injury in the 
juvenile and adult rat. J Neurotrauma, 2009. 26(4): p. 497-506. 
393. Drake, J., et al., Elevation of brain glutathione by gamma-glutamylcysteine 
ethyl ester protects against peroxynitrite-induced oxidative stress. J 
Neurosci Res, 2002. 68(6): p. 776-84. 
394. Reed, T.T., et al., Proteomic identification of nitrated brain proteins in 
traumatic brain-injured rats treated postinjury with gamma-
glutamylcysteine ethyl ester: insights into the role of elevation of 
glutathione as a potential therapeutic strategy for traumatic brain injury. J 
Neurosci Res, 2009. 87(2): p. 408-17. 
395. Thomale, U.W., et al., The effect of N-acetylcysteine on posttraumatic 
changes after controlled cortical impact in rats. Intensive Care Med, 2006. 
32(1): p. 149-155. 
396. Thomale, U.W., et al., The antioxidant effect of N-acetylcysteine on 
experimental contusion in rats. Acta Neurochir Suppl, 2005. 95: p. 429-31. 
397. Xiong, Y., P.L. Peterson, and C.P. Lee, Effect of N-acetylcysteine on 
mitochondrial function following traumatic brain injury in rats. J 
Neurotrauma, 1999. 16(11): p. 1067-1082. 
398. Eakin, K., et al., Efficacy of N-Acetyl Cysteine in Traumatic Brain Injury. 
PLoS One, 2014. 9(4). 
399. Silva, L.F.A., et al., The involvement of Na+, K+-ATPase activity and free 
radical generation in the susceptibility to pentylenetetrazol-induced 
seizures after experimental traumatic brain injury. J Neurol Sci, 2011. 
308(1-2): p. 35-40. 
400. Yi, J.H. and A.S. Hazell, N-acetylcysteine attenuates early induction of 
heme oxygenase-1 following traumatic brain injury. Brain Res, 2005. 
1033(1): p. 13-19. 
401. Chen, G., et al., Inhibitory effect on cerebral inflammatory response 
following traumatic brain injury in rats: A potential neuroprotective 
mechanism of N-acetylcysteine. Mediators of Inflammation, 2008. 
402. Baki, S.G.A., et al., Minocycline Synergizes with N-Acetylcysteine and 
Improves Cognition and Memory Following Traumatic Brain Injury in Rats. 
PLoS One, 2010. 5(8). 
403. Haber, M., et al., Minocycline plus N-acetylcysteine synergize to modulate 
inflammation and prevent cognitive and memory deficits in a rat model of 
mild traumatic brain injury. Exp Neurol, 2013. 249: p. 169-77. 
 194 
404. Hoffer, M.E., et al., Amelioration of Acute Sequelae of Blast Induced Mild 
Traumatic Brain Injury by N-Acetyl Cysteine: A Double-Blind, Placebo 
Controlled Study. PLoS One, 2013. 8(1). 
405. Grinberg, L., et al., N-acetylcysteine amide, a novel cell-permeating thiol, 
restores cellular glutathione and protects human red blood cells from 
oxidative stress. Free Radic Biol Med, 2005. 38(1): p. 136-45. 
406. Offen, D., et al., A low molecular weight copper chelator crosses the 
blood-brain barrier and attenuates experimental autoimmune 
encephalomyelitis. J Neurochem, 2004. 89(5): p. 1241-51. 
407. Patel, S., et al., N-Acetylcysteine Amide (Naca) Treatment Improved 
Mitochondrial Bioenergetics and Hindlimb Functional Recovery Following 
Contusion Spinal Cord Injury. J Neurotrauma, 2012. 29(10): p. A19-A19. 
408. Patel, S., et al., Effects of Continuous Subcutaneous Delivery of N-
Acetylcysteine Aamide (Naca) on Acute and Chronic Pathophysiology 
after Spinal Cord Injury. J Neurotrauma, 2013. 30(15): p. A18-A18. 
409. Patel, S.P., et al., N-acetylcysteine amide preserves mitochondrial 
bioenergetics and improves functional recovery following spinal trauma. 
Exp Neurol, 2014. 257: p. 95-105. 
410. Mbye, L.H., et al., Attenuation of acute mitochondrial dysfunction after 
traumatic brain injury in mice by NIM811, a non-immunosuppressive 
cyclosporin A analog. Exp Neurol, 2008. 209(1): p. 243-53. 
411. Okonkwo, D.O. and J.T. Povlishock, An intrathecal bolus of cyclosporin A 
before injury preserves mitochondrial integrity and attenuates axonal 
disruption in traumatic brain injury. J Cereb Blood Flow Metab, 1999. 
19(4): p. 443-51. 
412. Sullivan, P.G., M. Thompson, and S.W. Scheff, Continuous infusion of 
cyclosporin A postinjury significantly ameliorates cortical damage following 
traumatic brain injury. Exp Neurol, 2000. 161(2): p. 631-7. 
413. Okonkwo, D.O., et al., Cyclosporin A limits calcium-induced axonal 
damage following traumatic brain injury. Neuroreport, 1999. 10(2): p. 353-
8. 
414. Mbye, L.H., et al., Comparative neuroprotective effects of cyclosporin A 
and NIM811, a nonimmunosuppressive cyclosporin A analog, following 
traumatic brain injury. J Cereb Blood Flow Metab, 2009. 29(1): p. 87-97. 
415. Hatton, J., et al., Dosing and safety of cyclosporine in patients with severe 
brain injury. J Neurosurg, 2008. 109(4): p. 699-707. 
416. Sullivan, P.G., et al., Exacerbation of damage and altered NF-kappaB 
activation in mice lacking tumor necrosis factor receptors after traumatic 
brain injury. J Neurosci, 1999. 19(15): p. 6248-56. 
417. Sullivan, P.G., et al., Mitochondrial uncoupling protein-2 protects the 
immature brain from excitotoxic neuronal death. Ann Neurol, 2003. 53(6): 
p. 711-7. 
418. Sullivan, P.G., et al., Dietary supplement creatine protects against 
traumatic brain injury. Ann Neurol, 2000. 48(5): p. 723-9. 
 195 
419. Sullivan, P.G., et al., Dose-response curve and optimal dosing regimen of 
cyclosporin A after traumatic brain injury in rats. Neuroscience, 2000. 
101(2): p. 289-95. 
420. Sullivan, P.G., et al., Mitochondrial uncoupling as a therapeutic target 
following neuronal injury. J Bioenerg Biomembr, 2004. 36(4): p. 353-6. 
421. Faden, A.I., et al., The role of excitatory amino acids and NMDA receptors 
in traumatic brain injury. Science, 1989. 244(4906): p. 798-800. 
422. Rego, A.C., M.W. Ward, and D.G. Nicholls, Mitochondria control 
ampa/kainate receptor-induced cytoplasmic calcium deregulation in rat 
cerebellar granule cells. J Neurosci, 2001. 21(6): p. 1893-901. 
423. Choi, D.W., Excitotoxic cell death. J Neurobiol, 1992. 23(9): p. 1261-76. 
424. Davis, L.M., J.M. Rho, and P.G. Sullivan, UCP-mediated free fatty acid 
uncoupling of isolated cortical mitochondria from fasted animals: 
correlations to dietary modulations. Epilepsia, 2008. 49 Suppl 8: p. 117-9. 
425. Chinetti, G., J.C. Fruchart, and B. Staels, Peroxisome proliferator-
activated receptors (PPARs): nuclear receptors with functions in the 
vascular wall. Z Kardiol, 2001. 90 Suppl 3: p. 125-32. 
426. Dreyer, C., et al., Control of the peroxisomal beta-oxidation pathway by a 
novel family of nuclear hormone receptors. Cell, 1992. 68(5): p. 879-87. 
427. Michalik, L., B. Desvergne, and W. Wahli, Peroxisome-proliferator-
activated receptors and cancers: complex stories. Nat Rev Cancer, 2004. 
4(1): p. 61-70. 
428. Michalik, L. and W. Wahli, Peroxisome proliferator-activated receptors: 
three isotypes for a multitude of functions. Curr Opin Biotechnol, 1999. 
10(6): p. 564-70. 
429. Torra, I.P., et al., Peroxisome proliferator-activated receptors: from 
transcriptional control to clinical practice. Curr Opin Lipidol, 2001. 12(3): p. 
245-54. 
430. Thal, S.C., et al., Pioglitazone reduces secondary brain damage after 
experimental brain trauma by PPAR-gamma-independent mechanisms. J 
Neurotrauma, 2011. 28(6): p. 983-93. 
431. Kapadia, R., J.H. Yi, and R. Vemuganti, Mechanisms of anti-inflammatory 
and neuroprotective actions of PPAR-gamma agonists. Front Biosci, 2008. 
13: p. 1813-26. 
432. Bieganski, R.M. and M.L. Yarmush, Novel ligands that target the 
mitochondrial membrane protein mitoNEET. J Mol Graph Model, 2011. 
29(7): p. 965-73. 
433. Zuris, J.A., et al., Facile transfer of [2Fe-2S] clusters from the diabetes 
drug target mitoNEET to an apo-acceptor protein. Proc Natl Acad Sci U S 
A, 2011. 108(32): p. 13047-52. 
434. Colca, J.R., et al., Identification of a novel mitochondrial protein 
("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe. 
Am J Physiol Endocrinol Metab, 2004. 286(2): p. E252-60. 
435. Wiley, S.E., et al., MitoNEET is an iron-containing outer mitochondrial 
membrane protein that regulates oxidative capacity. Proc Natl Acad Sci U 
S A, 2007. 104(13): p. 5318-23. 
 196 
436. Geldenhuys, W.J., T.C. Leeper, and R.T. Carroll, mitoNEET as a novel 
drug target for mitochondrial dysfunction. Drug Discov Today, 2014. 
19(10): p. 1601-6. 
437. Divakaruni, A.S., et al., Thiazolidinediones are acute, specific inhibitors of 
the mitochondrial pyruvate carrier. Proc Natl Acad Sci U S A, 2013. 
110(14): p. 5422-7. 
438. Panzer, U., et al., Effects of different PPARgamma-agonists on MCP-1 
expression and monocyte recruitment in experimental glomerulonephritis. 
Kidney Int, 2002. 62(2): p. 455-64. 
439. Gilmer, L.K., et al., Early mitochondrial dysfunction after cortical contusion 
injury. J Neurotrauma, 2009. 26: p. 1271-1280. 
440. Jin, Y., et al., The mitochondrial uncoupling agent 2,4-dinitrophenol 
improves mitochondrial function, attenuates oxidative damage, and 
increases white matter sparing in the contused spinal cord. J 
Neurotrauma, 2004. 21(10): p. 1396-404. 
441. Mattiasson, G. and P.G. Sullivan, The emerging functions of UCP2 in 
health, disease, and therapeutics. Antioxid Redox Signal, 2006. 8(1-2): p. 
1-38. 
442. McEwen, M.L., P.G. Sullivan, and J.E. Springer, Pretreatment with the 
cyclosporin derivative, NIM811, improves the function of synaptic 
mitochondria following spinal cord contusion in rats. J Neurotrauma, 2007. 
24(4): p. 613-24. 
443. Patel, S.P., et al., Acetyl-L-carnitine ameliorates mitochondrial dysfunction 
following contusion spinal cord injury. J Neurochem, 2010. 114(1): p. 291-
301. 
444. Scheff, S.W. and P.G. Sullivan, Cyclosporin A significantly ameliorates 
cortical damage following experimental traumatic brain injury in rodents. J 
Neurotrauma, 1999. 16(9): p. 783-92. 
445. Cole, J.T., et al., Dietary branched chain amino acids ameliorate injury-
induced cognitive impairment. Proc Natl Acad Sci U S A, 2010. 107(1): p. 
366-71. 
446. Avery, M.A., et al., WldS prevents axon degeneration through increased 
mitochondrial flux and enhanced mitochondrial Ca2+ buffering. Curr Biol, 
2012. 22(7): p. 596-600. 
447. Sauerbeck, A., et al., Analysis of regional brain mitochondrial 
bioenergetics and susceptibility to mitochondrial inhibition utilizing a 
microplate based system. J Neurosci Methods, 2011. 198(1): p. 36-43. 
448. Kaplon, J., et al., A key role for mitochondrial gatekeeper pyruvate 
dehydrogenase in oncogene-induced senescence. Nature, 2013. 
498(7452): p. 109-12. 
449. Bai, F., et al., The Fe-S cluster-containing NEET proteins mitoNEET and 
NAF-1 as chemotherapeutic targets in breast cancer. Proc Natl Acad Sci 
U S A, 2015. 112(12): p. 3698-703. 
450. Tamir, S., et al., Structure-function analysis of NEET proteins uncovers 
their role as key regulators of iron and ROS homeostasis in health and 
disease. Biochim Biophys Acta, 2015. 1853(6): p. 1294-315. 
 197 
451. Kusminski, C.M., et al., MitoNEET-driven alterations in adipocyte 
mitochondrial activity reveal a crucial adaptive process that preserves 
insulin sensitivity in obesity. Nat Med, 2012. 18(10): p. 1539-49. 
452. Kusminski, C.M., J. Park, and P.E. Scherer, MitoNEET-mediated effects 
on browning of white adipose tissue. Nat Commun, 2014. 5: p. 3962. 
453. Li, M., et al., Glutamate dehydrogenase: structure, allosteric regulation, 
and role in insulin homeostasis. Neurochem Res, 2014. 39(3): p. 433-45. 
454. Li, M., et al., The structure and allosteric regulation of mammalian 
glutamate dehydrogenase. Arch Biochem Biophys, 2012. 519(2): p. 69-80. 
455. Li, M., et al., The structure and allosteric regulation of glutamate 
dehydrogenase. Neurochem Int, 2011. 59(4): p. 445-55. 
456. Smith, T.J. and C.A. Stanley, Untangling the glutamate dehydrogenase 
allosteric nightmare. Trends Biochem Sci, 2008. 33(11): p. 557-64. 
 
 
 
  
 198 
VITA 
 
HEATHER MARIE YONUTAS 
 
Education PhD in Anatomy and Neurobiology 
University of Kentucky, Lexington, KY 
Investigated mitochondrial function and the role of 
mitoNEET in pioglitazone mediated neuroprotection 
following traumatic brain injury in rodent models. 
 
2010-2015 
 PhD in Physical Chemistry, program not 
completed 
University of California, Los Angeles, Los 
Angeles, CA 
Studied controlled radiation damping with various 
pulse sequences, primarily Balanced Steady State 
Free Precession (BSSFP) under the advisement of 
Dr. Yung-Ya Lin PhD 
 
2009-2010 
 B.S. Degree in Biology, Minor in Chemistry 
Mount St. Mary’s College, Los Angeles, CA 
2001-2005 
 
 
Academic and Professional Honors 
 
• Funded F31 through NINDS 
 
• Neurotrauma Student Travel Award, 32nd Annual Symposium of the 
National Neurotrauma Society, San Francisco, CA, June 2014  
 
• Voted Graduate Student Representative for the Bluegrass Society for 
Neuroscience 
o 2014-2015 School Year 
o 2012-2013 School Year 
 
• Voted President of Graduate Student Congress, University of Kentucky 
o 2014-2015 School Year 
o 2013-2014 School Year 
 
• Poster winner, Bluegrass Society for Neuroscience Research Day, 
Lexington, Kentucky 
o March 2015 
o April 2014 
o April 2013 
 
 199 
• Voted Committee Member for See Tomorrow: The University of Kentucky 
Strategic Plan 2014-2020 Committee (Voted by Provost Office), Fall 2013 
to Present 
 
• Issued the Medical Neuroanatomy Teaching Certificate, Anatomy and 
Neurobiology Department, University of Kentucky, June 2013  
 
• Finalist in the 2013 Three Minute Thesis (3MT) Competition, University of 
Kentucky, Lexington, KY Spring 2013, 
http://www.youtube.com/watch?v=z1MegzEKtTk 
 
• Top Research Student Award in the Physical Science Department, Spring 
2005 
 
• Award to Graduate with Honors due to the completion of my Honors 
Thesis and other prerequisites, Spring 2004 
 
• Outstanding Progress in the Physical Sciences, at Mount St. Mary’s 
College, April 2004, April 2003 
 
• American Chemical Society Travel Grant for the 225th ACS National 
Meeting, New Orleans, LA, March 23-27, 2003 
 
• St. Catherine Medal, National Achievement Award, Kappa Gamma Pi, 
April 26th 2003 
 
• Outstanding Freshman in Biology Student, 2002 at Mount St. Mary’s 
College  
 
Peer-Reviewed Publications and Abstracts 
 
• Yonutas, HM, Vekaria, H., Pandya, JD, Sebastian, A, Sullivan; 
Pioglitazone neuroprotection following CNS injury is mediated via 
interaction with mitoNEET; Cell Metabolism; submitted 
 
• Yonutas, HM, Vekaria, H., Sullivan, PG; Mitochondrial Specific 
Therapeutic Targets Following Brain Injury; Brain Research special issue 
on therapies for TBI; In Press 
 
• Yonutas, H.M; Sullivan, P.G., Mechanism of Action of PPAR Agonists in 
CNS Injury, Current Drug Targets, 14, 7 (2013) PMID: 23627890 
 
• Yonutas HM, Hall ED, Sullivan PG; The Functions, Disease-Related 
Dysfunctions, and Therapeutic Targeting of Neuronal Mitochondria. 
 200 
Gribkoff VK, Jonas EA, Hardwick J, editors. United States: Wiley; 2015. 
Therapeutic Targeting of Neuronal Mitochondria in Brain Injury; 400p 
 
• Yonutas HM, Pandya JD, Sullivan PG; Changes in mitochondrial 
bioenergetics in the brain versus spinal cord become more apparent with 
age. J Bioenerg Biomembr. 2015 Apr;47(1-2):149-54. doi: 
10.1007/s10863-014-9593-5. PubMed PMID: 25472025; PubMed Central 
PMCID: PMC4323922 
 
• Yonutas H.M., Pandya, J.D., Sebastian, A.H., Geldenhuys, W.J., Carroll, 
R.T, Sullivan, P.G., A “NEET” target to improve outcomes following TBI: 
Pioglitazone and mitoNEET , Bluegrass Society for Neuroscience Spring 
Neuroscience Day, Lexington, KY, March 2015 – Poster Presentation – 
Student Poster Winner 
 
• Pandya JD, Grondin R, Yonutas HM, Haghnazar H, Gash DM, Zhang Z, 
Sullivan PG; Decreased mitochondrial bioenergetics and calcium buffering 
capacity in the basal ganglia correlates with motor deficits in a nonhuman 
primate model of aging. Neurobiol Aging. 2015 Jan 28. pii: S0197-
4580(15)00051-2. doi: 10.1016/j.neurobiolaging.2015.01.018. PubMed 
PMID: 25726361 
 
• Yonutas HM, Head E, Sullivan PG; Foods and Dietary Supplements in 
the Prevention and Treatment of Disease in Older Adults. Watson RR, 
editor. Boston, MA, USA: Elsevier; 2015. Chapter 8, Targeting 
Mitochondria for Healthy Brain Aging; p.71-83. 380p. 
 
• Yonutas H.M., Pandya, J.D., Sebastian, A.H., Geldenhuys, W.J., Carroll, 
R.T, Sullivan, P.G., A “NEET” mitochondrial target: The Importance of 
mitoNEET in Pioglitazone Mediated Neuroprotection following TBI; Society 
of Neuroscience 2014, Washington, DC, November 2014 – Poster 
Presentation and asked to present a 3MT of my research to Francis 
Brooke, Legislative Assistant for U.S. Representative Andy Barr, KY-6 
 
• Yonutas H.M., Pandya, J.D., Sebastian, A.H., Geldenhuys, W.J., Carroll, 
R.T, Sullivan, P.G., Interactions between Pioglitazone and mitoNEET 
Ameliorate Mitochondrial Dysfunction following Traumatic Brain Injury; 
Neurotrauma 2014 Symposium; San Francisco, CA; July 2014 – Poster 
Presentation - Student Travel Grant Winner 
 
• Yonutas H.M., Pandya, J.D., Geldenhuys, W.J., Carroll, R.T, Sullivan, 
P.G., Using Pioglitazone to Target Mitochondrial Dysfunction following 
Traumatic Brain Injury, Kentucky Spinal Cord and Head Injury Research 
Trust Symposium, Lexington, KY, May 2014 – Invited Speaker, Oral 
Presentation 
 
 201 
• Patel SP, Sullivan PG, Pandya JD, Goldstein GA, VanRooyen JL, 
Yonutas HM, Eldahan KC, Morehouse J, Magnuson DS, Rabchevsky 
AG.; N-acetylcysteine amide preserves mitochondrial bioenergetics and 
improves functional recovery following spinal trauma. Exp Neurol. 2014 
Jul;257:95-105. doi: 10.1016/j.expneurol.2014.04.026. Epub 2014 May 5. 
PubMed PMID: 24805071; PubMed Central PMCID: PMC4114148. 
 
• Pandya JD, Readnower RD, Patel SP, Yonutas HM, Pauly JR, Goldstein 
GA, Rabchevsky AG, Sullivan PG; N-acetylcysteine amide confers 
neuroprotection, improves bioenergetics and behavioral outcome following 
TBI. Exp Neurol. 2014 Jul;257:106-13. doi: 
10.1016/j.expneurol.2014.04.020. Epub 2014 May 1. PubMed PMID: 
24792639; PubMed Central PMCID: PMC4086163. 
 
• Yonutas H.M., Geldenhuys, W.J., Carroll, R.T, Sullivan, P.G., The Pivotal 
Role of mitoNEET in Pioglitazone-Mediated Neuroprotection Following TBI 
, Bluegrass Society for Neuroscience Spring Neuroscience Day, 
Lexington, KY, March 2014 – Poster Presentation 
 
• Yonutas H.M., Geldenhuys, W.J., Carroll, R.T, Sullivan, P.G., A 
mechanism of neuroprotection provided by pioglitazone following 
traumatic brain injury, Society of Neuroscience 2013, San Diego, CA, 
November 2013 – Poster Presentation  
 
• Patel, S.P., Sullivan P.G., Yonutas, H.M., Vanrooyen J.L., Eldahan K.C., 
Rabchevsky, A.G., Effects of continuous N-acetylcysteine amide (naca) 
treatment on acute and chronic pathophysiology after contusion spinal 
cord injury, Society of Neuroscience 2013, San Diego, CA, November 
2013 – Poster Presentation 
 
• Yonutas H.M., Geldenhuys, W.J., Carroll, R.T, Sullivan, P.G., An 
Investigation into the Role of mitoNEET and Mitochondrial Bioenergetics 
in Pioglitazone Mediated Neuroprotection Following TBI, Neurotrauma 
2013 Symposium, Nashville, TN, August 2013 – Poster Presentation 
 
• Patel, S.P., Sullivan P.G., Yonutas, H.M., Vanrooyen J.L., Effects of 
continuous subcutaneous delivery of N-Acetylcysteine Amide (NACA) on 
acute and chronic pathophysiology after spinal cord injury, Neurotrauma 
2013 Symposium, Nashville, TN, August 2013 – Poster Presentation 
 
• Pandya, J., Yonutas, H.M., Sebastian, A., Freeman, M.R., Geddes, J.G., 
Sullivan, P.G., Investigating mitochondrial mechanisms of neuroprotection 
using WLDS and SARM -/- mice following traumatic brain injury, 
Neurotrauma 2013 Symposium, Nashville, TN, August 2013 – Poster 
Presentation 
 
 202 
• Yonutas H.M., Geldenhuys, W.J., Carroll, R.T, Sullivan, P.G., A 
Neuroprotective Mechanism of Pioglitazone following Traumatic Brain 
Injury, Bluegrass Society for Neuroscience Research Day, Lexington, 
Kentucky, April 2013 – Poster Presentation 
 
• Crowdus, C., Pandya, J., Power, L., Sebastian, A., Yonutas, H., Hopkins, 
D., Jones, J., Pauly, J., Sullivan, P.G., Power, R., Geddes, J., Selenium 
for the treatment of traumatic brain injury, Bluegrass Society for 
Neuroscience Research Day, Lexington, Kentucky, April 2013 – Poster 
Presentation 
 
• Yonutas H.M., Geldenhuys, W.J., Carroll, R.T, Sullivan, P.G., The Role of 
Pioglitazone, mitoNEET and Mitochondria in TBI, Neurotrauma 2012 
Symposium, Phoenix, AZ, July 2012 – Poster Presentation 
 
• Yonutas H.M., Carroll, R.T, Geldenhuys, W.J., Sullivan, P.G., 
Pioglitazone as a Mitochondrial Therapeutic following TBI, 2012 KSCHIRT 
Conference, Lexington, KY, May 2012 – Poster Presentation 
 
• Yonutas H.M., Carroll, R.T, Geldenhuys, W.J., Sullivan, P.G., A 'NEET' 
mitochondrial target: Pioglitazone and mitoNEET in Brain Injury. 
Appalachian Health Summit and Bluegrass Society for Neuroscience 
Research Day, Lexington, Kentucky, March 2012 – Poster Presentation 
 
• Amboya, A.; Nguyen, T.; Huynh H.; Brown, A.; Ratliff, G.K.; Yonutas, 
H.M.; Cizmeciyan D.*; Natarajan, A.; and Garcia Garibay, M. A*., “ Radical 
Pairs with Rotational Fluidity in the Photochemical Reaction of 
Acetophenone and Cyclohexane in the Zeolite NaY: A 13C CPMAS NMR 
and Product Analysis Study”, Organic & Biomolecular Chemistry, 7, 11 
(2009) DOI: 10.1039/B815266G 
 
• Cizmeciyan, D.; Yonutas, H.M.; Karlen, S.D.; and Garcia-Garibay, M.A.; 
2H NMR and X-ray diffraction studies of methyl rotation in crystals of 
orthomethyldibenzocycloalkanones, Solid State Nuclear Magnetic 
Resonance, 28, 1 (2005) DOI: 10.1016/j.ssnmr.2005.02.006 
 
Teaching Experiences 
 
Title Beginnin
g Date 
End 
Date 
Department Institution Supervisor 
Teaching 
Assistant 01/13 05/13 
Anatomy and 
Neurobiology 
University of 
Kentucky, College of 
Medicine 
Bruce Maley, 
PhD 
Teaching 
Assistant 09/09 06/10 Chemistry 
University of California 
– Los Angeles 
Yung-Ya Lin, 
PhD 
Instructor 01/06 05/08 Chemistry Mount St. Mary’s Eric Stemp, PhD 
 203 
College – Los 
Angeles, CA 
Long Term 
Substitute 
Teacher 
08/05 12/05 Science 
Rosemont Middle 
School – La 
Crescenta, CA 
Sally Buckley, 
PhD 
 
 
Lecture Experiences 
 
• Principles of Human Anatomy – ANA 209 – 1 Hour Lecture on Peripheral 
and Central Nervous System, February 2015  
 
• Neuroanatomy for PT students – ANA 802 – 2 Hour Lecture on the 
Peripheral Nervous System, September 2014 
 
• Neuroanatomy for PT students – ANA 802 – 2 Hour Lecture on the 
Peripheral Nervous System, September 2013 
• Medical Neuroanatomy – MD 816 – 2 Hour Lecture on the Sensory 
Receptors in the Peripheral Nervous System, March 2013 
 
Memberships & Affiliations 
 
• Student Member, National Neurotrauma Society  
 
• Student Member, Society for Neuroscience 
 
• Student Member, Bluegrass Society for Neuroscience  
      2012-2013 Graduate Student Representative 
      2014-2015 Graduate Student Representative 
 
• Member, Graduate Student Congress, University of Kentucky 
      2013-2014 President 
      2014-2015 President 
 
• Member, Delta Epsilon Iota Honor Society, University of Kentucky 
 
 
